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ABSTRACT 
Drug Delivery Systems Based on Polymer Blends:  
Synthesis, Characterization & Application 
Xinyin Liu 
Anthony M. Lowman, Ph.D. 
 
 
 
 
 Polymer blending is the physical mixing of two or more existing polymers. It 
offers an effective way to produce new polymeric materials with combined excellent 
properties. With this technique, non-toxic, biocompatible hydrogels can be synthesized 
through mixing biocompatible polymers in the absence of the toxic agents, such as 
crosslinking agents, initiators and residual monomers, which are inevitable in regular 
polymerization processes. In this regard, this project focuses on the development of new 
drug delivery systems based upon blending of polymers with known biocompatibility. 
The first part of the project was to synthesize hydrogels from blending of two hydrophilic 
polymers—polyvinyl alcohol (PVA) and polyvinyl pyrrolidone (PVP). The hydrogel 
characteristics and model drug release were evaluated. The second part of the research 
was to incorporate biodegradable poly (D, L- lactide-co-glycolide) microparticles (~10mm) 
containing a model drug into hydrogel matrices of PVA, with the crystallites of PVA 
serving as the crosslinking points. The release of the drug formulated in the polymeric 
composite was controlled by the degradation of the microparticles and the diffusion 
through the hydrogel matrix. Furthermore, a multilayer approach was adopted to reduce 
the initial burst effect by offering additional diffusion barriers. An empirical model of 
drug release from the multilayer composite was developed and applied to estimate the 
effects of outer layer thickness and particle size on the release from the delivery system.  
 
1 
CHAPTER 1:INTRODUCTION 
Polymeric materials have been widely used and investigated in the field of 
controlled drug delivery as carriers for the delivery of small molecules, peptides or 
proteins with therapeutic effects. Biocompatibility and toxicity of the carrier materials are 
critical issues that should be considered when designing such devices for drug delivery. 
In this work, two different types of drug delivery systems are developed based on 
physical blending of polymers with known biocompatibility, in order to eliminate the 
toxic effects of residual crosslinking agents, initiators or monomers. It also offers a 
convenient route to develop new polymeric materials, with combined properties of more 
than one existing polymer. A wide range of material properties can be obtained by merely 
changing the blend composition. In addition, it is usually less expensive and less time-
consuming to prepare new polymeric materials through blending than development of 
new monomers and/or new polymerization routes.  
Polyvinyl alcohol (PVA) is a polymer that attracts great interests, due to its semi-
crystalline nature to form physically crosslinked hydrogels with the advantages of non-
toxic, non-carcinogenic and bioadhesive properties [1]. With PVA as the main polymer, 
two strategies based on polymer blending are adopted in this research to develop novel 
drug delivery systems which would offer better control of drug release. 
Strategy I. Development of hydrogel systems based on the blending of PVA with 
a hydrophilic polymer—polyvinyl pyrrolidone (PVP). PVA and PVP have been reported 
to form homogenous polymer blends in aqueous solution [2, 3]. Hydrogels can be formed 
with the presence of the crystallites of PVA and the hydrogen bonds between PVA and 
PVP. 
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Strategy II. Fabrication of polymer composites—hydrophobic biodegradable 
microparticles embedded in PVA hydrogel matrix. Poly (D, L-lactide-co-glycolide) 
(PLGA) microparticles containing model drugs are formulated using single oil- in-water 
emulsion method,  and then incorporated in PVA hydrogel matrices. The release of the 
model drug is governed by the degradation of PLGA microparticles and the diffusion of 
the drug through the particles and the hydrogel barriers.  
The overall goals of this work are therefore to construct new polymeric drug 
delivery systems, including hydrogels and composites based on polymer blending, and 
evaluate their properties as potential dosage forms for sustained release of therapeutic 
agents.  
 
3 
CHAPTER 2:BACKGROUND 
2.1 Controlled Drug Delivery 
 Important classes of drugs have yet to benefit from advances in drug delivery 
technology to enhance or facilitate the action of these therapeutic agents. Choosing the 
suitable delivery systems is important to maximize the potential therapeutic impact of 
each drug candidate.  
Since the initiation of pharmacological therapy, maintaining steady therapeutic 
drug concentration levels while minimizing side effects has been a major challenge. For 
the traditional drug delivery systems, typically tablets or intravenous (IV) injections, the 
administration of the entire dose of drug in one portion would result in high, sometimes 
close to toxic, plasma concentrations of the drug, leading to adverse reactions. By 
effective management of the dose size and dose frequency, it is possible to achieve 
therapeutic steady state levels of a drug through multiple doses [4]. However, the drug 
concentration in plasma may cause toxic side effects if the drug level swings above the 
maximum level or a lack of efficacy if the drug level falls below the minimum level 
(Figure 2.1). For drugs with linear, one-compartment characteristics, the dosing interval 
(t ) is related to the half- time (t1/2) of the drug as [5]: 
1 2
ln
ln2
TI
t<t                          (2.1)
Here, TI is the therapeutic index, which is often defined as the ratio of median 
lethal dose (LD50) to median effective dose (ED50). As TI for most drugs is around 2, it is 
necessary to dose the patients at intervals shorter than the half- life of the drug [6]. Drugs 
with short half- lives usually require frequent dosing to maintain therapeutically effective 
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plasma levels, which is inconvenient for the patients and sometimes even difficult to 
achieve if the half- life of a drug is extremely short. Therefore, the idea of having a 
prolonged drug delivery system which can maintain a long-term appropriate therapeutic 
plasma concentration by releasing drugs in a controlled fashion became appealing and 
popular, leading to the rise of  controlled delivery.  
As indicated in the term, controlled release is the technique to control the release 
of drugs so as to maintain a relatively constant, effective plasma level for an extended 
period of time by reproducible and predictable kinetics. A successful controlled delivery 
system should reduce the frequency of administrations, which would be a relief to many 
patients including the elderly and those chronically ill. In addition, a steady-state level of 
the drug could be maintained to minimize side effects through reducing fluctuations in 
drug level. The basic rationale for controlled drug delivery is to alter the  
pharmacokinetics and pharmacodynamics of therapeutic agents by using novel drug 
delivery systems or by modifying the molecular structure and/or physiological parameters 
inherent in a selected route of administration [7] . It is thus desirable that the duration of 
drug action becomes more a design property of a rate-controlled dosage form and less a 
property of the drug’s inherent kinetic properties.  
2.2 Polymers in Controlled Delivery Systems  
Polymeric controlled delivery systems can be classified according to their major 
rate controlling mechanism: diffusion, swelling, erosion or chemical reactions and 
osmosis controlled process. The classification of a device into any of these categories is 
determined by the nature of the interaction between the polymeric systems and 
environmental fluid [8, 9].  
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 A device is considered to be diffusion controlled if the diffusion of the active 
agent through any part of the device controls the release rate. The major types of 
diffusion controlled devices are reservoir devices and monolithic devices. Reservoir 
devices usually consist of a core of an active agent surrounded by a polymeric membrane 
(Figure 2.2 A). The penetration of a solvent, usually water, into the device initiates the 
drug release through diffusion process. Diffusion of drug molecules through non-porous 
polymer membranes depends on the size of the drug molecules and the spaces available 
between the polymer chains. In monolithic or matrix devices, the active agent is 
distributed in a polymer matrix as a separate phase or dissolved in the polymer (Figure 
2.2 B). Regardless of the physical state of a given drug in the matrix, the release rate 
normally decreases over time. Initially, drug molecules closest to the surface are released. 
As release continues, drug molecules have to travel a greater distance to reach the 
exterior of the device and thus increase the time required for release, which leads to a 
decrease in the release rate from the device with time. It is generally easier to fabricate a 
matrix type device than a reservoir system. However, if drug release profile is the main 
concern, then a reservoir system may be chosen in preference, as it can provide zero-
order release.  
 In erosion or reaction controlled delivery systems, the polymer is not merely a 
passive carrier but an active participant in the release process. The active agent in an 
erosion controlled device is physically immobilized in the polymer and is only released 
via erosion of the polymer (Figure 2.2C). As the diffusion controlled systems, erosion 
controlled systems can be fabricated into reservoir and monolithic forms, however, the 
monolithic forms are more suitable for the purpose of erosion control.  
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 Swelling controlled delivery systems are devices which control or influence drug 
release by polymer morphology change through interaction with the release medium 
(Figure 2.2D). The drug incorporated in this type of systems can not diffuse to any 
significant extent in the initial form. When the matrix is placed in an environmental fluid, 
if the medium is not thermodynamically compatible with the polymer, the morphological 
structure is time independent and the release from the device is diffusion controlled. If 
the medium is thermodynamically compatible with a polymer in the glassy state, the glass 
transition temperature of the polymer will be lowered below the system temperature, 
leading to a glass-to-gel transition. The polymer chains in the gels state are more flexible 
than those in the glass state, resulting in a more rapid release of the incorporated drugs. A 
swellable controlled release system can consist of a hydrophilic polymer that undergoes 
swelling continuously throughout the matrix or exhibiting spatially discontinuous 
swellings. If chain relaxation and swelling are not restricted, the polymer matrix will 
eventually dissolve at the end of glass-to-gel transition. To solve this problem, the 
polymers can be chemically or physically crosslinked with the crosslinking points serve 
as permanent bonds holding the matrix together.   
2.3 Hydrogels  
Hydrogels are three-dimensional, hydrophilic polymeric networks capable of 
absorbing and retaining different amounts of water or biological fluids. The networks are 
insoluble due to the presence of chemical crosslinks (junctions, tie-points) or phys ical 
crosslinks (crystallites, entanglement), which permit hydrogels to be thermodynamically 
compatible with water and swell in aqueous media [10]. As a result, in comparison to 
other synthetic materials, hydrogels resemble nature living tissue closely in their physical 
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properties due to their high water contents and soft, rubbery elastic consistency, which 
also contribute to their biocompatibility. The properties of hydrogels, such as water 
contents, permeability and mechanical strength, can be tailored for particular application 
of choice, and thus make hydrogels competitive candidates as biomaterials for tissue 
repair or replacement and as devices of controlled drug delivery.   
2.3.1 Evaluation of Hydrogel Network  
The suitability of hydrogels as drug delivery devices and their performances in a 
particular application depend on their bulk structures. The most important parameters 
used to characterize the network structure of hydrogels are the polymer volume fraction 
in the swollen state ( 2,su ), the average molecular weight of the polymer chains between 
crosslinks ( cM ), and the corresponding mesh size (x ) (Figure 2.3). The polymer volume 
fraction in the swollen state is a measure of the amount of fluid absorbed and retained in 
the hydrogel network. The molecular weight between crosslinks (either chemical or 
physical) can represent the degree of crosslinking of the hydrogel network. The 
corresponding mesh size provides an estimation of the space available between the 
macromolecular chains for diffusion of drugs. These parameters, which are related to one 
another, can be determined theoretically or through the experimental techniques, among 
which, the equilibrium swelling theory and the rubber elasticity theory have been 
frequently used to evaluate the hydrogel structures.  
 The structure of hydrogels that do not contain ionic moieties can be analyzed 
using the Flory-Rehner theory [11]. This thermodynamic theory states that a crosslinked 
polymer gel, which is immersed in a fluid and allowed to reach equilibrium with its 
surroundings, is subject only to two opposing forces, the thermodynamic force of mixing 
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and the retroactive force of the polymer chains. At equilibrium, the increase of elastic 
energy of the chains forming the network balances the decrease in the mixing energy. 
This leads to an expression to determine the molecular weight between two adjacent 
crosslinks of a neutral hydrogel network prepared in the absence of a solvent [12]: 
( ) ( ) 21 2 2 1 2
1 3 2
2
11 2
2
,s ,s ,s
,sc n
,s
/ V ln -
-
M M -
é ù+ +ë û=
u u u c u
u
u
      (2.2)
 Here, nM  is the number-average molecular weight of the primary chains, u  is 
the specific volume of bulk polymer in the amorphous state, V1 is the molar volume of 
water, 2,su  is the equilibrium volume fraction of the polymer, and 1c  is the Flory 
polymer-solvent interaction parameter.  
The above expression was modified by Flory for the case of a swollen network 
where the crosslinks were introduced into the polymer which was already in the solution 
state and which has a volume fraction 2,ru  after the crosslinking process but prior to the 
equilibrium with the surrounding solvent. The presence of water effectively modifies the 
change of chemical potential due to the elastic forces. In this case, the molecular weight 
between crosslinks in presence of water is [13]: 
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Here, 2,ru  is the polymer volume fraction in the relaxed state, which is defined as 
the state of the polymer immediately after crosslinking but prior to swelling.  
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Hydrogels resemble natural rubbers in their ability to respond to applied stress 
elastically. Hydrogel networks subjected to a relatively small deformation (less than 20%) 
can fully recover to their original dimensions rather rapidly. This elastic behavior of 
hydrogels can be employed to estimate their structures using the rubber elasticity theory. 
When an initially unswollen, crosslinked polymer network is first swollen, the volume 
fraction of polymer decreases to 2u . The tensile stress t expressed as force per unit area 
of the swollen unstretched sample, is related to the extension ratio a  [14]: 
1 3
22
2
1-
-1
c
nc
MRT
MM
æ ö
= ç ÷
è ø
t
u
a a u
             (2.4) 
For the case that the polymer is initially prepared in presence of a solvent, the 
above expression was modified by Peppas and Merrill [12]: 
1 3
2,
2,2
2,
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r
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= ç ÷ç ÷ ç ÷è ø è ø
ut
r
a a u
                        (2.5) 
Here, 2,rr  is the density of the polymer in the relaxed state, immediately after 
crosslinking but prior to swelling, 2,ru  and 2,su  have the meanings as defined earlier, R 
is the universal gas constant, T is the absolute experimental temperature.  
For the analysis based on the equilibrium swelling theory, no experiments are 
required if the Flory polymer-solvent interaction parameter c  is known. However, the  
value of c  is usually obtained from literature values where conditions may vary from 
experiment to experiment. On the contrary, all the parameters involved in the rubber 
elasticity theory can be determined through experiments on site. The experiments for
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the structure analysis usually include tensile testing and equilibrium swelling studies. The 
tensile testing offers information on the stress-strain behavior for the left side of Equation 
2.5. The polymer volume fraction in the swollen state, 2,su , is usually calculated as the 
inverse of the volume swelling ratio which is determined from swelling studies: 
1
2
0
gel-
,s
V
Q
V
= =u                    (2.6) 
 Here, Vgel is the volume of the swollen polymer, and V0 is the volume of the 
polymer before swelling. The polymer volumes are determined through weight 
measurement on a balance equipped with a density determination accessory. A 
nonsolvent, normally heptane, is used in the experiment. The volume of the polymer is 
calculated based on the buoyant theory: 
air hep
hep
W -W
V =
r
        (2.7) 
 Here, Wair is the weight of the polymer measured in air, Whep is the weight of the 
same polymer measured in heptane, and hepr  is the density of heptane (0.684 g/mL). 
The above equation can be used to calculate both Vgel and V0. Therefore, the volume 
swelling ratio, Q, can be calculated as: 
air hep gel
air hep 0
(W -W )
Q=
(W -W )
         (2.8) 
 If the polymer is stable over the period of swelling studies, the experiment can be 
simplified that the density determination accessory is only used for the determination of 
dry polymer volume. Q can be calculated as: 
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r
r
         (2.9) 
 Here, pr   is the density of the dry polymer and wr  is the density of the solvent. 
The assumption here is that the polymer does not dissolve in the solvent and its weight 
remains constant during the swelling process.  
2.3.2 Power Law  
With the advance of controlled release polymeric systems for the delivery of 
therapeutic agents at desired rate and duration, numerous empirical or theoretical models 
have been developed to describe and estimate the release of the incorporated drugs from 
the polymer matrix. Among the variety of models, power law, a simple yet 
comprehensive, semi-empirical equation has been widely used due to its simplicity and 
acceptable accuracy: 
ntM =kt
M¥
        (2.10) 
Here,  tM  and M¥  are the absolute cumulative amount of drug released at time t 
and infinite time, respectively; k is the kinetic constant incorporating structural and 
geometric characteristics of the device, and n is the release exponent, indicative of the 
mechanism of drug release.  
The drug release rate can be calculated from Equation 2.10: 
n-1t
0
dM
=nC kt
A dt×
       (2.11) 
Consider a thin polymer film undergoing drug release under Case-II transport, a 
process with very rapid diffusion compared with the relaxation process. The fractional 
drug release can be written as [15]:  
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0
0
2tM k t
M C l¥
=        (2.12) 
Here, k0 is the Case-II relaxation constant, C0 is the initial drug concentration, and 
l is the half thickness of the film. With K=2k0/C0l, Equation 2.12 expresses a zero-order 
release process with n=1. In the relaxation process, the polymer chains movement occurs 
with water imbibition into the system, and serves as the rate control step in the drug 
release process, and the release thus is the swelling controlled. Water acts as a plasticizer 
and decreases the glass transition temperature of the polymer. Once the glass transition 
temperature equals the temperature of the system, the polymer chains undergo the 
transfer from the glassy to rubbery state, in which process the mobility of the chains and 
volume expansion increase, leading to the release of incorporated drugs.  
For the case of diffusion controlled release from a monolithic system, the release 
is given in the form of an error function series [16]: 
( )
1 2
n-1 2t
2
n=1
M D t n
= 4 p + 2 -1 ierfc
M 2 D t
¥
¥
ì üæ ö× dï ï
í ýç ÷ ×dè ø ï ïî þ
å    (2.13) 
As the error function vanishes at short times, a sufficiently accurate expression 
can be obtained when the total release is less than 60% (Mt/ M¥  <60%) [17]: 
0.5
0.5t
2
M D t
=4 =K t
M pl¥
æ ö×
×ç ÷
è ø
           (2.14) 
Here, K is a constant as the diffusivity of the drug is assumed to be constant. 
Therefore, plots of the initial drug release verses the square root of release time should 
give a linear curve. Comparing Equation 2.14 to Equation 2.10, one can see that when 
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n=0.5 in Equation 2.10, the two expressions are identical. Hence, the value 0.5 for the 
exponent n stands for diffusion controlled release for thin films in power law.  
As discussed above, the power law expression (Equation 2.10) has two distinct 
physical realistic meanings in two special cases: n=0.5 for diffusion controlled release 
and n=1 for swelling controlled release. Therefore, the values of n can offer the 
information on the mechanisms of a given drug delivery system. For the cases of n 
between 0.5 and 1, anomalous transport is obtained with both diffusion and swelling 
affecting the drug release at a comparable level. The values of n discussed so far are only 
for slabs with the aspect ratio at least 10/1 (length/thickness or width/thickness) [18]. The 
power law can also be applied to devices of cylindrical and spherical shapes with varied 
values of n based on the geometry. Ritger and Peppas [17] applied the power law for first 
60% release from cylindrical and spherical systems, and derived values of n for diffusion-
controlled and swelling-controlled cases, respectively. The values of three common 
systems are listed in Table 2.1. Therefore, when using the power law to estimate the 
release mechanism of the drug from a polymeric system, the dependency of n values on 
geometries should also be considered.  
2.4 Polyvinyl Alcohol (PVA) and Crystalline Analysis 
PVA is produced by polymerization of vinyl acetate to polyvinyl acetate (PVAc) 
followed by hydrolysis of PVAc to PVA [19]. The hydrolysis reaction does not go to 
completion, and thus PVA is always a copolymer of PVA and PVAc. The content of 
acetate groups affects the properties of PVA, such as water solubility and the crystallinity 
of PVA [20]. This is due to the bulky acetate groups hinder the formation of intra- and 
inter-molecular hydrogen bonds in PVA. It has shown that the solubility of PVA in water 
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decreases as increasing the degree of hydrolysis. As a result, PVA with high degree of 
hydrolysis above 90% normally needs to be heated to a temperature above 80 ºC to 
dissolve in water [21].  
In order to form hydrogels, PVA has to be crosslinked to become suitable 
hydrogels. PVA hydrogels can be formed through chemical crosslinking with 
crosslinking agents, such as glutaraldehyde, acetaldehyde and other monoaldehydes [22-
24]. When these crosslinking agents are used in the presence of sulfuric acid, acetic acid, 
or methanol, acetal bridges will form between the hydroxyl groups of PVA. However, the 
residual amounts of these toxic agents are present in the hydrogel network after the 
reaction. The extraction process to remove the toxic residue is usually time-consuming, 
and thus not desirable for biomedical applications. Another method that researchers use 
to generate PVA hydrogel networks is g -irradiation [25, 26]. This method does not 
involve any toxic crosslinking agents. However, one problem associated with this method 
is bubble formation, which brings difficulties to control the hydrogel structures [27]. 
Interestingly, researchers found the formation of crystallites during the dehydration and 
annealing of chemically crosslinked PVA gels [28]. The crystallites served as crosslinks 
in addition to the ones formed through g -irradiation. Therefore, a physical crosslinking 
method, which involves in crystallite formation, became popular over the chemical 
methods in recent studies [29]. The hydrogel is obtained by physical crosslinking due to 
formation of crystallites, which serve as crosslinks and hold the hydrogel structure 
together (Figure 2.4). This method addresses toxicity issues as no crosslinking agents are 
required for the formation of hydrogels, resulting in a 3-D hydrogel network with no 
residues of toxic agents present.  
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2.4.1 Semicrystalline PVA  
On a molecular level, the crystallites of PVA can be described as a layered 
structure [30]. A double layer of molecules is held together by hydrogen bonds while 
weaker van der Waals forces operate between the double layers [31, 32]. A folded chain 
structure of PVA chains leads to crystallites, which are small, ordered regions, in an 
unordered, amorphous polymer matrix [32]. In contrast to crystalline of low molecular 
weight compounds which melt at exact temperatures, polymers with high molecular 
weight have a wider range of melting temperatures. This behavior is due to the crystallite 
size distribution in semi-crystalline polymers [33]. Crystallites with small dimensions 
melt at lower temperature, compared to larger crystallites. As a result, the melting of 
PVA occurs over a range of temperatures as the crystallites vary in size [34, 35]. The 
reported crystalline melting range of PVA is between 220 and 240°C. The high melting 
temperature is a result of the high level of hydrogen bonding in the crystalline regions. 
Assender et al. [36] stated that there are opportunities for hydrogen bonding formation 
every second carbon atom for high degree of hydrolyzed PVA. The water solubility of 
PVA is also governed by hydrogen bonding. The polymer will not dissolve until the 
crystalline structure is broken down with the polymer-polymer hydrogen bonds replaced 
with polymer-water hydrogen bonds.  
Semicrystalline PVA is characterized by the degree of crystallinity, which is 
defined as the ratio of the volume of PVA crystallites to the total volume of the polymer. 
Density measurements, calorimetric methods, spectroscopic methods, and X-ray analysis 
have been used to determine the degree of crystallinity of PVA hydrogels [37].  
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The calculation of degree of crystallinity using density measurements is based on 
the principle of additivity of volumes and densities of crystalline and amorphous PVA. It 
also assumes that the network is absent of voids or other imperfections. The degree of 
crystallinity of PVA on a dry basis is then calculated as [38]: 
1 1-
g c a
X X
= +
r r r
      (2.15) 
Here, X is the degree of crystallinity, gr  is the density of the sample, cr  and ar  
are the densities for 100% crystalline and 100% amorphous PVA, respectively. The 
density of the sample can be measured using the density determination experiment.  
Calorimetric methods can also be used to determine the crystallinity of PVA 
hydrogels. The methods include differential thermal analysis (DTA), differential 
scanning calorimetry (DSC), and thermogravimetric analysis (TGA). DSC is the most 
commonly used method. The degree of crystallinity is calculated as the ratio of the 
melting enthalpy of a PVA sample ( HD ) to the melting enthalpy of 100% crystalline 
PVA ( cHD ): 
(%) 100%
c
H
X
H
D
= ´
D
       (2.16) 
The melting of PVA occurs over a range of temperatures due to the crystallite size 
distribution. Crystallites with small dimensions melt at lower temperature, compared to 
larger crystallites. Therefore, the calorimetric methods can also offer information on 
crystallite size distributions. 
Infrared (IR) spectroscopy has been used to determine PVA crystallinity. The 
intensity of the peak at 1141 cm-1 in the IR spectrum of PVA is related to the degree of 
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crystallinity [39]. It was proposed to be a C-C stretching mode and increase with 
increasing the degree of crystallinity. Peak heights obtained from ATR-FTIR spectra 
have been used to calculate crystallinity of PVA. The height of the 1141 cm-1 peak was 
analyzed in terms of the height of the peak at 854 cm-1 [39] or 1425 cm-1 [40] which 
remain constant.  
A comparison of these three methods for the determination of the degree of 
crystallinity of PVA was obtained from Peppas and Hassan’s work [1] (Table 2.2). The 
values of the degree of PVA crystallinity obtained in the three different methods were in 
good agreement. 
2.4.2 Application of PVA Hydrogels  
Polyvinyl alcohol (PVA) hydrogels have been studied for numerous biomedical 
and pharmaceutical applications due to the advantages of non-toxic, non-carcinogenic 
and bioadhesive properties. Oka et al. [41] discussed the clinical implications of the 
possible use of polyvinyl alcohol hydrogel in articular resurfacing and joint replacement, 
and they found that the hydrogel composite replacement caused minimal damage 
compared to the implants made of aluminum and titanium. Previous studies by Morimoto 
et al. [42] have shown that several drugs such as glucose, insulin, heparin and albumin 
can be released from PVA gels.  
Different types of model drugs have been incorporated into PVA hydrogel 
networks through freeze-thawing method, including bovine serum album (BSA) [37], 
theophylline [43, 44], oxprenolol [44], and miconazole [45].  
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2.5 Polyvinyl Pyrrolidone (PVP) 
Polyvinyl pyrrolidone (PVP) is a highly amorphous polymer with a glass 
transition temperature around 150°C [2, 46, 47]. It is synthesized through polymerization 
of the monomer N-vinyl-2-pyrrolidone. PVP readily dissolves in water at room 
temperature due to the formation of strong hydrogen bonds between its carbonyl groups 
with water molecules.  
 Povidone is the generic name for PVP, and was evaluated for acceptable daily 
intake for man (ADI) by the Joint FAO/WHO Expert Committee on Food Additives 
(JECFA) [48]. No carcinogenicity has been reported for povidone as a consequence of 
oral administration. PVP has applications in controlled release pharmaceutical devices 
and blood substitute/preservative. During World War II, PVP was used extensively as a 
blood plasma substitute in Germany, and is still used as a blood plasma substitute for 
emergency use in some countries [49].  
Due to its pharmacologically inert and non-toxic properties, PVP has been used as 
solid dispersion to enhance dissolution rates of hydrophobic drugs [50-54]. For drugs 
with poor water solubility, the absorption rate is limited by dissolution, and thus the 
bioavailability of the drugs is limited. The commonly used methods to improve the 
bioavailability involve reduction of particle sizes and using the water-soluble salts of the 
poorly soluble compounds. However, the fine particles with reduced size may not 
produce desired fast dissolution and absorption rate due to the possible aggregation of the 
particles, which is a result of increased surface energy and stronger van der Waal’s forces 
between the nonpolar molecules. The water-soluble salts of many poorly soluble acidic or 
basic drugs have been shown to produce better absorption than their parent forms. 
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However, it has been shown that the potassium or sodium salts may react with 
atmospheric carbon dioxide and water to precipitate out the parent compounds, which 
normally occur on the outer layer of a dosage form to retard the dissolution and 
absorption [55]. As a result, an approach of solid dispersion has been adopted to reduce 
the particle size and thus increase the bioavailability of poorly water-soluble drugs. The 
increased dissolution rate using the solid dispersion is attributed to the reduction of 
particle size of the drug within the dispersions and increased wettability using water-
soluble substances as carriers. PVP has been used to solubilize many drugs, including 
sulphoamides, hypoglycemics, steroids, antimicrobials [56]. The nabilone-PVP 
formulation has been marketed under the trade name of Cesametâ by Eli Lily.  
 PVP was also used to modify the surfaces of catheter materials with reduced 
bacterial adhesion and less encrustation [57, 58] due to its hydrophilic property. When 
indwelling urethral stents and catheters are placed in contact with urine, microbial 
biofilms and encrustation tend to form on the interface, which leads to obstruction of 
urine flow with discomfort for patients. Therefore, the application of hydrophilic 
hydrogel coatings which render the material surface unattractive to bacteria and 
encrusting deposits might be the solution. PVP has been studied in this regard by 
different research groups. Tunney et al. [58] reported that the adherence of hydrophobic 
Enterococcus faecalis isolate to the PVP coated polyurethane was significantly less than 
adherence to uncoated polyurethane. They also showed that the surface of PVP coated 
polyurethane was only partially covered by encrusting deposits, comparing to the 
complete coverage of uncoated polyurethane surface after 6 weeks. Bridgett et al. [59] 
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showed that the PVP coated silicone significantly reduced the adherence of five strains of 
Staphylococcus epidermidis and one strain of Staphylococcus aureus. 
2.6 Polymer Blending 
Polymer blends are produced by physical mixing of two or more existing 
polymers. It is a convenient route to develop new polymeric materials, which combine 
the properties of more than one existing polymer. This strategy is usually cheaper and 
less time-consuming than the development of new monomers and/or new polymerization 
routes. A wide range of material properties can be obtained by merely changing the blend 
composition. The market for polymer blend based materials has increased continuously in 
the past two decades, and is expected to increase by 8-10% in the coming decade [60].  
2.6.1 Blends Miscibility  
 Polymer blends are either homogeneous or heterogeneous. In homogeneous 
blends, both blend components lose part of their identity and the final properties usually 
are the arithmetical average of both blend components. In heterogeneous blends, on the 
other hand, the properties of all blend components are present.  
Homogeneous miscibility in polymer blends requires a negative free energy of 
mixing [61]: 
-mix mix mixG H T SD = D × D       (2.17) 
When two polymers are mixed together, due to their high molecular weight, the 
entropy of mixing, mixSD , is negligible. The free energy of mixing, mixGD , can only be 
negative if the enthalpy of mixing, mixHD , is negative, which means the mixing must be 
exothermic. Exothermic mixing requires specific interactions between the blend 
components. These interactions may range from strongly ionic to weak and nonbonding 
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interactions, such as hydrogen bonding, ion-dipole, dipole-dipole and n- p  complexes. A 
well known example of compatible blends is polystyrene/ poly (dimethylphenylene oxide) 
(PS/PPO), which is miscible over a wide temperature range and in all compositions [62]. 
The PS/PPO blends combine the heat resistance, the inflammability and the toughness of 
PPO with the good processability and the low cost of PS [63]. The most commonly used 
criterion to determine the homogeneity of two polymers is the existence of a single glass 
transition temperature for the blends, which is usually between the two glass transition 
temperatures of the blending polymers [64-66]. 
When a semicrystalline polymer and an amorphous polymer form miscible blends, 
the melting temperature of the semicrystalline polymer will be depressed due to the 
presence of the amorphous polymer [60, 61, 67, 68]. This depression behavior of the 
crystalline component has been widely used to study interactions between the polymer 
segments. The data obtained in the studies are usually analyzed in terms of the equation 
derived by Nishi and Wang [69]: 
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Here, the subscript 1 is the amorphous polymer and 2 crystalline polymer; Vi is 
the molar volume of the repeating unit of polymers; Mi is the degrees of polymerization; 
iF  the volume fractions; DH2 is the enthalpy of fusion per mole of repeating unit of the 
pure crystalline; Tm and Tmo are the equilibrium melting temperatures in the blend and in 
pure crystalline polymer, respectively. 12c  is the Flory-Huggins interaction parameter. 
For polymers, M1 and M2 are both of large values. The left-hand side of the above 
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equation becomes a linear function of 21F  . Therefore, the value of 12c  can be 
determined.  
The Flory-Huggins interaction parameter is associated with the enthalpy of 
mixing. A negative 12c  usually means exothermic mixing, which indicates the 
crystalline-amorphous polymer pair is thermodynamically miscible [11]. 
2.6.2 Blends of PVA/PVP  
PVA is a semicrystalline polymer with a melting temperature about 230°C, and a 
glass transition temperature about 80°C [70]. PVP is a highly amorphous polymer with a 
glass transition temperature around 150°C [46]. Homogeneous polymer blends can be 
formed with these two polymers due to the formation of hydrogen bonds between the 
PVA hydroxyl group and the PVP carbonyl group (Figure 2.5). The presence of hydrogen 
bonds in PVA and PVP blends was confirmed with Fourier transform infrared 
spectroscopy [68, 71] and high-resolution solid-state 13C nuclear magnetic resonance [72].  
A single glass transition was reported by several groups based on differential scanning 
calorimetry data [2, 46, 47, 68, 73], indicating PVA and PVP formed homogeneous 
blends.  
For the case of blends prepared from a semicrystalline polymer and an amorphous 
polymer, the melting temperature of the semicrystalline polymer as well as the degree of 
crystallinity will be depressed [61, 74]. The melting temperature of PVA was reported to 
be depressed systematically with an increase in PVP content using differential scanning 
calorimetry, and negative values of the Flory-Huggins interaction parameter 12c  were 
calculated to be -0.35 at 240°C [2] and -0.52 at 230°C [68]. The degree of crystallinity of 
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PVA was reported to decrease with increasing content of PVP using both wide-angle X-
ray diffraction (WAXD) [2] and small-angle X-ray scattering [3]. Nishio et al.. further 
confirmed that no crystallites formed in blends containing more than 60 wt% PVP [2].  
While significant work has been done to understand the miscibility of PVA and 
PVP blends, no work has focused on synthesis or application of these PVA/PVP blends 
as biomaterials. The purpose of the first part of this research is to synthesize hydrogels 
from PVA/PVP blends that contain physical crosslinks consisting of PVA crystallites and 
PVA/PVP hydrogen bonds. Additionally, we intend to study the structure and properties 
of the swollen networks in vitro. As PVA and PVP are both biocompatible, these new 
hydrogels may have promising characteristics that could make them candidates for 
biomaterial applications such as controlled drug delivery. 
2.7   Biodegradable Polymers  
2.7.1 Polymer Properties 
Biodegradable microparticles fabricated from natural and synthetic polymers have 
been extensively investigated as drug carriers in controlled drug delivery. Natural 
biodegradable polymers such as bovine serum albumin (BSA), human serum albumin 
(HSA), collagen, gelatin and hemoglobin have been studied for drug delivery. However, 
the use of these natural polymers is usually limited due to questionable purity (different 
origins from natural sources) and sometimes requirement of chemical crosslinking, which 
leads to denaturation of incorporated drugs [73]. Synthetic degradable polymers, on the 
other hand, are free from most of the problems associated with the natural polymers. 
Polyamides, poly (acrylamides), poly (alkyl-a-cyanoacrylates), polyesters and 
polyurethanes have been used as various drug carriers. Among them, the linear aliphatic 
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polyesters like polylactide (PLA), polyglycolide (PGA)  and their copolymer poly 
(lactide-co-glycolide) (PLGA) have been widely investigated due to their excellent 
biocompatibility and biodegradability [75].  
These polymers are prepared from lactide and glycolide, which are cyclic esters 
of lactic and glycolic acids. Polymers with low molecular weight (less than 20,000) are 
directly synthesized from lactic acid and glycolic acid via condensation. Polymers with 
high molecular weight (> 20,000) are prepared through ring-opening polymerization [76]. 
Polyglycolide (PGA) is a hard, tough, crystalline polymer with a melting 
temperature of 215-230°C and a glass transition temperature of 35-40°C [77]. Due to its 
high degree of crystallization (45-55%), PGA is not soluble in most organic solvents [78]; 
the exceptions are highly fluorinated organics such as hexafluoroisopropanol (HFIP) [79]. 
PGA has excellent fiber- forming properties and was marketed as the first synthetic 
absorbable suture as DexonTM by Davis and Geck, Inc. in 1960s [80]. However, fibers 
from PGA exhibit high strength and modulus and are too stiff to be used as sutures except 
in the form of braided material. Sutures of PGA lose about 50% of their strength after 2 
weeks and 100% at 4 weeks, and are completely absorbed in 4-6 months [81]. However, 
the low solubility and high melting temperature of GA limits its use for drug delivery 
applications, as it is difficult to make film, capsules or microspheres through solvent or 
melt techniques[82].   
Polylactide (PLA) can exist in an optically active L-form, or an optically inactive 
racemic D, L-form. L-PLA is naturally occurring and semicrystalline due to its 
steroregular structure. It is a relatively hard material of 37% crystallinity with a melting 
temperature in the range of 170-180°C and a Tg of 55-64°C [83, 84]. Polymerization of 
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the diasteroisomer (D, L-lactide) or a racemic mixture of D-, and L- lactide yields an 
amorphous poly (D, L-lactide), which has a Tg around 50-60°C [85, 86]. D, L-PLA is 
soluble in halogenated solvents, ethyl acetate, tetrahydrofuran (THF), acetone, and HFIP; 
while L-PLA is only soluble in halogenated solvents and HFIP due to its semi-crystalline 
nature [87]. Therefore, the application of D, L-PLA is wider than L-PLA in the field of 
controlled drug delivery, due to its ease of fabrication and capability of generating more 
homogeneous dispersion of drugs in polymer matrix.  
PLGA is synthesized through ring opening polymerization of glycolide and 
lactide with different ratios of the two monomers [88]. PLGA prepared from L-PLA and 
PGA is crystalline copolymers while those from D, L-PLA and PGA are amorphous in 
nature. However, PLGA containing less than 70% glycolide is amorphous due to the 
disruption of the regularity of the polymer chain by the other monomer [78]. It is 
important to note that there is not a linear relationship between the copolymer 
composition and the mechanical and degradation properties of the materials. PLGA 
containing 50:50 ratio of lactic and glycolic acids are hydrolyzed faster than those 
containing higher proportion of either of the two monomers [89].  A copolymer of 90% 
glycolide and 10% L-lactide was developed by Ethicon as an absorbable suture material 
under the trade name VicrylTM. It absorbs within 3-4 months but has a slightly longer 
strength-retention time [90].  
The degradation of PLGA both in vitro and in vivo is generally considered to 
undergo hydrolysis in presence of water through cleavage of its backbone ester linkages 
(Figure 2.6). The final products of PLA and PLGA degradation are lactic acid and 
glycolic acid, which are water soluble and non-toxic products of normal metabolism [89, 
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91-93]. Lactic acid can be excreted in the urine, or further metabolized by liver and 
expired as through lungs, as revealed in a study using 14C-labled PLA implant [94].  
Glycolic acid is either excreted unchanged in the kidney or enters the tricarboxylic acid 
cycle and eventually metabolized by liver into water and carbon dioxide [95, 96]. 
Therefore, the polymers are considered as biocompatible and suitable for applications as 
biomedical devices and drug delivery systems.  
2.7.2 Fabrication of Microparticles  
 Biodegradable microspheres produced from a variety of synthetic and natural 
polymers may provide a continuous or pulsatile release of incorporated therapeutic agents 
over a period of weeks or months  [75, 97, 98]. The process that one chooses to produce 
these microparticles depends on the properties of incorporated drugs so that the stability 
and biological activity of the drug are not adversely affected during the fabrication 
process. The production technique also depends on the properties of the polymers which 
serve as the matrix for the drugs, such as the solubility of the polymer in solvents will 
affect the choice of the types of organic solvent and even the following procedure. In this 
section, the techniques used in the fabrication of microparticles are discussed. 
 The solvent evaporation method is the most popular method to produce 
microparticles due to their relative ease of processing [99-102]. This technique includes a 
variety of processes that involves either single or multi-emulsion with different types of 
solvents. The most commonly used single emulsion process is oil- in-water (O/W) 
emulsion [103-105]. In this process, the polymer is first dissolved in a water immiscible, 
volatile organic solvent, and the drug is then added to the polymer solution to produce a 
solution or dispersion of drug particles. If dispersion of drug particles is used, the particle 
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size should be smaller than 20µm [93]. The resultant solution or dispersion is then 
emulsified in an aqueous continuous phase to form discrete droplets. The emulsion is 
then subjected to solvent removal by either evaporation or extraction process to harden 
the oil droplets. In solvent evaporation process, the emulsion is maintained at either 
reduced pressure or at atmospheric pressure with stirring rate reduced so that the volatile 
solvent can evaporate [106]. In solvent extraction process, the emulsion is transferred to a 
large quantity of water with or without surfactant or other quench medium, which should 
extract the organic solvent from oil droplets and not affect the polymer or drug [107]. 
After the solvent removal process, the microparticles can be obtained after suitable 
filtration, sieving or centrifugation.  
The rate of solvent removal from the emulsion affects the properties of the 
microparticles and thus affects the release of incorporated drugs. Rapid solvent removal 
may cause local explosion inside the droplets and result in porous or even irregular 
structures, leading to fast drug release from the microparticles [107-109]. The rate of 
extraction depends on the temperature of quench medium, ratio of emulsion volume to 
quench medium volume, the solubility of polymers in the solvent and the quench medium, 
and the solubility of solvent and quench medium in each other, if other conditions are 
fixed. The rate of evaporation also depends on the pressure, temperature, solubility of 
solvent and the continuous phase [97]. Therefore, both solvent evaporation and extraction 
involve the diffusion of the organic solvent from the oil droplets to the external aqueous 
phase before it can evaporate off the system. The extraction process just introduces larger 
amount of the aqueous phase so that the organic solvent would diffuse out of the oil 
droplets faster and thus shorten the duration of the evaporation.  
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One of the disadvantages of the oil- in-water emulsion is low loading efficiency 
for incorporation of water-soluble drugs [95, 106, 110]. During the emulsion and solvent 
removal processes, water-soluble drugs tend to diffuse out or partition from the dispersed 
oil phase in to the continuous aqueous phase and microcrystalline fragments of the 
hydrophilic drugs tend to deposit on the surface of the microparticles [111, 112]. This 
would lead to rapid release of drugs or ‘initial burst’. Therefore, the oil- in-water emulsion 
is normally used to incorporated hydrophobic drugs.  
In order to increase the incorporation efficiency of water soluble drugs, an oil- in-
oil emulsion has been adopted to incorporate water soluble drugs, such as timolol maleate 
[113], glycine and its homopeptides [114] and even proteins like bovine serum albumin 
(BSA) [115]. In this process, a water-miscible organic solvent like acetonitrile is 
employed to dissolve the drug and the polymer. The solution is then dispersed in to an oil 
phase such as light mineral oil in presence of an oil soluble surfactant like Span to yield 
the emulsion. Microparticles are obtained by removal the organic solvent and the oil is 
washed off by solvents like n-hexane, in which the polymer does not dissolve. The 
elimination of water significantly reduces the tendency of drug partitioning into the 
continuous phase.  
A more commonly used method to incorporate water soluble therapeutic agents, 
such as peptides, proteins and vaccines [116-118], into microparticles is multiple 
emulsion. In this process, protein is first dissolved in a buffered solution and added to an 
organic phase containing PLA/PLGA to form the first w/o emulsion by ultrasonication 
for a short period on the order of seconds. The primary emulsion is then added into a 
large volume of water containing emulsifiers to form the w/o/w emulsion. The emulsion 
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is also subjected to solvent removal to harden the particles. A number of hydrophilic 
drugs have been incorporated into PLA/PLGA microparticles using this technique. An 
excellent example of using double emulsion to produce PLA/PLGA microparticles is the 
commercially available Lupron Depotâ from Takada, which contains a peptide, 
leuprolide, in PLGA microparticles for a sustained release over one month period [119].  
Although leuprolide has been successfully incorporated into PLGA microparticles 
using the solvent evaporation technique through w/o/w emulsion, the water-solvent 
interface has been a major stress factor resulting in protein adsorption, denaturation and 
aggregation for less stable proteins [120, 121]. In this regard, a solid-in-oil- in-water 
(S/O/W) emulsion method involving disperse fine protein particles in PLGA solvent 
solutions as protein unfolding is extremely slow in organic solvents [122, 123]. Takada et 
al.. [124] produced PLGA microparticles containing rhGH using DCM as the solvent. 
The rhGH particle size was 2.8-11.8 µm and the ensuing PLGA microparticles were 35-
40 µm with loading efficiency of 91-95%.  
An alternative method to produce microparticles is spray drying, which is 
preferred in industrial field [125-127]. In this process, a solution of polymer and drug is 
sprayed into a heated nozzle, and the organic solvent is rapidly evaporated by a hot gas 
flow. This method offers the advantage of allowing considerable control of the particle 
size by altering the flow rate and ease to scale-up. Chaw et al. [128] reported increased 
encapsulation efficiency of physostigmine, an anti-cholinesterase, in PLGA 
microparticles less than 5 µm with varied LA: GA ratios using spray drying technique 
(>93%) than the conventional single emulsion process (<23%). Wagenaar et al. [129] 
incorporated piroxicam into PLA microparticles of 1-15 µm with high encapsulation 
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efficiency of 99%. However, the temperature involved in spray drying is usually around 
or even above 50°C, which may denature proteins even though the duration of exposure 
to the high temperature is often very short [123, 130]. A variation of the conventional 
spray drying is a low temperature spraying method, which has been used as ProLease® 
technique at Alkermes [131]. First, the protein powder and optional excipients are 
suspended in the PLA/PLGA solution in acetone, ethyl acetate or DCM. The suspension 
is then ultrasonically sprayed into a vessel containing liquid nitrogen overlaying a frozen 
extraction solvent (ethanol). During the evaporation of liquid nitrogen, the frozen ethanol 
melts and extracts the organic solvent from the droplets. The resulting microparticles are 
normally 50-60 µm in size with drug encapsulation more than 95% [132]. This technique 
has been used to prepare PLGA microparticles containing recombinant human growth 
hormone (rhGH) over a one month release period, which has been marketed under the 
trade name of NutropinTM Depot [123]. 
2.7.3 Degradation & Erosion of Biodegradable Systems 
The drug entrapped in biodegradable polymer matrix is released at a sustained 
rate controlled by the diffusion of the drug through the polymer matrix and degradation 
of the polymer matrix. Therefore, the degradation of the polymer matrix plays a cruc ial 
role in the release profile of a given drug.  
Degradations of polymers are the chemical reactions resulting in a cleavage of 
polymer backbone producing oligomers with shorter chain length, monomers and/or 
other low molecular weight degradation products [89, 91, 110]. A polymer is considered 
to be biodegradable if the degradation is due to environmental action, either by 
 
31 
bioprocesses, involving enzymes, bacteria or by chemical or radical processes alone, such 
as hydrolysis, oxidation, and UV irradiation [92].  
Erosion is defined as the physical disintegration of a polymer matrix as a result of 
degradation [133]. It is usually characterized as material loss from the polymer bulk. 
Depending on the erosion mechanism, polymers can undergo either surface erosion or 
bulk erosion (Figure 2.7). Hydrolysis starts with the intrusion of water into the polymer 
bulk. If water penetration is slow compared to the erosion process, mass loss is confined 
to the surface layers of the device only. The size of the device gradually decreases, while 
the bulk phase remains undegraded. Due to the difference in degradation rates between 
the surface and the center of the polymer matrix, the process is also termed as 
heterogeneous erosion [134].  
If hydrolysis is slow compared to water penetration, degradation will occur 
throughout the bulk polymer and is termed as bulk erosion or homogeneous erosion [135]. 
The polymers do not erode for long period of time, after which erosion begins 
spontaneously. The size of device remains constant even at late stages of degradation, 
while the micro-structure within the bulk changes considerably.  
Polymer characteristics play an important role in determination of which erosion 
process that the drug delivery system undergoes. However, the dimension and structure 
of delivery systems also determines the erosion process. Therefore, theoretically, all 
degradable polymers can undergo surface erosion or bulk erosion if they are constructed 
with the right size and structure. If water is readily able to penetrate the polymeric 
devices, the entire matrix is easily hydrated and the polymer undergoes bulk erosion. On 
the contrary, if water penetration into the center of the devices is limited, the erosion 
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front is restricted to the surface of the polymer matrix and the matrix undergoes surface 
erosion [134]. Normally, materials containing functional groups with short hydrolysis 
half lives tend to be surface eroding, such as polyanhydrides and poly (ortho esters). 
Grizzi et al. [136] studied the size dependence of hydrolytic degradation of devices based 
on PLA and PLGA. In vitro studies verified that a heterogeneous degradation (surface 
erosion) occurred in large size plates (15x10x2 mm) and microspheres of 500-1000 µm, 
and thin films of 300 µm thick and microspheres of 125-250 µm showed homogeous 
degradation. Spenlehauer et al. [137] also reported that microspheres smaller than 300 
µm in diameter exhibited a homogenous degradation with the rate of degradation of the 
core being equivalent to that at the surface. Burkersroda et al. [133] developed a 
theoretical model to predict the erosion mechanism of biodegradable polymer matrices. A 
critical device dimension Lcritical was calculated based on a dimensionless ‘erosion 
number’, e , whose value indicated the mode of erosion. When e > 1, the matrix will 
undergo surface erosion; when e <1, it will be bulk erosion. Based on the criteria, 
polyanhydrides, poly (ketal), poly (ortho esters) will undergo surface erosion, while poly 
(acetal), poly (e -carpolatone), poly (a -hydroxy esters) and poly (amides) will undergo 
bulk erosion. The values of critical device dimension Lcritical were also obtained. Below 
the critical dimension, a polymer matrix will undergo bulk erosion; while above the value, 
surface erosion will occur. Polyanhydrides were found to be surface eroding down to a 
size of 75 µm; while for polyesters, a device should be larger than 7.4 cm to undergo 
surface erosion. A figure of the critical thickness, Lcritical, which a polymer device has to 
exceed to undergo surface erosion, was obtained from their work [133] and shown in 
Figure 2.8. Therefore, drug delivery systems based on PLA and PLGA microspheres 
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would always undergo bulk erosion, which is characterized by a decrease in molecular 
weight and a constant mass over a long period and followed by a sudden mass loss. The 
degradation and erosion of PLGA delivery systems are thus proposed as a three stages 
mechanism. During the first stage, the molecular weight of the polymer decreases 
dramatically through random chain scission, but no significant mass loss and no soluble 
monomer products are formed. In the second stage, the decrease of molecular weight is 
followed by rapid mass loss and formation of soluble oligomers and monomers. In the 
last stage, the hydrolysis of soluble oligomers continues until the polymer is totally 
hydrolyzed to monomers [95].  
Factors affecting the hydrolysis of PLGA includes: water permeability, polymer 
composition, additives (drugs, solvents, etc.), crystallinity, device dimensions, porosity, 
molecular weight and distribution and site of implantation [96, 138, 139]. Among these 
factors, the polymer composition, or lactide to glycolide ratio is very important. As lactic 
acid is more hydrophobic than glycolic acid with the presence of a methyl group, lactide-
rich PLGA copolymers are less hydrophilic, absorb less water and subsequently degrade 
with a slower rate. Visscher et al.  reported the microparticles prepared using PLA 
exhibited extensive erosion at 360 days and breakdown at 480 days [140]; while for 
50:50 PLGA microparticles, the complete degradation occurred at 63 days with a half- life 
of 15 days [141], which is 50% loss of molecular weight. From one of the commercial 
manufacturer, a relation of degradation duration and different glycolide and lactide 
composition can be obtained (Figure 2.9). The polymer composition also affects the 
crystallinity of PLGA, as PLGA containing 25-70% glycolide was found to be 
amorphous in nature. The degree of crys tallinity of PLGA affects polymer degradation 
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through its effect on water uptake. PLGA with high degree of crystallinity resist to water 
intrusion more than the polymers with lower degree of crystallinity. For semi-crystalline 
polyesters, degradation first occurs in the amorphous domains and then the crystalline 
regions. During the degradation process, the crystallinity gradually increases resulting in 
a highly crystalline material. Therefore, post-fabrication treatments, such as heat or 
annealing or shelf time, would affect drug release [92, 96].  
The types of end groups and molecular weight of polyesters also play important 
roles in polymer degradation rate. Tracy and coworkers [142] from Alkermes reported 
that end groups of 50:50 PLGA have great effect on degradation with uncapped polymers 
(free carboxyl group) degrading faster than capped (alkyl groups). They also observed 
that the microparticles prepared from 50:50 PLGA with molecular weight of 8000 
degraded faster than the ones prepared with molecular weight of 21,000. The effect of 
end groups is greater than the molecular weight on the degradation rate in their research 
with uncapped PLGA of Mw=21,000 degraded faster than capped PLGA of Mw=9,500. 
Kamei et al. [143] studied the molecular weight effect on microparticles of 53-75 µm 
prepared using 75:25 PLGA. They observed that Mw=10,000 polymer degraded 
approximately twice as fast as Mw=20,000 polymer. The half- life of degradation for 
Mw=10,000 polymer was found to be about 8 days, while Mw=20,000 polymer had a half-
life of 18 days.  
2.7.4 Modeling of Biodegradable Systems  
Drug release from biodegradable polymeric delivery systems is governed by 
degradation of the polymer, erosion of the device and the diffusion of the drug, which is 
more complicated than the non-degradable systems. It is a result of both physical and 
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chemical phenomena, and thus, the modeling of such systems remains a challenge to 
researchers. Both empirical and physical models have been developed to describe the 
drug release [9, 144-146].  
Hopfenberg [144] assumed that the rate of drug release from the degradable 
system is proportional to the surface area of the device which changes with time, and the 
mass transfer is a single zero-order process with ignored edge and end effects. The 
fractional release of drug is written as: 
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Here, k0 is the rate constant, C0 is the uniform initial drug concentration within the 
system; a is the radius of a cylinder or sphere or the half-thickness of a slab; n is a shape 
factor representing spherical (n=3), cylindrical (n=2) or slab geometry (n=1). This model 
is more suitable to surface eroding systems where a zero order surface detachment of the 
drug is the rate limiting step.  
Heller et al. [147] developed a model with the assumption that the polymer 
matrices undergo bulk erosion, and degradation can be described as first order kinetics: 
( )0 0t 2 P exp k t CdM A=
dt 2 t
× × × ×
×       (2.20) 
Here, A is the surface area of both sides of the film; P0 is the initial drug 
permeability; k is the first order rate constant for degradation; C0 is the initial drug 
concentration within the system. According to this model, the drug release rate first 
decreases and then increases with the diffusion pathlength changes.  
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 Charlier and coworkers [148] developed a model for drug release from bulk 
eroding polymer films with polymer degradation and drug diffusion occurring 
simultaneously. They also assumed that the drug diffusion coefficient, D, increases 
exponentially with time while the polymer chain cleavage follows first order kinetics. 
The cumulative amount of drug released was derived as: 
( )0 s 0
t
2C C D exp k t -1
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k
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 Here, A is the surface area of the film exposed to the release medium; C0 is the 
initial drug concentration, Cs is the solubility of the drug in the system; D0 is the diffusion 
coefficient of the drug prior to degradation and k is the polymer degradation rate constant. 
The model showed good agreement with the release of mifepristone from PLGA films.  
Mathematical models based on the physicochemical phenomena such as 
diffusional mass transfer and chemical reaction have also been applied to simulate the 
drug release from biodegradable systems. Zygourakis et al. [149] developed a discrete 
model based on cellular automata concept to simulate the drug release from surface 
eroding matrices. The basic idea is to represent polymer matrix by 2-dimentiona l grids 
with each pixel accounts for one of the system components. Their model predictions 
agreed qualitatively with experimental results for the polyanhydrides systems based on 
poly (bis-p-carboxyphnoxy) propane anhydride) (PCPP) and its copolymers with sebacic 
acid (SA). Tzafriri [146] used finite element method (FEM) to simulate drug release from 
homogeneous matrix degradation with the assumption that the diffusion coefficient of the 
active agent is constant and the most of the drug is released prior to matrix erosion. Their 
model fitted the release from a biodegradable gelatin matrix well after 24 hours release. 
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Gopferich and coworkers [133, 150] simulated the degradation and erosion of bulk 
eroding polymer matrices based on polymer degradation and diffusional mass transport 
processes. Newton et al. [151] modeled drug release from degradable polymeric devices 
by a combination of diffusion and surface erosion. They reported that the period needed 
to achieve zero-order release decreases as the erosion rate constant increases and the drug 
diffusion coefficient decreases using their model.  
2.7.5 Applications of PLA/PLGA 
The outstanding biocompatibility and the nontoxic nature of degradation end 
products of PLA and PLGA have made them leading biomaterials for medical 
applications for over 30 years.  For semi-crystalline polymers such as PGA, L-PLA and 
PLGA with high molecular weight can be fabricated into surgical sutures and bone 
fixation nails and screws, where high mechanical strength is required; while amorphous 
D, L-PLA and PLGA are extensively studied in controlled drug delivery applications  
[152-157].  
With the promising properties, a huge variety of  pharmaceutical compounds with 
different properties have been formulated into PLA/PLGA systems, including anti-cancer 
drugs, steroids, and hydrophilic agents like peptides, proteins and vaccines with the 
advantages of improved drug efficacy and patient compliance. Some examples of drugs 
that have been incorporated into PLA/PLGA microsphere systems are listed in Table 2.3.  
ZoladexTM is a commercially available PLA/PLGA rod-shape implant, designed 
to deliver goserelin, a gonadotrophin release hormone (GnRH) agonist analog, over a 1-
or 3-month period [158-160]. Chronic administration of GnRH agonist evokes an initial 
agonist phase, which subsequently causes antagonistic effects and a suppression of 
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gonadotrophin secretion. Therefore, implants of GnRH analogues can be used clinically 
in the treatment of sex-hormone responsive tumors and endometriosis. Zoladex implants 
are indicated for use in the palliative treatment of advanced breast cancer in pre- and peri-
menopausal women [161, 162] and advanced carcinoma of the prostate [163, 164], and in 
the management of endometriosis, including pain relief and the reduction of 
endometriotic lesions [165].  
Several microsphere delivery systems produced from PLA/PLGA for sustained 
release have received regulatory approval by FDA. In 1989, Lupron Depot® microspheres 
from Takeda/TAP became the first FDA approved parental sustained-release drug 
formula involving PLA and PLGA as a once a month injection [119, 166]. It comprises a 
PLA/PLGA microsphere delivery system for leuprorelin acetate, also a GnRH analog, 
which is for the palliative treatment of advanced prostate cancer and endometriosis with 
choices of 1-, 3-, or 4-month release [167-169]. Sandostatin LARTM Depot of Novartis 
obtained FDA approval in 1998, which is indicated for long-term maintenance therapy of 
acromegaly, a rare hormonal disorder which leads to excess growth hormone secretion 
[170-173]. It is a once-monthly injection that reduces and normalizes levels of insulin-
like growth factor-1 (IGF-1) and growth hormone in the majority of patients [174, 175]. 
It is also indicated to control symptoms, such as severe diarrhea and flushing of 
metastatic carcinoid tumors [176],  and the profuse, watery diarrhea associated with 
vasoactive intestinal peptide-secreting tumors [177]. Human NutropinTM Depot from 
Alkermes/Genentech, which was FDA approved in 1999 for the long-term treatment of 
growth failure due to lack of adequate endogenous growth hormone secretion in pediatric 
patients [178, 179]. It is a long-acting form of Genentech's recombinant human growth 
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hormone (rhGH) for pediatric growth hormone deficiency using Alkermes' ProLease® 
injectable extended-release drug delivery system with micron-sized particles of rhGH 
embedded in biocompatible, biodegradable PLGA microspheres [180, 181].  
2.8   Composite of Microparticles in Polymer Matrices  
Within the field of controlled drug delivery, it has been difficult to achieve the 
desired release kinetics for many therapeutic agents from general polymeric systems such 
as hydrogels or microparticles. It is therefore an object of this part of research to 
investigate the efficacy of a polymer composite for releasing the incorporated therapeutic 
agents at a desired rate and quantity. Polymer composites prepared using different 
materials or in various shapes thus become promising candidates, as the release of 
incorporated pharmaceuticals is controlled through combined mechanisms.  The polymer 
composites usually consist of a continuous matrix embedded with micro-/nano-sized sub-
matrices, which could be particles, fibers, probes or needles [182, 183]. Bioactive 
compounds are entrapped within the sub-matrices, and then released while stimuli are 
present. With multiple controls of the main polymer matrix and the sub-matrices, the 
release of the incorporated compounds can be modulated.  
The techniques used to prepare polymer composites mostly involve physical 
methods, such as solvent removal, polymer melts and compression of powders. In solvent 
removal process, the sub-matrices containing drugs are first fabricated, and then 
suspended in a viscous solution of the main matrix polymer in a solvent, in which the 
sub-matrix polymer is not soluble. The solution is required to be viscous to ensure the 
even distribution of the sub-matrices. The composite is formed after removal of the 
solvent. The solvent removal should be fast to prevent the sub-matrices settling down, 
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and thus volatile solvents are preferred. Polymer melts can also be used to produce 
polymer composites with the sub-matrices dispersed in the melts of the main matrix 
polymer to form a composite. In this method, the melting temperature of the main matrix 
polymer should be low enough so that the sub-matrices would not be affected. 
Compression of the sub-matrices with the powders of the main polymer is another 
physical method to prepare polymer composite. Other than these physical methods, 
chemical reaction like polymerization can also be used:  mix the sub-matrices in a 
monomer solution and the polymer composite is obtained by polymerization. 
Determinations of which method should be adopted depend on the properties of 
the polymers and the application of the composite. The key consideration is to maintain 
the integrity of the sub-matrices when incorporated into the main matrix. Therefore, when 
choosing the polymers for the main and sub-matrices, the possible interactions between 
the polymers should be taken into consideration. Polymers which are not miscible with 
each other are preferred so that the integrity of the sub-matrices is maintained during the 
formation of the composite. 
Compared to the other three methods, solvent removal for the formation of 
polymer composite has the advantages of maintaining the physical properties and 
integrity of the sub-matrices if the right solvent is chosen. The general procedure for 
making a polymeric composite device using solvent removal method includes: 1) 
incorporating the compound to be released into polymeric sub-matrices; 2) dissolving the 
main matrix polymer in a solvent, in which the sub-matrix polymer are not soluble, to 
produce a viscous solution; 3) suspending the sub-matrices in the polymer solution; 4) 
formation of composite by removing the solvent.   
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Biodegradable microparticles fabricated from natural and synthetic polymers have 
been extensively investigated as drug carriers in controlled drug delivery. The linear 
aliphatic synthetic polyesters like polylactide (PLA), polyglycolide (PGA) and their 
copolymer poly (lactide-co-glycolide) (PLGA) have been fabricated into micro-/nano-
particles for sustained drug delivery due to their excellent biocompatibility and 
biodegradability (Section 2.7.5). However, just like the other forms of drug delivery 
systems, linear release is not easy to obtain even with particles of apparently uniform 
diameter. As a result, the idea of incorporation microparticles containing therapeutic 
agents into another polymeric matrix became promising to achieve better controlled 
release.  
Several delivery composite systems based on this concept have been synthesized 
and characterized by some researchers.  In US Patent 4,898,734, Mathiowitz et al. [184] 
described an approximately zero-order release of heparin from PLA microspheres 
embedded in a polyurethane or polystyrene matrix for an extended period. Slower release 
was obtained using polystyrene instead of polyurethane as the matrix polymer. Brannon-
Peppas [185] constructed a composite of PLGA particles within silicone matrices for the 
release of b -estradiol. The release rate of b -estradiol from the composite was found to 
be between the release rates from the microparticles and silicone films alone, respectively. 
However, the PLGA microparticles were incorporated into the silicone matrices by 
curing the mixture at 100°C, which is considerably higher than the Tg of PLGA (~40°C). 
The high temperature would cause PLGA microparticles to deform and lose their 
integrity. Since no SEM images were shown for the composite or the particles in the 
article, the structure or morphology of the PLGA-silicone composite was not revealed. 
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Marra et al. [186, 187] synthesized a tissue engineering scaffold incorporated with drug 
containing microparticles. Both scaffold and microparticles were fabricated using PLGA, 
but with varied PLA to PGA ratio. PVA was used to coat PLGA (50/50) microparticles to 
protect the particle from the organic solvent when incorporated into PLGA (65/35) 
scaffolds. The release of bovine serum albumin was evaluated.  
However, these composite systems described above are mainly focused on 
incorporation of microparticles into hydrophobic polymer matrices. Little work has been 
done on incorporating biodegradable particles into a hydrogel matrix. As discussed 
earlier, hydrogels resemble nature living tissue closely in physical properties due to their 
high water contents and soft, rubbery elastic consistency. A composite of microparticles 
embedded in a hydrogel matrix can thus be a promising candidate for controlled release 
of therapeutic agents in different forms of administration. The release of incorporated 
therapeutic agents would show different kinetics than using hydrophobic polymers as 
matrices. 
Physically crosslinked PVA hydrogels has been synthesized and studied intensely 
in this lab. The crystallites of PVA can serve as crosslinking points to hold a 3-D 
structure, resulting in a toxicant free hydrogel network. The temperature that PVA 
dissolves in water is usually higher than room temperature and related to the degree of 
hydrolysis. PVA used in this research is 99% hydrolyzed and dissolves in water at a 
temperature above 80ºC.  Viscous solution can be formed when the PVA aqueous 
solution is cooled down to room temperature. PLGA is a hydrophobic polymer, and not 
soluble in water. A composite system can be prepared taking the advantage of the 
different solubility of PVA and PLGA in the same solvent—water, and the ability of 
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crystallite formation of PVA through solvent casting. First, PLGA microparticles 
encapsulated therapeutic agents are produced and then dispersed in viscous PVA aqueous 
solutions to generate a viscous mixture. After removal of water though evaporation, 
composites of continuous PVA hydrogel matrix with PLGA microparticles are formed 
with the formation of PVA crystallites (Figure 2.10).  
Based on this hypothesis, we propose a delivery system consists of a PVA 
hydrogel matrix embedded with PLGA microparticles for sustained release of therapeutic 
agents to an extended duration. The release of the encapsulated agents will be modulated 
by both PLGA microparticles and PVA matrix. Furthermore, a porous structure can be 
formed after the degradation of PLGA microparticles. This makes the PLGA-PVA 
composite system a possible candidate for tissue engineering scaffolds.  
 
44 
List of References 
 
 
 
[1] Hassan, C.M. and Peppas, N.A., Structure and Application of Poly(vinyl alcohol) 
Hydrogels Produced by conventinal Crosslinking or by Freezing/Thawing 
Methods, in Advances in Polymer Science, A. Abe, A.C. Albertsson, and H.J. 
Cantow, Editors. 2000, Springer: New York. 
[2] Nishio, Y., Haratani, T. and Takahashi, T. "Miscibility and Orientation Behavior 
of Poly (vinyl alcohol) /Poly (vinyl pyrrolidone) Blends". Journal of Polymer 
Science: Part B: Polymer Physics, 1990, 28: p. 355-376. 
[3] Zhang, H. and Yin, J. "Small-angle X-ray scattering studies on poly (vinyl 
alcohol)/ poly(N-vinyl-2-pyrrolidone) blends". Makromolecule Chemistry, 1990, 
191: p. 375-380. 
[4] Dash, A. and Cudworth II, G.C. "Therapeutic applications of implantable drug 
delivery systems". Journal of Pharmacological and Toxicological Methods, 1998, 
40: p. 1-12. 
[5] Theeuwes, F. and Bayne, W. "Dosage form index and objective criterion for 
evaluation of controlled-release drug delivery systems". Journal of 
Pharmaceutical Sciences, 1977, 66: p. 1388. 
[6] Robinson, R.L. and Lee, V.H.L., Controlled drug delivery: Fundamentals and 
applications. 2nd ed. Drugs andthe pharmaceutical sciences, A series of textbooks 
and monographs, ed. J. Swarbick. Vol. 29. 1987, New York: Marcel Dekker, Inc. 
[7] Jantzen, G.M. and Robinson, J.R. "Sustained- and controlled-release drug-
delivery systems". Drugs and the Pharmaceutical Sciences, 2002, 121: p. 501-
528. 
[8] Sershen, S. and West, J. "Implantable, polymeric systems for modulated drug 
delivery". Advanced Drug Delivery Reviews, 2002, 54: p. 1225-1235. 
[9] Fan, L.T. and Singh, S.K., Controlled release: A quantitative treatment. Polymers: 
Properties and Applications, ed. H.-J. Cantow, et al.. Vol. 13. 1989, Berlin: 
Springer-Verlag. 
[10] Peppas, N.A. and Stauffer, S.R. "Reinforced uncrosslinked poly (vinyl alcohol) 
gels produced by cyclic freezing-thawing processes: a short review". Journal of 
Controlled Release, 1991, 16: p. 305-310. 
 
45 
[11] Flory, P.J., Principles of Polymer Chemistry. 1953, Ithaca: Cornell University 
Press. 
[12] Peppas, N.A. and Merrill, E.W. "Crosslinked poly (vinyl alcohol) hydrogels as 
swollen elastic networks". Journal of Applied Polymer Science, 1977, 21: p. 
1963-1770. 
[13] Peppas, N.A., Bures, P., Leobandung, W., and Ichikawa, H. "Hydrogels in 
pharmaceutical formulations". European Journal of Pharmaceutics and 
Biopharmaceutics, 2000, 50: p. 27-46. 
[14] Lowman, A.M. and Peppas, N.A. "Analysis of the Complexation/Decomplexation 
Phenomena in Graft Copolymer Networks". Macromolecules, 1997, 30: p. 4959-
4965. 
[15] Ritger, P.L. and Peppas, N.A. "A simple equation for decription of solute release I. 
Fickian and non-fickian releae from non-swellable devices in the form of slabs, 
spheres, cylinders or discs". Journal of Controlled Release, 1987, 5: p. 23-36. 
[16] Crank, J., The Mathematics of Diffusion. 2nd ed. 1975, Oxford: Oxford University 
Press. 
[17] Ritger, P.L. and Peppas, N.A. "A simple equation for description of solute release 
II. Fickian and anomalous release from swellable devices". Journal of Controlled 
Release, 1987, 5: p. 37-42. 
[18] Peppas, N.A. and Sahlin, J.J. "A simple equation for the description of solute 
release. III. Coupling of diffusion and relaxation". International Journal of 
Pharmaceutics, 1989, 57: p. 169-172. 
[19] Ahmed, I. and Pritchard, J.G. "Partly alcoholized poly(vinyl acetate) polymers.  
Properties of polymers hydrolyzed by different routes". Polymer, 1979, 20: p. 
1492-1496. 
[20] Friedlander, H.N., Harris, H.E. and Pritchard, J.G. "Structure-property relations of 
poly(vinyl alcohol). I. Influence of polymerization solvents and temperature on 
the structure and properties of poly(vinyl alcohol) derived from poly (vinyl 
acetate)". Journal of Polymer Science Polymer Chemistry Edition, 1966, 4: p. 
649-664. 
[21] Kroschwitz, J.I., ed. Kirk-Othmer Concise Encyclopedia of Chemical Technology. 
4th ed. 1999, Wiley: New York. 
 
 
46 
[22] Ushakov, S.N. and Szanto, I. "Cross-linked polymers. I. Preparation of cross-
linked poly(vinyl acetate) and poly(vinyl alcohol), and characterization of their 
properties". Acta Chimica Academiae Scientiarum Hungaricae, 1960, 24: p. 343-
356. 
[23] Thanoo, B.C., Sunny, M.C. and Jayakrishnan, A. "Controlled release of oral drugs 
from cross-linked polyvinyl alcohol microsphere". Journal of Pharmacy and 
Pharmacology, 1993, 45: p. 16-20. 
[24] Braun, D. and Walter, E. "Intra- and intermolecular crosslinking of poly(vinyl 
alcohol) with dialdehydes". Colloid and Polymer Science, 1980, 258: p. 795-801. 
[25] Danno, A. "Gel formation of aqueous solutions of poly(vinyl alcohol) irradiated 
with a cobalt-60 source". Journal of the Physical Society of Japan, 1958, 13: p. 
722-727. 
[26] Saito, O. "Effects of gamma rays on aqueous solutions of poly(vinyl alcohol)". 
Journal of the Physical Society of Japan, 1959, 14: p. 792-797. 
[27] Bray, J.C. and Merrill, E.W. "Poly(vinyl alcohol) hydrogels for synthetic articular 
cartilage material". Journal of Biomedical Material Research, 1973, 7: p. 431-443. 
[28] Peppas, N.A. "Crystallization of poly(vinyl alcohol)-water films by slow 
dehydration". European Polymer Journal, 1976, 12: p. 495-498. 
[29] Hickey, A.S. and Peppas, N.A. "Mesh size and diffusive characteristics of 
semicrystalline poly (vinyl alcohol) membranes prepared by freezing/thawing 
techniques". Journal of Membrane Science, 1995, 107: p. 229-237. 
[30] Bunn, C.W. "Crystal structure of polyvinyl alcohol". Nature, 1948, 161: p. 929-
930. 
[31] Takahashi, Y. "Neutron diffraction by crystalline polymers". Polymeric Materials 
Science and Engineering, 1998, 79: p. 356-357. 
[32] Assender, H.E. and Windle, A.H. "Crystallinity in poly (vinyl alcohol) 1. An X-
ray diffraction study of atactic PVOH". Polymer, 1998, 39: p. 4295-4302. 
[33] Wlochowicz, A. and Eder, M. "Distribution of lamella thicknesses in isothermally 
crystallized polypropylene and polyethylene by differential scanning calorimetry". 
Polymer, 1984, 25: p. 1268-1270. 
[34] Kenney, J.F. and Holland, V.F. "Crystallization and dissolution temperatures of 
poly (vinyl alcohol) crystal lamellae". Journal of Polymer Science: Part A-1, 
1966, 4: p. 699-706. 
 
47 
[35] Lu, L., Alamo, R.G. and Mandelkern, L. "Lamellar thickness distributions in 
linear polyethylene and ethylene copolymers". Macromolecules, 1994, 27: p. 
6571-6576. 
[36] Assender, H.E. and Windle, A.H. "Crystallinity in poly (vinyl alcohol) 2. 
Computer modelling of crystal structure over a range of tacticities". Polymer, 
1998, 39: p. 4303-4312. 
[37] Hassan, C.M., Stewart, J.E. and Peppas, N.A. "Diffusion characteristics of 
freeze/thawed poly (vinyl alcohol) hydrogels: Applications to protein controlled 
release from multilaminate devices". European Journal of Pharmaceutics and 
Biopharmaceutics, 2000, 49: p. 161-165. 
[38] Tanigami, T., Yano, K., Yamaura, K., and Matsuzawa, S. "Anomalous swelling 
of poly (vinyl alcohol) film in mixed solvents of dimethylsulfoxide and water". 
Polymer, 1995, 36: p. 2941-2946. 
[39] Mallapragada, S.K. and Peppas, N.A. "Dissolution mechanism of semicrystalline 
poly (vinyl alcohol) in water". Journal of Polymer Science: Part B: Polymer 
Physics, 1996, 34: p. 1339-1346. 
[40] Peppas, N.A. and Scott, J.E. "Controlled release from poly (vinyl alcohol) gels 
prepared by freezing- thawing processes". Journal of Controlled Release, 1992, 18: 
p. 95-100. 
[41] Oka, M., Chang, Y.-S., Nakamura, T., Ushio, K., Toguchida, J., and Gu, H.-O. 
"Synthetic osteochondral replacement of the femoral articular surface". Journal of 
Bone and Joint Surgery - Series B, 1997, 79: p. 1003-1007. 
[42] Morimoto, K., Nagayasu, A., Fukanoki, S., Morisaka, K., Hyon, S.-H., and Ikada, 
Y. "Evaluation of polyvinyl alcohol hydrogel as a sustained-release vehicle for 
rectal administration of indomethacin". Pharmaceutical Research, 1989, 6: p. 
338-341. 
[43] Shaheen, S.M. and Yamaura, K. "Preparation of theophylline hydrogels of atactic 
poly (vinyl alcohol)/NaCl/H2O system for drug delivery system". Journal of 
Controlled Release, 2002, 81: p. 367-377. 
[44] Peppas, N.A. and Mongia, N.K. "Ultrapure poly (vinyl alcohol) hydrogels with 
mucoadhesive drug delivery characteristics". European Journal of Pharmaceutics 
and Biopharmaceutics, 1997, 43: p. 51-58. 
[45] Mandal, T.K. "Swelling-controlled release system for the vaginal delivery of 
miconazole". European Journal of Pharmaceutics and Biopharmaceutics, 2000, 
50: p. 337-343. 
 
48 
[46] Cassu, S.N. and Flisberti, M.I. "Poly(vinyl alcohol) and poly (vinyl pyrrolidone) 
blends: miscibility, microheterogeneity and free volume change". Polymer, 1997, 
38: p. 3907-3911. 
[47] Eguazabal, J.I., Calahorra, E., Cortazar, M., and Guzman, G.M. "Miscibility of 
mixtures from partially hydrolyzed poly(vinyl acetate) and poly (N-vinyl-2-
pyrrolidone)". Makromolecule Chemistry, 1986, 187: p. 2439-2444. 
[48] Howell, J. and Dodgen, D., Summary of Evaluations Performed by the Joint 
FAO/WHO Expert Committee on Food Additives. 2003, ILSI Press International 
Life Sciences Institute: Washington DC. 
[49] Odian, G., Principles of Polymerization. 3rd ed. 1991, New York: John Wiley & 
Sons, Inc. 317. 
[50] Tantishaiyakul, V., Kaewnopparat, N. and Ingkatawornwong, S. "Properties of 
solid dispersions of piroxicam in polyvinylpyrrolidone". International Journal of 
Pharmaceutics, 1999, 181: p. 143-151. 
[51] Nabekura, T., Ito, Y., Cai, H., Terao, M., and Hori, R. "Preparation and in vivo 
ocular absorption studies of disulfiram solid dispersion". Biology Pharmaceutical 
Bulletin, 2000, 23: p. 616-620. 
[52] Iannuccelli, V., Coppi, G., Leo, E., Fontana, F., and Bernabei, M. "PVP solid 
dispersions for the controlled release of furosemide from a floating multiple-unit 
system". Drug Development and Industrial Pharmacy, 2000, 26: p. 595-603. 
[53] Akin, H., Heller, J. and Harris, F.W., Effect of surfactants on the release of 
griseofulvin from polyvinyl pyrrolidone dispersions, in Tailored polymeric 
materials for controlled delivery systems, I. McCulloch and S.W. Shalaby, Editors. 
1998, American Chemical Society: Washington, DC. p. 212-222. 
[54] Crowley, K. and Zografi, G. "Water vapor absorption into amorphous 
hydrophobic drug/poly(vinylpyrrolidone) dispersions". Journal of 
Pharmaceutical Sciences, 2002, 91: p. 2150-2165. 
[55] Chiou, W.L. and Riegelman, S. "Pharmaceutical applications of solid dispersion 
systems". Journal of Pharmaceutical Sciences, 1971, 60: p. 1281-1302. 
[56] Ford, J.L. "The current status of solid dispersion". Pharmaceutical acta Helvetial, 
1986, 61: p. 69-88. 
 
 
 
49 
[57] Boelens, J.J., Dankert, J., Murk, J.L., Weening, J.J., Van der Poll, T., Dingemans, 
K.P., Koole, L., Laman, J.D., and Zaat, S.A.J. "Biomaterial-associated persistence 
of Staphylococcus epidermidis in pericatheter macrophages". Journal of 
Infectious Diseases, 2000, 181: p. 1337-1349. 
[58] Tunney, M.M. and Gorman, S.P. "Evaluation of a poly (vinyl pyr rolidone)-coated 
biomaterial for urological use". Biomaterials, 2002, 23: p. 4601-4608. 
[59] Bridgett, M., Davies, M. and Denyer, S. "In vitro assessment of bacterial adhesion 
to hydromer-coated cerebrospinal- fluid shunts". Biomaterials, 1993, 23: p. 4601-
4608. 
[60] Koning, C., Duin, M.V., Pagnoulle, C., and Jerome, R. "Strategies for 
compatibility of polymer blends". Progress in Polymer Science, 1998, 23: p. 707-
757. 
[61] Coleman, M.M. and Painter, P.C. "Hydrogen bonded polymer blends". Progress 
in Polymer Science, 1995, 20: p. 1-59. 
[62] Cowie, J.M.G., Harris, S., Gomez Ribelles, J.L., Meseguer, J.M., Romero, F., and 
Torregrosa, C. "Glass Transition and Structural Relaxation in 
Polystyrene/Poly(2,6-dimethyl-1,4-phenylene oxide) Miscible Blends". 
Macromolecules, 1999, 32: p. 4430-4438. 
[63] Tomita, H. and Register, R.A. "Miscibility of polystyrene-based ionomers with 
poly(2,6-dimethyl-1,4-phenylene oxide)". Macromolecules, 1993, 26: p. 2796-
2801. 
[64] You, C. "Advances in the studies of thermodynamics of polymer blend 
miscibility". Hecheng Xiangjiao Gongye, 1988, 11: p. 247-252. 
[65] Pearce, E.M. and Kwei, T.K. "Hydrogen bonding interaction in polymer blends". 
Studies in Polymer Science, 1992, 11: p. 133-149. 
[66] Cowie, J.M.G. and Arrighi, V. "Miscibility and relaxation processes in blends". 
Plastics Engineering, 1999, 52: p. 81-124. 
[67] Nishio, Y. and Suzuki, H. "Molecular orientation and optical anisotropy induced 
by the stretching of poly (vinyl alcohol)/ poly (N-vinyl-pyrrolidone) blends". 
Polymer, 1994, 35: p. 1452-61. 
[68] Li, L., Chan, C.-M. and Weng, L.-T. "The effects of specific interactions on the 
surface structure and composition of miscible blends of poly(vinyl alcohol) and 
poly (N-vinyl-2-pyrrolidone)". Polymer, 1998, 39: p. 2355-2360. 
 
50 
[69] Nishi, T. and Wang, T.T. "Melting point depression and kinectic effects of 
cooling on crystallization in poly (vinylidene fluoride)-poly (methyl 
methacrylate)". Macromolecules, 1975, 8: p. 909-915. 
[70] Kroschwitz, J.I., ed. Concise Encyclopedia of Polymer Science & Engineering. 
2nd ed. 1985, John Wiley and Sons: New York. 
[71] Dean, L. and Brisson, J. "Hydrogen boneds in poly (methyl mathacrylate)-poly 
(4-vinyl phenol) blends 1. Quantitative analysis using FTIR spectroscopy". 
Polymer, 1998, 39: p. 793-800. 
[72] Zhang, X., Takegoshi, K. and Hikichi, K. "High-resolution solid-state 13C nuclear 
magnetic resonance study on poly (vinyl alcohol)/ poly (vinyl pyrrolidone) 
blends". Polymer, 1992, 33: p. 712-717. 
[73] Cheng, Y.-H., Illum, L. and Davis, S.S. "A poly (D, L- lactide-co-glycotide) 
microsphere depot system for delivery of haloperidol". Journal of Controlled 
Release, 1998, 55: p. 203-212. 
[74] Sperling, L.H., Introduction to Physical Polymer Science. 2nd ed. 1992, New 
York: John Wiley & Sons, Inc. 320-322. 
[75] Scholes, P.D., Coombes, A.G.A., Davies, M.C., Illum, L., and Davis, S.S., 
Particle engineering of biodegradable colloids for site-specific drug delivery, in 
Controlled drug delivery: Challenges and strategies, K. Park, Editor. 1997, 
American Chemical Society: Washington, DC. p. 73-106. 
[76] Hillery, A.M., Lloyd, A.W. and Sarbrick, J., Drug delivery and targeting for 
pharmacists and pharmaceutical scientists. 2001, London: Taylor & Francis. 
[77] Varma-Nair, M., Pan, R. and Wunderlich, B. "Heat capacities and entropies of 
linear, aliphatic polyesters". Journal of Polymer Science, Part B:  Polymer 
Physics, 1991, 29: p. 1107-1115. 
[78] Gilding, D.K. and Reed, A.M. "Biodegradable polymers for use in surgery.  
Polyglycolic/poly(lactic acid) homo- and copolymers: 1." Polymer, 1979, 20: p. 
1459-1464. 
[79] Pinkus, A.G. and Subramanyam, R. "New high-yield, one-step synthesis of 
polyglycolide from haloacetic acids". Journal of Polymer Science, Polymer 
Chemistry Edition, 1984, 22: p. 1131-1140. 
[80] Kapadia, C.R., Mann, J.B., McGeehan, D., Biglin, J.E.J., Waxman, B.P., and 
Dudley, H.A.F. "Behavior of synthetic absorbable sutures with and without 
synergistic enteric infection". European surgical Research, 1983, 15: p. 67-72. 
 
51 
[81] Bourne, R.B., Bitar, H., Andreae, P.R., Martin, L.M., Finlay, J.B., and Marquis, F. 
"In-vivo comparison of four absorbable sutures: Vicryl, Dexon Plus, Maxon and 
PDS". Canadian Jourmal of Surgery, 1988, 31: p. 43-45. 
[82] Albertsson, A.C. and Varma, I.K., Aliphatic polyesters: synthesis, properties and 
applications, in Degradable aliphatic polyesters, A.C. Albertsson, Editor. 2002, 
Springer: Berlin. p. 1-40. 
[83] Cohn, D., Younes, H. and Marom, G. "Amorphous and crystalline morphologies 
in glycolic acid and lactic acid polymers". Polymer, 19872018-2022. 
[84] Hoogsteen, W., Postema, A.R., Pennings, A.J., Ten Brinke, G., and Zugenmaier, 
P. "Crystal structure, conformation and morphology of solution-spun poly(L-
lactide) fibers". Macromolecules, 1990, 23: p. 634-642. 
[85] Hiljanen-Vainio, M., Karjalainen, T. and Seppala, J. "Biodegradable lactone 
copolymers. I. Characterization and mechanical behavior of e-caprolactone and 
lactide copolymers". Journal of Applied Polymer Science, 1996, 59: p. 
[86] Jamshidi, K. and Hyon, S.H.I., Y. "Thermal characterization of polylactides". 
Polymer, 1988, 29: p. 
[87] Schindler, A. and Harper, D. "Polylactide.  II.  Viscosity-molecular weight 
relationships and unperturbed chain dimensions". Journal of Polymer Science, 
Polymer Chemistry Edition, 1979, 17: p. 2593-2599. 
[88] Wang, N., Wu, X., Li, C., and Feng, M. "Synthesis, characterization, 
biodegradation, and drug deliverly application of obiodegradable lactic/glycolic 
acid polymers: I. Synthesiss and characterization". Journal of Biomaterial Science 
Polymer Edition, 2000, 11: p. 301-318. 
[89] Lewis, D.H., Controlled release of bioactive agents from lactide/glycolide 
polymers, in Biodegradable polymers as drug delivery systems, M. Chasin and R. 
Langer, Editors. 1990, Marcel Dekker: New York. p. 1–41. 
[90] Debus, E.S., Geiger, D., Sailer, M., Ederer, J., and Thiede, A. "Physical, 
biological and handling characteristics of surgical suture material: a comparison 
of four different multifilament absorbable sutures". European surgical Research, 
1997, 29: p. 52-61. 
[91] Cohen, S., Alonso, M.J. and Langer, R. "Novel approaches to controlled-release 
antigen delivery". International Journal of Technology Assessment in Health 
Care, 1994, 10: p. 121-130. 
 
52 
[92] Hakkarainen, M., Aliphatic polyesters: Abiotic and biotic degradation and 
degradation products, in Degradable Aliphatic Polyesters, A.C. Albertsson, 
Editor. 2002, Springer: Berlin. p. 113-138. 
[93] Wu, X. and Wang, N. "Synthesis, characterization, biodegradation, and drug 
delivery application of biodegradable lactic/glycolic acid polymers. Part II: 
Biodegradation". Journal of Biomaterial Science Polymer Edition, 2001, 12: p. 
21-34. 
[94] Brady, J.M., Cutright, D.E., Miller, R.A., and Battistone, G.C. "Resorption rate, 
route of elimination and ultrastructure of the implant site of polylactic acid in the 
abdominal wall of the rat". Journal of Biomedical Material Research, 1973, 7: p. 
155-166. 
[95] Jain, R.A. "The manufacturing techniques of various drug loaded biodegradable 
poly (lactide-co-glycolide) (PLGA) devices". Biomaterials, 2000, 21: p. 2475-
2490. 
[96] Wu, X.S., Synthesis and properties of biodegradable lactic/glycolic acid polymers, 
in Encyclopedic Handbook of Biomaterials and Bioengineering, D.L. Wise, 
Editor. 1995, Marcel Dekker: New York. p. 1015–1054. 
[97] Cleland, J.L. "Solvent evaporation processes for the production of controlled 
release biodegradable microsphere formulations for therapeutics and vaccines". 
Biotechnology Progress, 1998, 14: p. 102-107. 
[98] Okada, H. and Toguchi, H. "Biodegradable microspheres in drug delivery". 
Critical Reviews in Therapeutic Drug Carrier Systems, 1995, 12: p. 1-99. 
[99] Liu, F., Kuo, J., Sung, K., and Hu, O. "Biodegradable polymeric microspheres for 
nalbuphine prodrug controlled delivery: in vitro characterization and in vivo 
pharmacokinetic studies". International Journal of Pharmaceutics, 2003, 257: p. 
23-31. 
[100] Jeong, Y., Song, J., Kang, S., Ryu, H., Lee, Y., Choi, C., Shin, B., Kim, K., Ahn, 
K., and Jung, S. "Preparation of poly(DL-lactide-co-glycolide) microspheres 
encapsulating all- trans retinoic acid". International Journal of Pharmaceutics, 
2003, 259: p. 79-91. 
[101] Seo, S., Khang, G., Rhee, J., Kim, J., and Lee, H. "Study on in vitro release 
patterns of fentanyl- loaded PLGA microspheres". Journal of Microencapsulation, 
2003, 20: p. 569-579. 
[102] Suzuki, K. and Price, J.C. "Microencapsulation and dissolution properties of a 
neuroleptic in a biodegradable polymer, poly(dl- lactide)". Journal of 
Pharmaceutical Sciences, 1985, 74: p. 21-24. 
 
53 
[103] Schaefer, M.J. and Singh, J. "Effects of tricaprin on the physical characteristics 
and in vitro release of etoposide from PLGA microspheres". Biomaterials, 2002, 
23: p. 3465-3471. 
[104] Yen, S., Sung, K., Wang, J., and Yoa-Pu, H.O. "Controlled release of nalbuphine 
propionate from biodegradable microspheres: in vitro and in vivo studies". 
International Journal of Pharmaceutics, 2001, 220: p. 91-99. 
[105] Bodmeier, R. and McGinity, J.W. "The preparation and evaluation of drug-
containing poly(dl- lactide) microspheres formed by the solvent evaporation 
method". Pharmaceutical Research, 1987, 4: p. 465–471. 
[106] Arshady, R. "Preparation of biodegradable microspheres and microcapsules: 2. 
Polylactides and related polyesters". Journal of Controlled Release, 1991, 17: p. 
1-22. 
[107] Sah, H. "Microencapsulation techniques using ethyl acetate as a dispersed solvent: 
effects of its extraction rate on the characteristics of PLGA microspheres". 
Journal of Controlled Release, 1997, 47: p. 233-245. 
[108] Izumikawa, S., Yoshioka, S., Aso, Y., and Takeda, Y. "Preparation of poly(l-
lactide) microspheres of different crystalline morphology and effect of crystalline 
morphology on drug release rate". Journal of Controlled Release, 1991, 15: p. 
133-140. 
[109] O'Donnell, P.B. and McGinity, J.W. "Preparation of microspheres by the solvent 
evaporation technique". Advanced Drug Delivery Reviews, 1997, 28: p. 25-42. 
[110] Jalil, R. and Nixon, J.R. "Biodegradable poly(lactic acid) and poly(lactide-co-
glycolide) microcapsules: problems associated with preparative techniques and 
release properties". Journal of Microencapsulation, 1990, 7: p. 297-325. 
[111] Cavalier, M., Benoit, J.P. and Thies, C. "The formation and characterization of 
hydrocortisone- loaded poly (DL-lactide) microspheres". Journal of Pharmacy 
and Pharmacology, 1986, 38: p. 249-253. 
[112] Fu, K., Harrell, R., Zinski, K., Um, C., Jaklenec, A., Frazier, J., Lotan, N., Burke, 
P., Klibanov, A.M., and Langer, R. "A potential approach for decreasing the burst 
effect of protein from PLGA microspheres". Journal of Pharmaceutical Sciences, 
2003, 92: p. 1582-1591. 
[113] Sturesson, C., Carifors, J., Edsman, K., and Andersson, M. "Preparation of 
biodegradable poly (lactic-co-glycolic) acid microspheres and their in vitro 
release of timolol maleate". International Journal of Pharmaceutics, 1993, 89: p. 
235-244. 
 
54 
[114] Pradhan, R.S. and Vasavada, R.C. "Formulation and in vitro release study on poly 
(DL-lactide) microspheres containing hydrophilic compounds: glycine 
homopeptides". Journal of Controlled Release, 1994, 30: p. 143-154. 
[115] Wang, H.T., Schmitt, E. and Flanagan, R.J. "Influence of formulation methods on 
the in vitro controlled release of protein from poly(ester) microspheres". Journal 
of Controlled Release, 1991, 17: p. 23-31. 
[116] Gupta, R.K., Alroy, M.J., Alonso, M.J., Langer, R., and Siber, G.R. "Chronic 
local tissue reactions, long term immunogenicity and immunologic priming of 
mice and guinea pigs to tetanus toxoid encapsulated in biodegradable polymer 
microspheres composed of poly lactide-co-glycolide polymers". Vaccine, 1997, 
15: p. 1716-1723. 
[117] Yan, C., Rill, W.L., Malli, R., Hewetson, J., Tommariella, R., and Kende, M. 
"Dependence of ricin toxoid vaccine efficacy on the structure of poly (lactide-co-
glycolide) microparticles carriers". Vaccine, 1995, 13: p. 645-651. 
[118] O'Hagan, D.T., Singh, M. and Gupta, R.K. "Poly(lactide-co-glycolide) 
microparticles for the development of single-dose controlled-release vaccines". 
Advanced Drug Delivery Reviews, 1998, 32: p. 225-246. 
[119] Okada, H., Heya, T., Igari, Y., Ogawa, Y., Toguchi, H., and Shimamoto, T. "One-
month release injectable microspheres of leuprolide acetate inhibit steroidogenesis 
and genital organ growth in rats". International Journal of Pharmaceutics, 1989, 
54: p. 231-239. 
[120] Crotts, G. and Park, T.G. "Protein delivery from poly(lactic-co-glycolic acid) 
biodegradable microspheres: release kinetics and stability issues". Journal of 
Microencapsulation, 1998, 15: p. 699-713. 
[121] Schwendeman, S.P. "Recent advances in the stabilization of proteins encapsulated 
in injectable PLGA delivery systems". Critical Reviews in Therapeutic Drug 
Carrier Systems, 2002, 19: p. 73-98. 
[122] Putney, S.D. and Burke, P.A. "Improving protein therapeutics with sustained-
release formulations". Nature Biotechnology, 1998, 16: p. 153-157. 
[123] van de Weert, M., Hennink, W.E. and Jiskoot, W. "Protein instability in poly 
(lactic-co-glycolic acid) microparticles". Pharmaceutical Research, 2000, 17: p. 
1159-1167. 
[124] Takada, S., Yamagata, Y., Misaki, M., Taira, K., and Kurokawa, T. "Sustained 
release of human growth hormone from microcapsules prepared by a solvent 
evaporation technique". Journal of Controlled Release, 2002, 88: p. 229-242. 
 
55 
[125] Blanco-Príeto, M.J., Besseghir, K., Zerbe, O., Andris, D., Orsolini, P., 
Heimgartner, F., Merkle, H.P., and Gander, B. "In vitro and in vivo evaluation of 
a somatostatin analogue released from PLGA microspheres". Journal of 
Controlled Release, 2000, 67: p. 19-28. 
[126] Wang, J., Ng, C., Win, K., Shoemakers, P., Lee, T., Feng, S., and Wang, C. 
"Release of paclitaxel from polylactide-co-glycolide (PLGA) microparticles and 
discs under irradiation". Journal of Microencapsulation, 2003, 20: p. 317-327. 
[127] Witschi, C. and Doelker, E. "Influence of the microencapsulation method and 
peptide loading on poly(lactic acid) and poly(lactic-co-glycolic acid) degradation 
during in vitro testing". Journal of Controlled Release, 1998, 51: p. 327-341. 
[128] Chaw, C., Tan, C., Yang, Y., Wang, L., and Moochhala, S. "Design of 
physostigmine- loaded polymeric microparitcles for pretreatment against exposure 
to organophosphate agents". Biomaterials, 2003, 24: p. 1271-1277. 
[129] Wagenaar, B.W. and Muller, B.W. "Piroxicam release from spray-dried 
biodegradable microspheres". Biomaterials, 1994, 15: p. 49-54. 
[130] Edlund, U. and Albertsson, A.C., Degradable polymer microspheres for 
controlled drug delivery, in Degradable Aliphatic Polyesters, A.C. Albertsson, 
Editor. 2002, Springer: Berlin. p. 113-138. 
[131] Johnson, O.L., Cleland, J.L., Lee, H.J., Charnis, M., Duenas, E., Jaworowicz, W., 
Shepard, D., Shahzamani, A., Jones, A.J.S., and Putney, S.D. "A month- long 
effect from a single injection of microencapsulated human growth hormone". 
Nature Medicine, 1996, 2: p. 795-799. 
[132] Johnson, O.L., Jaworowicz, W., Cleland, J.L., Bailey, L., Charnis, M., Duenas, E., 
Wu, C., Shepard, D., Magil, S., Last, T., Jones, A.J.S., and Putney, S.D. "The 
stability and encapsulation of human growth hormone into biodegradable 
microspheres". Pharmaceutical Research, 1997, 14: p. 730-735. 
[133] Burkersroda, F.V., Schedl, L. and Gopferich, A. "Why degradable polymers 
undergo surface erosion or bulk eroosion". Biomaterials, 2002, 23: p. 4221-4231. 
[134] Gopferich, A. and Langer, R. "Modeling of polymer erosion". Macromolecules, 
1993, 26: p. 4105-4112. 
[135] Tamada, J.A. and Langer, R. "Erosion kinetics of hydrolytically degradable 
polymers". Proceedings of the National Academy of Sciences of the United States 
of America, 1993, 90: p. 552-556. 
 
56 
[136] Grizzi, I., Garreau, H., Li, S., and Vert, M. "Hydrolytic degradation of devices 
based on poly (DL-lactic acid) size-dependence". Biomaterials, 1995, 16: p. 305-
311. 
[137] Spenlehauer, G., Vert, M., Benoit, J.P., and Boddaert, A. "In vitro and In vivo 
degradation of poly(D,L lactide/glycolide) type microspheres made by solvent 
evaporation method". Biomaterials, 1989, 10: p. 557-563. 
[138] Isobe, M., Yamazaki, Y., Oida, S.- i., Ishihara, K., Nakabayashi, N., and Amagasa, 
T. "Bone morphogenetic protein encapsulated with a biodegradable and 
biocompatible polymer". Journal of Biomedical Material Research, 1996, 32: p. 
433-438. 
[139] Pistner, H., Bendix, D.R., Muhling, J., and Reuther, J.F. "Poly(- lactide): a long-
term degradation study in vivo Part III. Analytical characterization". Biomaterials, 
1993, 14: p. 291-304. 
[140] Visscher, G.E., Robinson, R.L., Maulding, H.V., Fong, J.W., Pearson, J.E., and 
Argentieri, G.J. "Note: Biodegradation of and tissue reaction to poly(DL-lactide) 
microcapsules". Journal of Biomedical Material Research, 1986, 20: p. 667-676. 
[141] Visscher, G.E., Robinson, R.L., Maulding, H.V., Fong, J.W., Pearson, J.E., and 
Argentieri, G.J. "Biodegradation of and tissue reaction to 50:50 poly (DL-lactide-
co-glycolide) microcapsules". Journal of Biomedical Material Research, 1985, 19: 
p. 349-365. 
[142] Tracy, M.A., Ward, K.L., Firouzabadian, L., Wang, Y., Dong, Y., Qian, R., and 
Zang, Y. "Factors affecting the degradation rate of poly (lactide-co-glycolide) 
microspheres in vivo and in vitro". Biomaterials, 1999, 20: p. 1057-1062. 
[143] Kamei, S., Inoue, Y., Okada, H., Yamada, M., Ogawa, Y., and Toguchi, H. "New 
method for analysis of biodegradable polyesters by high-performance liquid 
chromatography after alkali hydrolysis". Biomaterials, 1992, 13: p. 953-958. 
[144] Hopfenberg, H.B., Controlled release from erodible slabs, cylinders, and spheres, 
in Controlled release polymeric formulations, D.R. Paul and F.W. Harris, Editors. 
1976, ACS: Washington. 
[145] Siepmann, J. and Gopferich, A. "Mathematical modeling of bioerodible, 
polymeric drug delivery systems". Advanced Drug Delivery Reviews, 2001, 48: p. 
229-247. 
[146] Tzafriri, A.R. "Mathematical modeling of diffusion-mediated release from bulk 
degrading matrices". Journal of Controlled Release, 2000, 63: p. 69-79. 
 
57 
[147] Heller, J. and Baker, R.W., Theory and practice of controlled drug delivery, in 
Controlled release of bioactive materials, R.W. Baker, Editor. 1980, Academic 
Press: New York. p. 1-18. 
[148] Charlier, A., Leclerc, B. and Couarraze, G. "Release of mifepristone from 
biodegradable matrices: experimental and theoretical evaluations". International 
Journal of Pharmaceutics, 2000, 200: p. 115-120. 
[149] Zygourakis, K. and Markenscoff, P.A. "Computer-aided design of bioerodible 
devices with optimal release characteristics: a cellular automata approach". 
Biomaterials, 1996, 17: p. 125-135. 
[150] Gopferich, A. "Polymer bulk erosion". Macromolecules, 1997, 30: p. 2598-2604. 
[151] Fischel-Ghodian, F. and Newton, J.M. "Analysis of drug release kinetics from 
degradable polymeric devices". Journal of Drug Targeting, 1993, 1: p. 51-57. 
[152] Stahelin, A.C., Weiler, A., Rufenacht, H., Hoffmann, R., Geissmann, A., and 
Feinstein, R. "Clinical degradation and biocompatibility of different 
bioabsorbable interference screws: a report of six cases". Arthroscopy, 1997, 13: p. 
238-244. 
[153] Mellonig, J.T., Nevins, M. and Sanchez, R. "Evaluation of a bioabsorbable 
physical barrier for guided bone regeneration. Part II. Material and a bone 
replacement graft." International Journal of Periodontics and Restorative 
Dentistry, 1998, 18: p. 129-137. 
[154] Miyamoto, S., Takaoka, K., Okada, T., Yoshikawa, H., Hashimoto, J., Suzuki, S., 
and Ono, K. "Polylactic acid-polyethylene glycol block copolymer. A new 
biodegradable synthetic carrier for bone morphogenetic protein." Clinical 
Orthopaedics and Related Research, 1993, 294: p. 333-343. 
[155] Hudon, E., Rondeau, J.J., Lenaerts, V., Wurthrich, P., Boutignon, F., Deghenghi, 
R., Marleau, S., Yamaguchi, N., Adam, A., and Ong, H. "Radioimmunoassay of 
meterelin and pharmacokinetics after single injection and implant administration 
in dogs". Journal of Pharmaceutical Sciences, 1997, 86: p. 172-178. 
[156] Hurzeler, M.B., Quinones, C.R. and Schupbach, P. "Guided bone regeneration 
around dental implants in the atrophic alveolar ridge using a bioresorbable barrier. 
An experimental study in the monkey". Clinial Oral Implants Research, 1997, 8: 
p. 323-331. 
[157] Aichelmann-Reidy, M.E. and Yukna, R.A. "Bone replacement grafts. The bone 
substitutes." Dental Clinis North America, 1998, 42: p. 491-503. 
 
58 
[158] Jonat, W., Kaufmann, M., Sauerbrei, W., Blamey, R., Cuzick, J., Namer, M., 
Fogelman, I., de Haes, J.C., de Matteis, A., Stewart, A., Eiermann, W., Szakolczai, 
I., Palmer, M., Schumacher, M., Geberth, M., and Lisboa, B. "Goserelin Versus 
Cyclophosphamide, Methotrexate, and Fluorouracil as Adjuvant Therapy in 
Premenopausal Patients With Node-Positive Breast Cancer: The Zoladex Early 
Breast Cancer Research Association Study." Journal of Clinical Oncology, 2002, 
20: p. 4628-4635. 
[159] Fontana, D., Mari, M., Martinelli, A., Boccafoschi, C., Magno, C., Turriziani, M., 
Maymone, S.S., Cunico, S., Cosciani, S., Zanollo, A., Montagna, G., Frongia, M., 
and Jacobellis, U. "3-Month Formulation of Goserelin Acetate ('Zoladex' 10.8-mg 
Depot) in Advanced Prostate Cancer: Results from an Italian, Open, Multicenter 
Trial". Urologia Internationalis, 2003, 70: p. 316-320. 
[160] Robertson, J.F.R. and Blamey, R.W. "The use of gonadotrophin-releasing 
hormone (GnRH) agonists in early and advanced breast cancer in pre- and 
perimenopausal women". European Journal of Cancer, 2003, 39: p. 861-869. 
[161] Jonat, W. "Goserelin (Zoladex) - its role in early breast cancer in pre- and 
perimenopausal women". British Journal of Cancer, 2001, 85: p. 1-5. 
[162] Berglund, G., Nystedt, M., Bolund, C., Sjoden, P.-O., and Rulquist, L.-E. "Effect 
of endocrine treatment on sexuality in premenopausal breast cancer patients: a 
prospective randomized study". Journal of Clinical Oncology, 2001, 19: p. 2788-
2796. 
[163] Gommersall, L.M., Hayne, D., Shergill, I.S., Arya, M., and Wallace, D.M.A. 
"Luteinising hormone releasing hormone analogues in the treatment of prostate 
cancer". Expert Opinion on Pharmacotherapy, 2002, 3: p. 1685-1692. 
[164] Nygard, R., Norum, J. and Due, J. "Goserelin (zoladex) or orchiectomy in 
metastatic prostate cancer? a quality of life and cost-effectiveness analysis". 
Anticancer Research, 2001, 21: p. 781-788. 
[165] Ludwig, M., Bauer, O., Wiedemann, G.J., and Diedrich, K. "Ureteric and 
pulmonary endometriosis". Archives of Gynecology and Obsterics, 2001, 265: p. 
158-161. 
[166] Okada, H., Yamada, M., Heya, T., Inoue, Y., Kamei, S., Ogawa, Y., and Toguchi, 
H. "Drug delivery using biodegradable microspheres". Journal of Controlled 
Release, 1994, 28: p. 1994. 
[167] Sharifi, R., Ratanawong, C., Jung, A., Wu, Z., Browneller, R., and Lee, M. 
"Therapeutic effects of leuprorelin microspheres in prostate cancer". Advanced 
Drug Delivery Reviews, 1997, 28: p. 121-138. 
 
59 
[168] Okada, H., Doken, Y. and Toguchi, H. "Preparation of three-month depot 
injectable microspheres of leuprorelin acetate using biodegradable polymers". 
Pharmaceutical Research, 1994, 11: p. 1143-1147. 
[169] Okada, H. "One- and three-month release injectable microspheres of the LH-RH 
superagonist leuprorelin acetate". Advanced Drug Delivery Reviews, 1997, 28: p. 
43-70. 
[170] Smith, J.C., Lane, H., Davies, N., Evans, L.M., Cockcroft, J., Scanlon, M.F., and 
Davies, J.S. "The effects of depot long-acting somatostatin analog on central 
aortic pressure and arterial stiffness in acromegaly". Journal of Clinical 
Endocrinology and Metabolism, 2003, 86: p. 2556-2561. 
[171] Biermasz, N.R., van den Oever, N.C., Frolich, M., Pereira Arias, A.M., Smit, 
J.W.A., Romijn, J.A., and Roelfsema, F. "Sandostatin LAR in acromegaly: a 6-
week injection interval suppresses GH secretion as effectively as a 4-week 
interval". Clinical Endocrinology, 2003, 58: p. 288-295. 
[172] Ayuk, J., Stewart, S.E., Stewart, P.M., and Sheppard, M.C. "Long-term safety and 
efficacy of depot long-acting somatostatin analogs for the treatment of 
acromegaly". Journal of Clinical Endocrinology and Metabolism, 2002, 87: p. 
4142-4146. 
[173] Floegstad, A.K., Halse, J., Bakke, S., Lancranjan, I., Marbach, P., Burns, C., and 
Jervell, J. "Sandostatin LAR in acromegalic patients: long term treatment". 
Journal of Clinical Endocrinology and Metabolism, 1997, 82: p. 23-28. 
[174] Shimon, I., Nass, D. and Hadani, M. "Acromegaly with normal growth hormone 
levels: Response to sandostatin-LAR treatment". Pituitary, 2000, 2: p. 289-294. 
[175] Stewart, P.M., Stewart, S.E., Clark, P.M.S., and Sheppard, M.C. "Clinical and 
biochemical response following withdrawal of a long-acting, depot injection form 
of octreotide (Sandostatin-LAR)". Clinical Endocrinology, 1999, 50: p. 295-299. 
[176] Altstadt, T.J., Azzarelli, B., Bevering, C., Edmondson , J., and Nelson, P.B. 
"Acromegaly caused by a growth hormone-releasing hormone-secreting carcinoid 
tumor: case report." Neurosurgery, 2002, 50: p. 1356-1359. 
[177] Yavuz, M.N., Yavuz, A.A., Aydin, F., Can, G., and Kavgaci, H. "The efficacy of 
octreotide in the therapy of acute radiation- induced diarrhea: a randomized 
controlled study". International Journal of Radiation Oncology, Biology, Physics, 
2002, 54: p. 195-202. 
 
 
60 
[178] Mauras, N., Attie, K.M., Reiter, E.O., Saenger, P., and Baptista, J. "High dose 
recombinant human growth hormone (GH) treatment of GH-deficient patients in 
puberty increases near- final height: a randomized, multicenter trial. Genentech, 
Inc., Cooperative Study Group." Journal of Clinical Endocrinology and 
Metabolism, 2000, 85: p. 3653-3660. 
[179] Reiter, E.O., Attie, K.M., Moshang, T., Jr., Silverman, B.L., Kemp, S.F., 
Neuwirth, R.B., Ford, K.M., and Saenger, P. "A multicenter study of the efficacy 
and safety of sustained release GH in the treatment of naive pediatric patients 
with GH deficiency". Journal of Clinical Endocrinology and Metabolism, 2001, 
86: p. 4700-4706. 
[180] Cleland, J.L., Duenas, E., Daugherty, A., Marian, M., Yang, J., Wilson, M., 
Celniker, A.C., Shahzamani, A., Quarmby, V., Chu, H., Mukku, V., Mac, A., 
Roussakis, M., Gillette, N., Boyd, B., Yeung, D., Brooks, D., Maa, Y.-F., Hsu, C., 
and Jones, A.J.S. "Recombinant human growth hormone poly(lactic-glycolic acid) 
(PLGA) microspheres provide a long lasting effect". Journal of Controlled 
Release, 1997, 49: p. 193-205. 
[181] Johnson, O.L., Jaworowicz, W., Cleland, J.L., Bailey, L., Charnis, M., Duenas, E., 
Wu, C., Shepard, D., Magil, S., Last, T., Jones, A.J.S., and Putney, S.D. "The 
stabilization and encapsulation of human growth hormone into biodegradable 
microspheres". Pharmaceutical Research, 1997, 14: p. 730-735. 
[182] Saltzman, W.M. and Olbricht, W.L. "Building drug dlievery into tissue 
engineering". Nature Reviews: Drug Discovery, 2002, 1: p. 177-186. 
[183] Martin, F.J. and Grove, C. "Microfabricated drug delivery systems: concepts to 
improve clinical benefit". Biomedical Microdevices, 2001, 3: p. 97-108. 
[184] Mathiowitz, E., Langer, R.S., Warshawsky, A., and Edelman, E. Polymer 
composite for controlled release or membrane formation. US Patent # 4,898,734. 
February 6, 1990. 
[185] Brannon-Peppas, L. "Controlled release of b -estradiol from biodegradable 
microparticles within a silicone matrix". Journal of Biomaterial Science Polymer 
Edition, 1994, 5: p. 339-351. 
[186] Hu, Y., Hollinger, J.O. and Marra, K.G. "Controlled release from coated polymer 
microparticles embedded in tissue-engineering scaffolds". Journal of Drug 
Targeting, 2001, 9: p. 431-438. 
[187] Meese, T.M., Hu, Y., Nowak, R.W., and Marra, K.G. "Surface studies of coated 
polymer microspheres and protein release from tissue-engineered scaffolds". 
Journal of Biomaterial Science Polymer Edition, 2002, 13: p. 141-151. 
 
61 
[188] Hickey, T., Kreutzer, D., Burgess, D.J., and Moussy, F. "Dexamthasone/PLGA 
microspheres for continuous delivery of an anti- inflammatory drug for 
implantable medical devices". Biomaterials, 2002, 23: p. 1649-1656. 
[189] Birnbaum, D., Kosmala, J.D., Henthorn, D.B., and Brannon-Peppas, L. 
"Controlled release of b-estradiol from PLAGA microparticles: the effect of 
organic phase solvent on encapsulation and release". Journal of Controlled 
Release, 2000, 65: p. 375-387. 
[190] Mu, L. and Feng, S.S. "Fabrication, characterization and in vitro release of 
paclitaxel (Taxol®) loaded poly (lactic-co-glycolic acid) microspheres prepared by 
spray drying technique with lipid/cholesterol emulsifiers". Journal of Controlled 
Release, 2001, 19: p. 239-254. 
[191] Wang, F.-J. and Wang, C.-H. "Sustained release of etanidazole from spray dried 
microspheres prepared by non-halogenated solvents". Journal of Controlled 
Release, 2002, 81: p. 263-280. 
[192] Blanco-Prieto, M., Lecaroz, C., Renedo, M., Kunkova, J., and Gamazo, C. "In 
vitro evaluation of gentamicin released from microparticles". International 
Journal of Pharmaceutics, 2002, 242: p. 203-206. 
[193] Jung, T., Koneberga, R., Hungerer, K.-D., and Kissel, T. "Tetanus toxoid 
microspheres consisting of biodegradable poly(lactide-co-glycolide)- and ABA-
triblock-copolymers: immune response in mice". International Journal of 
Pharmaceutics, 2002, 234: p. 75-90. 
[194] Quaglia, F., De Rosa, G., Granata, E., Ungaro, F., Fattal, E., Immacolata, L., and 
Rotonda, M. "Feeding liquid, non-ionic surfactant and cyclodextrin affect the 
properties of insulin- loaded poly(lactide-co-glycolide) microspheres prepared by 
spray-drying". Journal of Controlled Release, 2003, 86: p. 267-278. 
[195] del Barrio, G., Novo, F. and Irache, J. "Loading of plasmid DNA into PLGA 
microparticles using TROMS (Total Recirculation One-Machine System): 
evaluation of its integrity and controlled release properties". Journal of Controlled 
Release, 2003, 86: p. 123-130. 
[196] Shi, L., Caulfield, M., Chern, R., Wilson, R., Sanyal, G., and Volkin, D. 
"Pharmaceutical and immunological evaluation of a single-shot hepatitis B 
vaccine formulated with PLGA microspheres". Journal of Pharmaceutical 
Sciences, 2002, 91: p. 1019-1035. 
 
 
 
62 
Table 2.1:   Exponent n of the power law of polymeric systems with different geometry 
 
Thin Film Cylinder Sphere Drug release mechanism 
n=0.5 n=0.45 n=0.43 Diffusion control 
0.5<n<1 0.5<n<1 0.5<n<1 Anomalous transport 
n=1 n=0.89 n=0.85 Swelling control 
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Table 2.2: Crystallinity as a function of preparation conditions as determined from 
various techniques* 
 
Annealing conditions Degree of crystallinity (%) 
Temperature (ºC) Time (min) From density From DSC From IR spectra 
90 30 30.0 35.6 31.1 
105 60 45.0 46.8 44.5 
120 30 50.8 50.1 52.3 
120 90 64.7 71.1 62.7 
 
*Table from Hassan and Peppas [1]. 
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Table 2.3: Examples of drugs incorporated into PLA/PLGA microsphere systems 
 
Drug Type of Drug Particle Size (mm) Polymer 
Preparation 
Method 
Dexamthasone 
[188] 
hydrophobic small 
molecule, 
anti-inflammatory 
1-50 PLGA 50:50 o/w1 
Etoposide [103] hydrophobic small molecule, anti-cancer 18-36 PLGA 50:50 o/w 
b -estradiol [189] 
hydrophobic small 
molecule, menopausal 
treatment 
50-70 PLGA 50:50 o/w 
All-trans Retiotic 
acid [100] 
hydrophobic small 
molecule, promotes cell 
differentiation 
10-94 PLGA 50:50 o/w 
Paclitaxel [190] hydrophobic small molecule, anti-cancer 0.8-3.0 PLGA 75:25 
Spray 
drying 
Estandazole [191] 
hydrophilic small 
molecule, radiosensitizer 
for cancer treatment 
1.4-2.6 PLGA 65:35 PLGA 85:15 
Spray 
drying 
Gentamicin [192] antibiotic  5-9 PLGA 50:50 w/o/w2 
Halperidol [73] 
hydrophobic small 
molecule, atypical 
antipsychotic  
0.5-15 PLGA 50:50 o/w 
Tetanus toxoid 
[193] 
vaccine for neonatal 
tetanus 11-25 
PLGA 50:50 
PLGA 75:25 w/o/w 
Insulin [194] peptide 11-50 PLGA 50:50 Spray drying 
Plasmid DNA 
[195] macromolecule  1.5-14 
PLGA 50:50 
PLGA 75:25 w/o/w 
Hepatitis B 
surface antigen 
[196] 
vaccine for hepatitis B 25-50 PLGA 50:50 PLGA 65:35 w/o/w 
Leuprorelin [169] peptide, anti-cancer 20-30 PLGA 75:25 PLA w/o/w 
Recombinant 
human growth 
factor [180] 
peptide/protein 20-150 PLGA 50:50 w/o/w 
 
1 o/w: oil- in-water emulsion 
2 w/o/w: water- in-oil- in-water emulsion
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Figure 2.1:  Plasma concentration of drug as a function of time after administration 
 
66 
     
 
A. Diffusion Controlled Reservoir System  
 
                                                                                       
 
 
 
 
 
 
B. Diffusion Controlled Monolithic System 
 
 
 
 
 
 
 
 
C. Erosion Controlled System  
 
 
 
 
 
 
 
 
 
D. Swelling Controlled System 
 
 
 
 
 
 
 
 
 
Figure 2.2:  Schematic of drug delivery systems based on different mechanisms 
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Figure 2.3:  Schematic of the crosslinked structure of a hydrogel.  cM  is the molecular 
weight between crosslinks (·) and x  is the network mesh size. 
Mc   x  
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Figure 2.4: PVA hydrogel network with crystallites serving as crosslinking points 
PVA crystallites serve as crosslinks 
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PVA= Polyvinyl Alcohol, PVP=Polyvinyl Pyrrolidone 
  
        
                             Hydrogen bonding between PVA and PVP 
 
 
 
Figure 2.5: Hydrogen bonding in PVA/PVP blends 
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Figure 2.6: Degradation of PLGA copolymers 
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Figure 2.7: Schematics of surface erosion and bulk erosion  
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Figure 2.8:  Critical thickness, Lcritical, that a polymer device has to exceed to undergo 
surface erosion. (Obtained from [133]) 
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Figure 2.9: Effect of lactide content on PLGA copolymer degradation 
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Figure 2.10: Schematic structure of PLGA-PVA composite 
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CHAPTER 3:RESEARCH GOALS 
In this research, two different types of polymeric drug delivery systems are 
proposed based on polymer blending for sustained drug release. Polyvinyl alcohol (PVA) 
is selected as the main polymer due to its semi-crystalline nature to form physically 
crosslinked hydrogels with the advantages of non-toxic, non-carcinogenic and 
bioadhesive properties. 
 In the first part of this work, PVA is blended with a hydrophilic polymer, 
polyvinyl pyrrolidone (PVP), which has been proved to be miscible with PVA through 
formation of hydrogen bonds. As no work has been done on applications of PVA/PVP 
blends as hydrogel materials for controlled drug delivery, we propose to synthesize 
hydrogels from the polymer blends and study the properties of these hydrogels to 
evaluate their potential as drug delivery systems. The second part of this research is 
contributed to the fabrication and evaluation of polymeric composite systems for 
sustained release to an extended duration based on PVA as well. The composites consist 
of biodegradable microparticles of poly (D, L- lactide-co-glycolide) (PLGA) containing a 
model drug in the hydrogel matrix of PVA. The crystallites of PVA serve as the 
crosslinks to hold the composite together, while the release of the incorporated drug is 
controlled by the degradation of PLGA microparticles and diffusion through the hydrogel 
matrix. The specific aims of this work are: 
1. To synthesize hydrogels from blending PVA and PVP using physical crosslinking 
methods with various ratios of these two polymers.  
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2. To characterize hydrogel systems using thermal, ATR-FTIR, mechanical and 
equilibrium swelling studies, and to estimate network structures using rubber 
elasticity theory.  
3. To evaluate the release of a model drug from PVA/PVP hydrogel systems with 
different PVA to PVP ratios.  
4. To incorporate PLGA microparticles containing a model drug into PVA hydrogel 
matrices with various ratios, evaluate particle distributions in the matrix, and 
investigate model drug release from single layer and three- layer PLGA-PVA 
composites with comparison to the release from PLGA microparticles and PVA 
hydrogel films alone, respectively. 
5. To develop a simple empirical mathematical model to describe the apparent drug 
release from the three- layer PLGA-PVA composite and estimate the effect of 
structure parameters of the composites on the drug release. 
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CHAPTER 4:SYNTHESIS & CHARACTERIZATION OF PVA/PVP BLENDS 
4.1   Introduction  
Polymer blends of PVA and PVP have been studied extensively on their 
miscibility and compatibility [1-5]. PVA is a semicrystalline polymer with a melting 
temperature about 230°C, and a glass transition temperature about 80°C [6]. PVP is a 
highly amorphous polymer with a glass transition temperature around 150°C. The 
pyrrolidone ring of PVP contains a carbonyl group which is a proton-accepting site, while 
the hydroxyl group of PVA can act as a proton-donor site (Figure 4.1). Therefore, 
hydrogen bonds can form between PVA and PVP, resulting in homogenous blends. The 
presence of hydrogen bonds in PVA and PVP blends was confirmed with high-resolution 
solid-state 13C nuclear magnetic resonance [5] and Fourier transform infrared 
spectroscopy [7].  A single glass transition was reported by several groups based on 
differential scanning calorimetry data [1-3], indicating PVA and PVP formed 
homogeneous blends.  
For the case of blends prepared from a semicrystalline polymer and an amorphous 
polymer, the melting temperature of the semicrystalline polymer as well as the degree of 
crystallinity will be depressed [8, 9]. For the blends of PVA and PVP, the melting 
temperature of PVA was reported to be depressed systematically with an increase in PVP 
content using differential scanning calorimetry, and negative values of the Flory-Huggins 
interaction parameter 12c  were calculated to be -0.35 at 240°C [3] and -0.52 at 230°C [7]. 
The degree of crystallinity of PVA was reported to decrease with increasing content of 
PVP using both wide-angle X-ray diffraction (WAXD) [3] and small-angle X-ray 
scattering [4]. Nishio et al. further confirmed that no crystallites formed in blends 
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containing more than 60 wt% PVP [3], while Zhang et al. reported that the crystalline 
phase of PVA disappeared completely when the PVP composition was higher than 54 
wt% [4]. 
While significant work has been done to understand the miscibility of PVA and 
PVP blends, no work has focused on synthesis or application of these PVA/PVP blends 
as biomaterials. The purpose of this part of the research is to synthesize hydrogels from 
PVA/PVP blends that contain physical crosslinks consisting of PVA crystallites and 
PVA/PVP hydrogen bonds. Additionally, we intend to study the structure and properties 
of the swollen networks in vitro. As PVA and PVP are both biocompatible, these new 
hydrogels may have promising characteristics that could make them candidates as 
carriers for controlled drug delivery.  
4.2    Experimental Section 
4.2.1 Synthesis of PVA/PVP Blends  
Polyvinyl alcohol (Elvanolâ, Grade 71-30, Mw=138,400-146,500) was obtained 
from duPont de Nemours & Co. (Wilmington, DE). Polyvinyl pyrrolidone (PVP, 
Mw=10,000) was obtained from Aldrich Chemical Company, Inc. (St. Louis, Mo). 
Polymer solutions containing 10 wt% polymers were prepared in deionized water 
with PVA to PVP ratios 100:0, 95:5, 90:10, 75:25 and 50:50. PVA and PVP powders 
were weighed and added into deionized water while stirring on a magnetic stir plate. The 
polymer-water mixture was stirred for 30 minutes and then put into oven at 84°C 
overnight to dissolve PVA. The ensuing polymer solutions were cast into Plexiglasâ trays 
and dried at 37°C for 72 hours. Transparent films were obtained after evaporation of 
water. This solvent evaporation process is a preferred method to prepare hydrogels for 
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biomedical proposes, since no toxic agents are present in the ensuing hydrogels, such as 
residual monomers, initiators and crosslinking agents, which are inevitable in regular 
chemical crosslinking process.  
4.2.2 ATR-FTIR Spectroscopy 
The compositions of the PVA/PVP hydrogels were evaluated by ATR-FTIR 
spectroscopy (Nicolet Magna-IR 560 spectrometer, Madison, WI). For the studies, thin, 
flat strips of the dried polymers were mounted on a zinc-selenium ATR crystal and the IR 
spectra were obtained using 2048 scans and resolution of 2 cm-1.  
4.2.3 Thermal Properties 
Thermal transitions of the blends were determined using differential scanning 
calorimetry (DSC) (Model 2010, TA Instruments, Wilmington, DE). DSC measures the 
temperatures and heat flows associated with transitions in materials as a function of time 
and temperature in a controlled atmosphere. It yields peaks relating to endothermic and 
exothermic transitions and show changes in the heat capacity. Additionally, the DSC 
output plots energy against average temperature. Therefore, the areas under the peaks can 
be related to the enthalpy quantitatively [9].  
In these experiments, 4 to 6 mg of a dried sample were placed in an aluminum 
pan and heated at a ramp rate of 5°C/min up to 250°C. Nitrogen was used as the purging 
gas, and the  flow rate was set at 20 mL/min. The glass transition temperature, the melting 
temperature, and melting enthalpy for blends of different compositions were determined 
for each of the samples using Universal Analysis Version 2.5H (TA Instruments,  Inc).  
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4.2.4 Stability of PVA/PVP Hydrogels  
The polymers were immersed in PBS solution (pH 7.4) and taken out at set times 
following immersion of 1, 4, 8, 12, and 24 hours. The swollen films were put between 
two glass slides in to order to get thin, flat strips. The films were then dried under 
vacuum at 37°C for 72 hours. The dried samples were mounted on a zinc-selenium ATR 
crystal and the IR spectra were obtained using 2048 scans and resolution of 2 cm-1. 
           These samples were weighed in air and heptane and placed in PBS solutions at 
37°C. At set times following immersion (1, 2, 4, 8, and 12 hours), the strips were 
removed from solution and weighed. These disks were then dried under vacuum for 72 
hours and the weights were recorded. 
4.2.5  Equilibrium Swelling Studies 
The ATR-FTIR spectra demonstrated that PVP dissolved out of the hydrogel 
network after immersion in water. To understand the true swelling behavior of the 
hydrogels, the blend films were immersed in phosphate buffered saline (PBS) solution of 
pH 7.4 for one week and dried under vacuum for 72 hours.  
 Discs with diameter 6.4 mm were cut from the vacuum-dried blend films. The 
mass of the dry discs was measured in air and heptane in order to determine the dry 
polymer volume and density using a buoyancy experiment. The discs were then swollen 
in PBS solution (pH 7.4) in a shaking bath at 37°C. The mass of the gels were measured 
after 30 minutes, 1 hour, 4 hours, 8 hours, 24 hours swelling, then daily for the first week, 
and then weekly up to 8 weeks (56 days). The PBS solutions were changed daily for the 
first 2 weeks and then weekly. The weight swelling ratio for the gels, q, was calculated as 
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the ratio of the gel weight to the dry weight of the discs. The equilibrium volume 
swelling ratio, Q, and the equilibrium polymer volume fraction, 2,su  were calculated as:  
( )12 1 1
p-
,s
w
Q q -= = +
r
u
r
        (4.1) 
Here, pr  is the density of the dry polymer blend and pr  is the density of the 
solvent. After 8 weeks, the swollen discs were removed from the solution and the dry 
weights were measured in air and heptane (n=5). 
4.2.6 Mechanical Properties 
The mechanical properties of the hydrogels were determined using an automated 
materials testing system (Instron, Model 4442, Canton, MA) with a 50 N load cell. The 
experiment was conducted according to the ASTM Designation D 882-95a (Standard 
Test Method for Tensile Properties of Thin Plastic Sheeting). The swollen PVA/PVP 
hydrogel films were cut into strips of 5 mm wide by 0.3 mm thick. The strips were then 
placed in the grips of the tester and elongated at a constant extension rate of 5 mm/min up 
to a maximum elongation of 20%.  
4.2.7 Model Drug Release 
The model drug selected for our study was Vitamin B12 (cyanocobalamin, 
Fw=1355, 99%, Sigma).Vitamin B12 readily dissolves in water and forms a solution with 
red color due to its high content of cobalt (Figure 4.2), which can be detected with 
UV/VIS spectrometry at the wavelength of 361.1 nm.  
1% (w/w) of vitamin B12 was added into 10 wt% aqueous solutions of PVA and 
PVP with ratios of 100:0, 95:5, 90:10, 75:25 and 50:50. The solutions were stirred on a 
magnetic stir plate to mix vitamin B12 with the polymers, and then cast into films as 
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previously described. After evaporation of water, the blend films were cut into discs with 
diameter of 6.4 mm and put in 8 mL PBS solution (pH 7.4) with stirring speed set at 350 
rpm. 3 mL solutions were taken out periodically, and 3 mL fresh PBS solution was added 
in each sample to maintain the constant volume of releasing medium. The concentration 
of vitamin B12 was detected using UV/VIS spectrometer (Lambda 40, PerkinElmer 
Instrument, Shelton, CT) at its maximum wavelength 361.1nm. The cumulative release of 
vitamin B12 was then calculated based on the concentration obtained from the 
experiment. 
4.3   Results and Discussion 
Preparation of PVA/PVP blends in aqueous solution is a convenient and efficient 
way to synthesize blends from these two polymers. PVA and PVP are both water soluble 
due to the interactions of their polar side groups with water. The carbonyl group of PVP 
forms strong hydrogen bonds with water, and assures PVP readily dissolves in water at 
room temperature. PVA has lower water solubility and requires a higher temperature to 
dissolve. The reported temperature for PVA to dissolve in water ranges from 85 to 90°C. 
The direct mixing of PVA and PVP powders in deionized water and heating up the 
polymer mixture at 84°C offered a more precise way to get the desired ratio of PVA to 
PVP in blends than previously reported methods, in which PVA/PVP solutions were 
prepared by mixing PVA solution and PVP solution [1-5, 7]. This physical method is a 
strong candidate routine to prepare hydrogels with none or less release of toxic agents, 
such as residual monomers, initiators and crosslinking agents, which are inevitable in 
regular chemical crosslinking process. 
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4.3.1 Confirmation of PVA/PVP Blends Components 
The components of blends with varied PVA/PVP ratio were verified using ATR-
FTIR spectroscopy. For the studies, thin, flat strips of the dried polymers were mounted 
on a zinc-selenium ATR crystal and the IR spectra were obtained using 2048 scans and 
resolution of 2 cm-1.  
The O-H stretching peak in IR spectrum is by far the most characteristic IR peak 
for alcohols. The free O-H vibration occurs as a sharp IR peak at above 3600 cm-1. 
Hydrogen bonding arises from the interaction between the O-H proton and the long-pair 
or p electrons of a nearby basic site, including nitrogen, oxygen, sulfur, halogen atoms 
and functional groups that contain p electrons. The interaction can be intermolecular or 
intramolecular. The effect of hydrogen bond formation is to increase the IR intensity and 
lower the O-H stretching frequency. Therefore, for the majority of condensed-phase 
(liquid or solid) samples, the O-H peak is broadened and shifted to 3500 – 2500 cm-1 due 
to various types of hydrogen bond formation.  
PVA studied in our research was 99% hydrolyzed, meaning 99% of the acetate 
groups are hydrolyzed into hydroxyl groups. The O-H groups form hydrogen bonds with 
each other. The hydrogen bonds can form either between PVA molecules (intermolecular) 
or within one PVA molecules (intramolecular).  As a result of formation of hydrogen 
bonds, the stretch peak of O-H shifts to lower frequency from the unassociated sharp  
absorption at 3600 cm-1. In Table 4.1, the characteristic IR peaks for polymeric alcohols 
are listed [10]. Compared to the above wavenumbers, the peaks of PVA film  in FTIR 
spectrum were identified (Figure 4.3). The 3262 cm-1 peak is the O-H stretch peak due to 
intermolecular hydrogen bonding, while the split peak at 2906 cm-1 is the O-H stretch 
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peak due to intramolecular hydrogen bonding. The peaks at 1415 cm-1 and 1325 cm-1 are 
C-O-H bend peaks, while the intense peak at 1085 cm-1 is the C-C-O stretch peak. The 
shoulder peak at 1142 cm-1 is reported to be related to the degree of crystallinity of PVA, 
which was proposed to be a C-C stretching mode and increase with an increase in the 
degree of crystallinity [11].  
PVP film cast from aqueous solution is very fragile and hard to peel off from the  
mold. A quick solvent casting method was thus used to cast PVP film onto the ATR 
crystal directly with dichloromethane as the solvent. The ATR-FTIR spectrum of PVP is 
shown in Figure 4.4. The absorbance peak at 1636 cm-1 was reported to be attributed to a 
mixed mode of carbonyl group stretch and –N-C stretch vibrations [12]. Anther two 
peaks which seem to have strong absorption are at  1418 cm-1 and 1264 cm-1, respectively.  
Figure 4.5 shows the IR spectra of the dried blend films. Since PVA and PVP 
both presented in the films, their characteristic peaks were shown in the spectra. The peak 
height of PVP’s 1660 cm-1 peak increased with increasing PVP in the blends, while the 
peak height of PVA’s 1085 cm-1 decreased, which was in agreement with the 
compositions in the blends. The peak at 1280 cm-1 was also associated with PVP 
composition in the blends, which was found in pure PVA spectrum. The peak height 
increases with increasing PVP composition in the blends.  
4.3.2 Miscibility of PVA/PVP Blends  
The presence of a single glass transition temperature has been widely accepted as 
the demonstration of miscibility of polymer blends. The melting point depression has also 
been reported for blends of a semicrystalline polymer and an amorphous polymer [8, 13]. 
From our DSC study, single glass transition temperatures were observed, which 
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suggested the miscibility of PVA and PVP in the whole range of the compositions we 
tested (Figure 4.6).  
The pure PVA samples yielded a relatively sharp endothermic peak with a 
melting temperature at 227°C. In Figure 4.6, the melting peak of PVA crystalline shifted 
to lower temperatures and the peak area suppressed rapidly with increasing PVP content, 
indicating the degree of crystallinity of PVA decreased. These results from DSC showed 
that even though PVA and PVP were miscible in the amorphous regions of the blends, 
the pyrrolidone ring of PVP hindered the formation of the crystallites of PVA and 
resulted in the shift and depression of PVA’s melting peak. On molecular levels, the 
crystallites of PVA can be described as a layered structure. A double layer of molecules 
is held together through hydrogen bonds between the hydroxyl groups of PVA, while the 
adjacent double layers are connected through van der Waals forces [14]. The degree of 
crystallinity of PVA/PVP blends was calculated by comparing the melting enthalpy of the 
samples to the enthalpy required to melt a 100% crystalline PVA, which was determined 
to be 138.6 J/g [15]. The melting enthalpy was obtained by integrating the area under the 
melting peak of PVA (Universal Analysis-NT, Version 2.5H, TA instrument, Inc.). The 
degree of crystallinity of the PVA/PVP blends was then calculated (Figure 4.7). 
From DSC thermograms, a wide and shallow endothermic peak other than the 
melting peak of PVA crystallites was observed for all the samples around 130°C. This 
peak is related to the dissociation of the hydrogen bonds in the crystalline structure. 
According to the X-ray diffraction analysis that Assender and Windle performed, there is 
a change in the thermal expansion coefficient at around 130°C [16]. The crystalline 
structure of PVA is highly hydrogen bonded. At a temperature around 130°C, the 
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polymer chains become more flexible and twist away from a planar zig-zag conformation 
due to the break-down of the hydrogen bonding.  
When a semicrystalline polymer and an amorphous polymer form miscible blends, 
the melting temperature of the semicrystalline polymer will be depressed due to the 
presence of the amorphous polymer. From our DSC study, the melting temperature of 
PVA was shown to be depressed with increasing PVP content in the blend systems 
(Figure 4.6). This depression phenomenon can be used to determine the Flory-Huggins 
interaction parameter, 12c , which is related to the enthalpy of mixing. When two 
polymers are mixed together, the entropy of mixing becomes negligible due to their high 
molecular weight. Therefore, the melting temperature depression can be expressed by the 
following equation [3, 7, 13]: 
0 22
1
2
m m
V B
T -T
H
æ ö
D = ç ÷Dè ø
f          (4.2) 
Here, the subscripts 1 and 2 are used to designate the amorphous (PVP) and 
semicrystalline (PVA) components, respectively; mTD is the equilibrium melting 
temperature depression; 0mT  is the melting temperature of the pure semicrystalline 
polymer (PVA); V2 is the molar volume of repeating unit of PVA; 2HD  is the molar 
enthalpy of fusion of repeating unit of PVA; and 1f  is the volume fraction of PVP. The 
term B refers to the interaction energy density of the two polymers and is related to the 
Flory-Huggins interaction parameter 12c  by: 
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Here, R is the gas constant, V1 is the molar volume of repeating unit of component 
1, and Tm is the melting temperature of the blend. With Tm0=227°C for pure PVA film, 
V1=92.0 cm3/mol, V2=32.8 cm3/mol and 2HD =6.7 KJ/mol, the term B was calculated 
from the slope of mTD  versus 
2
1f  plot (Figure 4.8).  
The value of 12c  was calculated for every blend composition studied in this 
research (Table 4.2). The negative values of 12c  indicated that the mixing of PVA and 
PVP was exothermic, which means the polymer pair formed thermodynamically stable 
compatible blends. The magnitude of the 12c  value appeared to be reasonable in 
comparison to the values in the literatures. However, the values of 12c  we obtained were 
more negative, compared to -0.52 [7] and -0.65 [3] at 230°C, respectively. The more 
negative values indicated stronger intermolecular interactions between the two polymers 
in our study. This is due to the fact that the polymers we used in the research had lower 
molecular weight, especially PVP (Mw=10,000 compared to 24,500 [3] and 360,000 [7]). 
PVP with shorter chain length can interact with PVA more easily than PVP with long 
chains. As a result, stronger intermolecular interaction between PVA and PVP were 
formed.  
4.3.3 Stability of PVA/PVP Hydrogels 
The main propose of this research was to develop a polymer system which can be 
used as biomedical devices, especially as carriers for therapeutic agents. Understanding 
the stability of the PVA/PVP hydrogels, especially after their immersion in buffered 
solutions, is critical to apply the hydrogels as biomaterials. IR spectra offered a 
straightforward way to evaluate the component change of the hydrogels by comparing the 
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characteristic peaks. The IR spectra were first taken for the vacuum-dried PVA/PVP thin 
films. The films were then immersed in PBS solution (pH 7.4) and taken out at set times 
following immersion of 1, 4, 8, 12, and 24 hours. The swollen films were put between 
two glass slides to avoid the curving of the films upon drying. The films were then dried 
under vacuum at 37°C for 72 hours, and IR spectra were collected for each sample using 
the same number of scans and the resolution as the original dry films.  
The IR spectra of dried films post swelling were obtained for each set time. For 
the pure PVA film, no significant changes were observed prior to and post immersion 
(Figure 4.9). However, the height of the 1636 cm-1 peak reduced dramatically for each 
blend film (Figure 4.10-Figure 4.13), indicating that the concentration of the carbonyl 
groups decreased after immersion in the buffered solutions. This decrease of carbonyl 
groups in the blend films showed that the amount of PVP decreased in the hydrogel 
network, which occurred during the swelling process. For the 1660 cm-1 peak of PVP, the 
peak height depression occurred mostly in the first hour of swelling for every 
composition studied in this research., indicating that most PVP dissolved out of the 
hydrogel network after immersion in water. In order to evaluate the composition change 
of the blends, quantitative analysis was performed. Beer’s law is the basis of all 
quantitative analysis, which relates concentration to absorbance: 
A l c= × ×e             (4.4) 
Here, A is the absorbance, expressed as log (I0/I), where I0  is the intensity of the 
incident light and I is the intensity of the light transmitted through the sample; e  is molar 
absorptivity or extinction coefficient; l is sample path length, and c is the sample 
concentration.  
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The Attenuated Total Reflectance (ATR) technique is performed using an 
accessory containing a crystal of infrared transparent material of high refractive index to 
mount in the sample compartment of FTIR. The crystal used in this research is zinc 
selenium (ZnSe), which is the most common ATR crystal material with transmission 
range from 20,000 to 600 cm-1. As the penetration depth of IR beam is on the order of 0.1 
to 5mm, the thickness of the sample is not a factor affecting the absorbance for regular 
polymer films [17].  Using Beer’s Law, the peak height ratio can be related to the 
polymer composition ratio: 
- -
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Here, A is the absorbance of the characteristic peaks (peak height in this case); C 
is the molar concentration of characteristic groups.  
As seen in Equation 4.5, the path length is cancelled out since it is the same for 
one specific sample. The extinction coefficient is a physical constant and characteristic of 
the sample. Therefore, the ratio of two extinction coefficients should also be a constant. 
A linear relation between the peak height ratio and the concentration ratio is thus 
obtained and does not depend on the path length of each sample.  
The standards were prepared with 0.5, 1, 2, 5, 10, 25 and 50 wt% of PVP in the 
blends. The peaks we chose to represent the blends were the C-C-O stretch peak of PVA 
at 1086 cm-1 and the mixed mode stretch peak of PVP at 1660 cm-1, so that the peak 
height ratios could be related to the concentrations of carbonyl groups of PVP and 
hydroxyl groups of PVA in the blends. FTIR spectra were collected for each standard. 
The heights of PVA’s 1085 cm-1 peak and PVP’s 1636 cm-1 were measured using Ominc 
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Version 4.1A (Nicolet Instrument Co.). The ratio of the two peak heights was calculated, 
and then a plot of the peak height ratio versus C=O/C-C-O molar ratio was drawn as the 
standard curve (Figure 4.14) 
Beer’s law is the most commonly used calibration analysis. A linear relation 
between the absorbance and the concentration is required. However, the plot of the whole 
concentration range didn’t give a linear equation for the standard curve. The linear region 
lay at the peak he ight ratio up to 0.3 which was correlated to PVP concentration of 10 
wt% in the blends, y=5.9154x+0.0342 (R2=0.9999). The compositions of PVA and PVP 
after swelling in PBS were calculated based on the correlation equation from the spectra 
(Figure 4.15). 
The FTIR analysis showed the final compositions of PVA and PVP after 
immersion in PBS solution. However, the result did not give information on dissolution 
of both components upon the immersion. To understand the dissolution behavior, a set of 
experiments were performed to record the weight change of samples prior to and post 
immersion. Dry films with varied PVA/PVP compositions were cut into disks with 
diameter of 6.4 mm, and weighed in air and heptane, respectively. The disks were then 
placed in PBS (pH 7.4) solutions at 37°C in shaking bath. At set times following 
immersion (1, 4, 8 and 24 hours), the disks were removed from solution and dried under 
vacuum for 72 hours and the weights were recorded. The percentage weight for the gels 
was calculated as: 
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Here, Wt is the post-swelling dry weight of the polymer disks at each set time, and 
W0 is the pre-swelling dry weight of the polymer disks. The weight change prior to and 
post swelling was calculated (Figure 4.16).  
For pure PVA films, the weight of samples almost stayed the same after 1 day 
swelling, while for the blend films, the dry weight decreased with varied degrees 
associated with the initial composition of PVP blended in the system. For initially 5 wt% 
PVP blends, the film was 96% of the original weight; for initially 10 wt% PVP, 92% 
component remained; for 25 wt% PVP, 78% component remained; for 50 wt% PVP, only 
53% of the original weight remained.  The trend of weight loss increased with increasing 
the amount of PVP initially blended in the system, indicating more polymers dissolved 
out with higher PVP content. Both weight calculation and FTIR spectra showed that the 
dissolution of PVP happened mostly in the first hour of swelling. Combine the 
quantitative IR analysis and the weight measurement, the percentage of PVP dissolved 
out of the blend network was calculated from mass balance: 
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Here, Wt is the post-swelling dry weight of the polymer disks at time t, and W0 is 
the pre-swelling dry weight of the polymer disks (from weight measurement); xt and x0 
are the compositions of PVP at time t and time 0, respectively (from FTIR data).  
By the end of the 24 hours swelling, more than 80% of PVP dissolved out of the 
hydrogel system after immersion in buffered solutions regardless the film composition 
(Figure 4.17). The dissolution rate of PVP increased with higher initial PVP content in 
the first hour. The carbonyl group of PVP is a stronger proton acceptor than the hydroxyl 
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group of PVA. When water is present in the system, water molecules begin to compete 
with PVA to form hydrogen bonds with PVP. Water molecules are much smaller than 
PVA molecules, and thus more PVP forms hydrogen bonds with water molecules than 
with PVA. As a result, most of PVP is isolated from PVA by the surrounding water 
molecules and dissolved out of the hydrogel network.  
The hydrogel network is held together by the crystallites of PVA and the 
hydrogen bonds between PVA and PVP in amorphous regions.  Even though more 
hydrogen bonds would form in the amorphous regions of the blends with higher PVP 
content, the hindrance of pyrrolidone ring to the formation of PVA crystallites has more 
effect on the hydrogel network. More PVP molecules present in the system, fewer 
crystallites are formed, resulting in a less crosslinked hydrogel network. Higher PVP 
composition in the blend system makes the hydrogel more hydrophilic and less 
crosslinked, which uptakes water more quickly, resulting in a faster dissolution of PVP 
out of the network. 
The dissolution of PVA upon hydrogel swelling was also calculated in the same 
way. For 5% and 10% blends, no significant loss of PVA was observed; while for 25% 
and 50% blends, PVA was found to lose about 3.5% and 6% of the initial weight by the  
end of 24 hours swelling. The dissolution of PVA is also a result of less crosslinked 
network resulting from the presence of more PVP pyrrolidone groups in the blend system. 
With less crosslinked network, the amorphous regions have more tendencies to dissolve 
in the presence of water.  
DSC studies were also performed along with the dissolution studies, and the 
melting temperature was recorded. After swelling in PBS solution, Tm of pure PVA, 5% 
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PVP and 10% PVP blends were found to decrease with varied degree, while Tm of 25% 
and 50% PVP blends increased. Especially for the film with 50 wt% PVP initially 
blended in the system, Tm increased dramatically after swelling. This increase of melting 
temperature was a result of dissolution of PVP and the presence of water. As the 
hindrance of pyrrolidone rings was removed with the dissolution of PVP, the polymer 
chains of PVP were able to rearrange in relaxed state when water was present. The 
hydroxyl groups of PVA formed hydrogen bonds to form crystallites. However, as shown 
in Figure 4.18, the melting temperature of lower PVP content blends, including pure PVA, 
actually decreased after the first hour of swelling. As analyzed in FTIR spectra and 
weight change calculation, PVA dissolved out of the blending system as well, which was 
at a very low level compared to PVP dissolution. The dissolution of PVA was proposed 
to be a result of unfolding of crystallite chains layer by layer in the presence of water. 
The unfolded chains then join the amorphous region surrounding them [18]. From Figure 
4.18, the Tm of all the PVA/PVP blends (including pure PVA film) were reaching an 
equilibrium value, which was around 220°C, indicating there might be an equilibrium 
crystallite size related to the dynamic equilibrium of hydrogen bonding in the system. 
Crystallites bigger than the equilibrium size would dissolve, as in pure PVA film, while 
crystallites smaller than the equilibrium size would grow when the polymer chains 
became flexible in the presence of a compatible solvent (water in this case).  
4.3.4 Equilibrium Swelling Behavior 
As shown in DSC results (Figure 4.6) , the degree of crystallinity of PVA 
decreased with increasing PVP content in the blend system, indicating fewer crystallites 
were formed with higher PVP content in the original blends. However, after immersion in 
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water, the components of the blends, mainly PVP, dissolved out of the hydrogel network, 
resulting in an equilibrium value of melting temperature regardless of the initial 
composition in the blends. The crystallites of PVA act as crosslinking points to hold the 
hydrogel network together, resulting in a 3-D structure which does not dissolve in water. 
Fewer crystallites or fewer crosslinks present in the network, resulting in a more flexible 
structure which is able to absorb more water. Therefore, the ability of water absorbing 
can be related to the network structure and offer the information on the degree of 
crosslinking of a given network, which can be correlated to the number of crystallites 
present in the hydrogel.  
To understand the true swelling behavior of the hydrogels, the blend films were 
cut into discs of diameter 6.4 mm and immersed in PBS solution for one week to let the 
system reach equilibrium. The disks were then dried under vacuum for 72 hours. In the 
swelling studies, the discs were swollen in PBS solution (pH 7.4) in a shaking bath at 
37°C. The mass of the gels were measured after 0.5, 1, 4, 8 and 24 hours swelling, then 
daily for the first week, and then weekly up to 8 weeks (56 days). The PBS solutions 
were changed daily for the first 2 weeks and then weekly. The weight swelling ratio for 
the gels, q, was calculated as the ratio of the gel weight to the dry weight of the discs at 
each set time. After 8 weeks, the swollen discs were removed from the solution and the 
dry weights were measured. No significant difference of weight change was observed for 
all the films. For pure PVA films, the dry weight was 99.4% of the original weight; while 
for 5% PVP blends, 98.7% of the original weight remained; 99.1% for 10% PVP blends, 
97.8% for 25% blends and 98.5% for 50% blends. Therefore, the density of each film 
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could be assumed to remain the same value. With this assumption, the volume swelling 
ratio was calculated using Equation 4.1. 
The hydrogels with more PVP initially present in the blends had higher 
equilibrium swelling ratios (Figure 4.19), indicating that the network was less physically 
crosslinked, which is in agreement with the DSC results. The networks with high PVP 
content are more expendable in water and capable of absorbing more water. The water 
content of each hydrogel at the end of 56 days swelling was calculated with the 
assumption that the weight of polymer didn’t change over time: 
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 Here, Wgel is the hydrogel weight at the end of 56 days swelling; Wp is the dry 
weight of the samples prior to swelling. The water content ranged from 65% for pure 
PVA films to 76% for 50/50 blends (Figure 4.20). 
4.3.5  Mechanical Properties and Structure Analysis 
 The mechanical properties are another standard to evalua te the structure of the 
hydrogels, as hydrogels with higher degree of crosslinking tend to be stronger. were 
determined using an automated materials testing system (Instron, Model 4442, Canton, 
MA) with a 50 N load cell. The swollen PVA/PVP gels were cut into strips 5 mm wide 
by 0.3 mm thick. The strips were placed in the grips of the tester and elongated at a 
constant extension rate of 5 mm/min up to a maximum elongation of 20%. The stress-
strain behavior was observed and used in evaluation of the crosslinked structure of the 
networks using rubber elasticity theory.  
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As shown in Figure 4.21, the tensile strength of the hydrogel decreased with more 
PVP initially blended in the system with lowest value for 50 wt% PVP blends. After 
immersion in PBS solution (pH 7.4) over a period of time, the tensile modulus almost 
remained the same from 1 week to 8 weeks swelling for every blending composition. The 
fluctuations of tensile modulus observed in pure PVA and blends of 95/5, 90/10 was 
probably due to the unevenly distributed crystallites. 
The structures of the hydrogels can be evaluated and characterized using rubber 
elasticity theory based on swelling studies and mechanical analysis [19]. The shear 
modulus, G, is related to the degree of swelling and calculated as: 
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Here, t  is the shear stress, a  is the elongation, and s,2u is the equilibrium 
polymer volume fraction, which is obtained from the swelling studies. 
For the hydrogel networks in the presence of a solvent, the following expression 
was developed by Peppas and Merrill [20]: 
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Here, 2 ,rr  is the density of the polymer in the relaxed state, immediately after 
crosslinking but prior to swelling, and was calculated as the weighted average of the 
densities for our physically blended gels; r,2u is the polymer volume fraction in the 
relaxed state. Mn is the number average molecular weight of the polymer blend chains. As 
studied earlier, PVP dissolves out of the hydrogel network when present in the buffer 
solution. We assumed that all PVP dissolved out by the end of the swelling studies (56 
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days). Therefore, Mn can be treated as the average number molecular weight of PVA 
alone (Mn =77,000). Combining Equation 4.9 and Equation 4.10, the molecular weight 
between crosslinks, cM  , was calculated for the hydrogels which were swollen for 56 
days (Figure 4.22). The values of  cM  increased for the hydrogels with more PVP 
initially blended in the system, indicating fewer crosslinks present.   
The hydrogel mesh size, x , is the linear distance between junction crosslinks and 
can be calculated as [19]: 
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Here, Cn is the characteristic ratio, M0 is molecular weight of the average 
repeating unit calculated, and l is the carbon-carbon bond length for vinyl polymer chains 
(l=1.54 Å). As we assumed that all PVP dissolved out by the end of 56 days, the values 
of PVA are used in Cn, PVA =8.3 [21] and M0=44 The average mesh sizes of the hydrogels 
ranged from 90 to 230 Å, and increased with increasing PVP content in the blends 
(Figure 4.23).  The mesh size is the average end-to-end distance between the crosslinks in 
polymer networks. Hydrogels with bigger mesh sizes are less crosslinked and more 
swellable in aqueous solution. The dissolution studies showed that most of the blended 
PVP dissolved out of the hydrogel network during the swelling process while most of 
PVA remained in the system, indicating the crystallites of PVA were the main source of 
the physical crosslinks present in the hydrogel. The presence of PVP in the blends while 
mixing PVA and PVP in aqueous solution hindered the formation of PVA crystallites, 
leading to less crosslinked hydrogel networks.  As a result, the calculated average mesh 
size for the network increased with increasing PVP content in the blends. 
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4.3.6 Release of Vitamin B12 
Vitamin B12, also called cobalamin, is a water soluble vitamin that belongs to the 
B vitamin complex. Its primary functions are in the formation of red blood cells and the 
maintenance of a healthy nervous system [22, 23]. B12 is necessary for the rapid synthesis 
of DNA during cell division. This is especially important in tissues where cells are 
dividing rapidly, particularly the bone marrow tissues responsible for red blood cell 
formation. The human body stores several years worth of vitamin B12, so nutritional 
deficiency of this vitamin is extremely rare. However, deficiency can result from being 
unable to use vitamin B12 caused by a lack of intrinsic factor, a substance that allows the 
body to absorb vitamin B12 from the digestive system [24]. The classic deficiency 
symptom of vitamin B12 deficiency is pernicious anemia [25]. However, a deficiency of 
vitamin B12 actually affects the brain and nervous system first. A vitamin B12 deficiency 
results in impaired nerve function, which can cause numbness, pins-and-needles 
sensations, or a burning feeling [26, 27]. It can also cause impaired mental function that 
in the elderly mimics Alzheimer’s disease. Vitamin B12 deficiency is thought to be quite 
common in the elderly and is a major cause of depression in this age group [28, 29]. In 
addition to anemia and nervous system symptoms, a vitamin B12 deficiency can also 
result in a smooth, beefy red tongue and diarrhea [30]. This occurs because rapidly 
reproducing cells such as those that line the mouth and entire gastrointestinal tract cannot 
replicate without vitamin B12. Vitamin B12 is necessary in only very small quantities. 
Dosing for vitamin B12 is dependent on the age of the individual. The recommended 
dietary allowance (RDA) for adults is 2.0 mg [31].  
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B12 was incorporated into PVA/PVP hydrogel network by mixing 1 wt% of the 
vitamin with the blend aqueous solution and then casting the solution into thin films. The 
concentration of B12 was detected using UV/VIS spectrometer at the wavelength of 
361.1nm. The release profile was presented in terms of cumulative release percentage of 
B12 versus time (Figure 4.24). For all compositions, the release was fast with most of B12 
dissolved out of the hydrogel networks within one hour. The release rate of B12 was 
found to be related to the PVP composition in the hydrogels, with faster release from the 
hydrogels with higher PVP compositions. In 5 minutes, 28% of B12 dissolved out of pure 
PVA hydrogel network, 32% from 5% PVP hydrogel, 40% from 10% PVP, 50% from 
25% PVP, and more than 70% from the 50% PVP system. This result agreed with the 
average mesh sizes obtained from rubber elasticity theory. As more PVP is present in the 
hydrogel system, the polymer chains between two adjacent crosslinking points are longer, 
resulting in bigger mesh for the incorporated drug molecules to diffuse out. Moreover, 
hydrogen bonds can form through the amide groups of B12, carbonyl groups in PVP, and 
hydroxyl groups of PVA. For B12 incorporated in the pure PVA hydrogel films, the 
interaction of the drug with PVA would be stronger than in other blending systems. As a 
result, the release of B12 from pure PVA hydrogels was slower. As increasing PVP 
composition in the blend systems, the three components would interact with each other 
through hydrogen bonds, leading to a weaker interaction between B12 and PVA, the 
polymer responsible for holding the hydrogel structure together. As a result, the release 
of B12 increased with increasing PVP composition in the blend systems. 
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4.4 Conclusions  
 
PVA/PVP blends were prepared over a range from 0 to 50 wt% PVP composition 
with water as the solvent. The miscibility of PVA and PVP in the blends was confirmed 
by DSC thermograms with the appearance of a single glass transition temperature for 
every blend composition. Negative values of Flory-Huggins interaction parameter, ?12, 
obtained from melting temperature depression also verified the homogeneous miscibility 
of the two polymers in the composition range of this research. 
The stability of the blends in PBS solution (pH 7.4) was studied for a period of 24 
hours. PVP was found to dissolve out of hydrogel networks upon swelling, with ATR-
FTIR spectra and DSC thermograms. The percentage of PVP dissolution was calculated 
from weight change measurement and quantitative analysis of FTIR spectra. More than 
80% of PVP dissolved out  of the originally 50 wt% PVP blends during the first hour of 
swelling, while for the blends of other compositions, the dissolution reached 80% by the 
end of 24 hours swelling.  
The blends were swollen in PBS solution for a period of 8 weeks and the ensuing 
hydrogels contained between 65% and 76% water by weight. These hydrogels were 
insoluble due to the presence of quasi-permanent physical crosslinks consisting of PVA 
crystallites which were found to unfold in the presence of water. The physically 
crosslinked structure of the hydrogels was evaluated using the rubber elasticity theory 
based on the results from swelling and mechanical studies. The average network mesh 
size ranged from 90 to 230 Å for the PVA/PVP hydrogels. The model drug release from 
the blend systems were fast with most of incorporated vitamin B12 dissolved within 30 
minutes.  
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Table 4.1: Characteristic infrared peaks for alcohols 
Characteristic Groups Wavenumbers 
Hydrogen bonded O-H stretch—intermolecular 3400-3200 cm-1 
Hydrogen bonded O-H stretch—intramolecular 3200-2500 cm-1 
Out-of-phase C-C-O stretch—secondary alcohols 1150-1075 cm-1 
In-phase C-C-O stretch—secondary alcohols 900-800 cm-1 
C-O-H bend—secondary alcohols 1430-1200 cm-1 
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Table 4.2: Flory-Huggins interaction parameter 12c  for PVA/PVP blends 
 
PVA/PVP 95/5 90/10 75/25 50/50 
Tm (°C) 225.5±0.1 223.6±0.2 219.2±0.1 201.6±0.7 
12c  - 0.773 - 0.776 - 0.783 - 0.812 
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PVA= Polyvinyl Alcohol 
PVP= Polyvinyl Pyrrolidone  
                             Hydrogen bonding between PVA and PVP 
 
Figure 4.1: Schematic structure of PVA/PVP blend with presence of hydrogen bonds 
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Figure 4.2:  Structure of vitamin B12 
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Figure 4.3: ATR-FTIR spectrum of PVA film cast from aqueous solution 
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Figure 4.4: ATR-FTIR spectrum of PVP film cast from DCM solution 
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* –C-C-O stretch peak of PVA, ** carbonyl group stretch peak of PVP 
 
Figure 4.5: ATR-FTIR spectra of PVA/PVP dry films prior to swelling (a) 100/0 
PVA/PVP, (b) 95/5 PVA/PVP, (c) 90/10 PVA/PVP, (d) 75/25 PVA/PVP, (e) 50/50 
PVA/PVP 
(e) 
(d) 
(c) 
(b) 
(a) 
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Figure 4.6: DSC thermograms of PVA/PVP blends
Tm 
Tg 
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Figure 4.7: Degree of crystallinity of PVA/PVP blends 
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Figure 4.8: Plot of the melting temperature depression as a function of the square of 
the volume fraction of PVP for the calculation of Flory-Huggins interaction parameter 
12c  
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Figure 4.9: ATR-FTIR spectra of pure PVA films (a) prior to swelling, (b) 1 hour 
swelling, (c) 4 hours swelling, (d) 8 hours swelling, (e) 12 hours swelling, (f) 24 hours 
swelling. 
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* –C-C-O stretch peak of PVA, ** carbonyl group stretch peak of PVP 
 
Figure 4.10: ATR-FTIR spectra of initially 95/5 PVA/PVP hydrogels (a) prior to 
swelling, (b) 1 hour swelling, (c) 4 hours swelling, (d) 8 hours swelling, (e) 12 hours 
swelling, (f) 24 hours swelling. 
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* –C-C-O stretch peak of PVA, ** carbonyl group stretch peak of PVP 
 
Figure 4.11: ATR-FTIR spectra of initially 90/10 PVA/PVP hydrogels (a) prior to 
swelling, (b) 1 hour swelling, (c) 4 hours swelling, (d) 8 hours swelling, (e) 12 hours 
swelling, (f) 24 hours swelling. 
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* –C-C-O stretch peak of PVA, ** carbonyl group stretch peak of PVP 
 
Figure 4.12: ATR-FTIR spectra of initially 75/25 PVA/PVP hydrogels (a) prior to 
swelling, (b) 1 hour swelling, (c) 4 hours swelling, (d) 8 hours swelling, (e) 12 hours 
swelling, (f) 24 hour swelling.  
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* –C-C-O stretch peak of PVA, ** carbonyl group stretch peak of PVP 
 
Figure 4.13: ATR-FTIR spectra of initially 50/50 PVA/PVP hydrogels (a) prior to 
swelling, (b) 1 hour swelling, (c) 4 hours swelling, (d) 8 hours swelling, (e) 12 hours 
swelling, (f) 24 hours swelling.  
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Figure 4.14: Calibration curve obtained from ATR-FTIR spectra 
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Figure 4.15: PVP composition change upon dissolution 
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Figure 4.16: Weight change for PVA/PVP blends 
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Figure 4.17: PVP dissolution from PVA/PVP network
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Figure 4.18: Change of PVA melting temperature upon swelling
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Figure 4.19: Volume swelling ration of PVA/PVP after 1 week of pre-dissolution. (·) 
initially 100/0 PVA/PVP,  (o) initially 95/5 PVA/PVP,  (p) initially 90/10 PVA/PVP, (r) 
initially 75/25 PVA/PVP, (¢) initially 50/50 PVA/PVP (n=5). 
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Figure 4.20: Water content of  PVA/PVP hydrogels after 56 days swelling (n=5). 
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Figure 4.21: Tensile modulus of swollen PVA/PVP hydrogels upon swelling (n=5)
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Figure 4.22: Average molecular weight between crosslinks after 56 days swelling 
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Figure 4.23: Mesh size, x , of hydrogels with different PVP content after 56 days of 
swelling (n=5) 
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Figure 4.24: Vitamin B12 release from PVA/PVP hydrogels 
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CHAPTER 5:PLGA-PVA COMPOSITE 
5.1   Introduction 
Within the field of controlled drug delivery, it has been difficult to achieve the 
desired release kinetics for many therapeutic agents from general polymeric systems such 
as hydrogels or microparticles. It is therefore an object of this part of research to 
investigate the efficacy of a polymer composite for releasing the incorporated therapeutic 
agents at a desired rate and quantity.  
In this work, we aim to prepare polymer composites consisting of a continuous 
hydrophilic polymer matrix embedded with micro-/nano-sized sub-matrices. Bioactive 
compounds are entrapped within the sub-matrices, and then released while stimuli are 
present. With dual control of the  main polymer matrix and the sub-matrices, the release 
of the incorporated compounds can be modulated.  
The techniques used to prepare polymer composites mostly involve physical 
methods, such as solvent removal, polymer melts and compression of powders. In solvent 
removal process, the sub-matrices containing drugs are first prepared and then suspended 
in a viscous solution of the main matrix polymer in a solvent, in which the sub-matrix 
polymer is not soluble. The solution is required to be viscous to ensure the even 
distribution of the sub-matrices. The composite is formed after removal of the solvent. 
The solvent removal should be fast to prevent the sub-matrices settling down, and thus 
volatile solvents are preferred. Polymer melts can also be used to produce polymer 
composites with the sub-matrices dispersed in the melts of the main matrix polymer to 
form a composite. In this method, the melting temperature of the main matrix polymer 
should be low enough so that the sub-matrices would not be affected. Compression of the 
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sub-matrices with the powders of the main polymer is another physical method to prepare 
polymer composite. Other than the physical methods, chemical reaction like 
polymerization can also be used to prepare composites through mixing the sub-matrices 
in a monomer solution, which undergoes polymerization to form composites.   
Determinations of which method should be adopted depend on the properties of 
the polymers and the application of the composite. The key consideration is to maintain 
the integrity of the sub-matrices when incorporated into the main matrix. Therefore, when 
choosing the polymers for the main and sub-matrices, the possible interactions between 
the polymers should be taken into consideration. Polymers which are not miscible with 
each other are preferred so that the integrity of the sub-matrices is maintained during the 
formation of the composite.  
Compared to the other methods, solvent removal for the formation of polymer 
composite has the advantages of maintaining the physical properties and integrity of the 
sub-matrices if the right solvent is chosen. The general procedure for making a polymeric 
composite device using solvent removal method is to first incorporate the drug into 
polymeric sub-matrices, and then suspend the sub-matrices in a solution of the main 
matrix polymer in a solvent, in which the sub-matrix polymer are not soluble, to produce 
a viscous solution. The composite is  formed after removing the solvent.   
Biodegradable microparticles fabricated from natural and synthetic polymers have 
been extensively investigated as drug carriers in controlled drug delivery. The linear 
aliphatic synthetic polyesters like polylactide (PLA), polyglycolide (PGA) and their 
copolymer poly (lactide-co-glycolide) (PLGA) have been widely investigated due to their 
excellent biocompatibility and biodegradability. A variety of  pharmaceutical compounds 
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with different properties have been formulated into PLA/PLGA systems, including anti-
cancer drugs [1-3], steroids [4], and hydrophilic agents like peptides [5, 6], proteins [6-10] 
and vaccines [11-13] with the advantages of improved drug efficacy and patient 
compliance. However, just like the other forms of drug delivery systems, linear release is 
not easy to obtain even with particles of apparently uniform diameter. As a result, the 
idea of embedding microparticles, which are incorporated therapeutic agents, inside 
another polymeric matrix became promising to achieve better controlled release.  
Several delivery composite systems based on this concept have been synthesized 
and characterized by some researchers.  In US Patent 4,898,734, Mathiowitz et al. [14] 
described an approximately zero-order release of heparin from PLA microspheres 
embedded in a polyurethane or polystyrene matrix for an extended period. Slower release 
was obtained using polystyrene instead of polyurethane as the matrix polymer. Brannon-
Peppas and coworkers [15] constructed a composite of PLGA particles within silicone 
matrices for the release of b -estradiol. The release rate of b -estradiol from the 
composite was found to be between the release rates from the microparticles and silicone 
films alone, respectively. However, the PLGA microparticles were incorporated into the 
silicone matrices by curing the mixture at 100°C, which is considerably higher than the 
Tg of PLGA (~40°C). The high temperature would cause PLGA microparticles to deform. 
Since no SEM images were shown for the composite or the particles, the structure or 
morphology of the PLGA-silicone composite was not revealed. Marra et al. [16, 17] 
synthesized a tissue engineering scaffold incorporated with drug containing 
microparticles. Both scaffold and microparticles were fabricated using PLGA, but with 
varied PLA to PGA ratio. PVA was used to coat PLGA (50/50) microparticles to protect 
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the particle from the organic solvent when incorporated into PLGA (65/35) scaffolds. 
The release of bovine serum albumin was evaluated.  
However, these composite systems described above are mainly focused on 
incorporation of microparticles into hydrophobic polymer matrices. Little work has been 
done on incorporating biodegradable particles into a hydrogel matrix. As discussed 
earlier, hydrogels resemble nature living tissue closely in physical properties due to their 
high water contents and soft, rubbery elastic consistency [18-20]. A composite of 
microparticles embedded in a hydrogel matrix can thus be a promising candidate for 
controlled release of therapeutic agents in different forms of administration.  
Physically crosslinked PVA hydrogels have been synthesized and studied 
extensively in this lab. The crystallites of PVA can serve as crosslinking points to hold a 
three dimensional structure, resulting in a toxicant free hydrogel network [21-24]. The 
temperature that PVA dissolves in water is usually higher than room temperature and 
related to the degree of hydrolysis [25]. PVA used in this research is 99% hydrolyzed and 
dissolves in water at a temperature above 80ºC [26].  Viscous solution can be formed 
when the PVA aqueous solution is cooled down to room temperature. PLGA is a 
hydrophobic polymer, and not soluble in water. A composite system can be prepared 
taking the advantage of the different solubility of PVA and PLGA in the same solvent, 
i.e., water, and the ability of crystallite formation of PVA through solvent casting. First, 
PLGA microparticles encapsulated therapeut ic agents are produced and then dispersed in 
viscous PVA aqueous solutions to generate a viscous mixture. After removal of water 
though evaporation, composites of continuous PVA hydrogel matrix embedded with 
PLGA microparticles are formed with the formation of PVA crystallites (Figure 5.1).  
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Based on this hypothesis, we propose a delivery system consisting of a PVA 
hydrogel matrix incorporated with PLGA microparticles for sustained release of 
therapeutic agents to an extended duration. The release of the encapsulated agents will be 
modulated by both PLGA microparticles and PVA matrix. Furthermore, a porous 
structure can be formed after the degradation of PLGA microparticles. This makes the 
PLGA-PVA composite system a potential candidate for tissue engineering scaffolds. 
In this chapter, PLGA microparticles were prepared and incorporated into PVA 
hydrogel matrix to form composites. The release of model drug from several composite 
systems was studied and analyzed in Chapter 6.  
5.2   Experimental Section 
5.2.1 Fabrication of PLGA Microparticles 
PLGA with lactide to glycolide ratio of 50:50 (Medisorb® 5050DL 3.5A, 
I.V.=0.40dL/g) was purchased from Alkermes.  PVA (Mw=25,000, 88% hydrolyzed) 
was purchased from Polysciences, Inc. Hydrocortisone and HPLC grade dichloromethane 
were purchased from Sigma.  
The nature and solubility of the drug being encapsulated are the factors to 
determine the microparticle fabrication method. For drugs which are insoluble or poorly 
soluble in water like steroids, single oil- in-water (o/w) emulsion process is most effective; 
while for water-soluble drugs, such as peptides, proteins and vaccines, a water- in-oil- in-
water (w/o/w) method is best suited [1, 27, 28]. In this research, hydrocortisone, a 
hydrophobic drug, was selected as the model drug for the release studies (Figure 5.2). 
Hydrocortisone is the principal glucocorticoid hormone produced by the adrenal cortex, 
with glucocorticoid activity and some mineralcorticoid effects (Merck Index 12, 4828). 
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Its solubility in water is 280 mg/L at 25°C [29], with a log P (octanol-water) value of 
1.61. Due to hydrocortisone’s hydrophobic nature, a single oil- in-water emulsion process 
is accepted to produce PLGA microparticles incorporated with hydrocortisone.  
PLGA 50:50 with varied amount of hydrocortisone were dissolved in organic 
solvent (acetone, ethyl acetate or dichloromethane). Dilute PVA aqueous solutions were 
prepared by dissolving 88% hydrolyzed PVA in deionized water at 83°C for 2 hours. 10 
mL solution containing drug and polymer was dispersed in continuous phase  and 
homogenized using a homogenizer (Kinematica Polytron® Benchtop Homogenizer 
PT3100, Brinkmann Instruments, Inc., Westbury, NY) equipped with a generator (PT-
DA3020/2T) at 5000 rpm for 5 minutes to produce an oil- in-water emulsion. The 
emulsion was transferred onto a magnetic stir plate to stir at 400 rpm for 4 hours to 
remove DCM and harden the microparticles. Microparticles were then collected through 
centrifuge (Sorvall Ultra 80, DuPont, Wilmington, DE) at 15,000 rpm (Rotor: AH-629) at 
10°C for 45 minutes. The pellets are frozen at -80°C and then freeze-dried overnight.  
5.2.2 Particle Size and Size Distribution 
Different techniques have been used to determine the particle size and size 
distribution, including optical particle counter, coulter counter, photon correlation 
spectroscopy and light scattering [30]. Laser scattering is to measure the laser light 
scattered by particles and based on Mie theory, the size and size distribution are 
calculated. In our research, laser scattering particle size distribution analyzer (Horiba LA-
910, Kyoto, Japan) with a capacity of detecting particle size from 0.02 to 1000 mm  was 
used to obtain the PLGA microparticle size and size distribution.  
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 The freeze-dried microparticles were re-dispersed in deionized water through 
sonication for 30 seconds with Tween® 80 (Aldrich Chem. Co.) as surfactant. The 
relative index of refraction for PLGA was chosen as 1.32-0.00i from Horiba reference 
book for polyester coating. The average particle size was expressed as volume mean 
diameter in microns. The volume diameters undersize of 10, 50 and 90% (D10.0, D50.0 
and D90.0) were also recorded as span to evaluate the size distribution: 
D 10.0-D 90.0
Span=
D 50.0
         (5.1) 
5.2.3 Morphologies of Microparticles 
Images of PLGA microparticles were taken using scanning electron microscopy 
(SEM) and environmental scanning electron microscopy (ESEM) to verify particle size 
and size distribution, and to investigate surface morphology. Freeze-dried particles were 
put on aluminum stub through two sided tapes, and gold sputter coated (Denton Desk 1 
Cold Sputter/etch, 35mA, Denton Vacuum, Inc. Cherry Hill, NJ). All images were taken 
with SEM (Amray 1830, Bedford, MA) and ESEM (Phillips XL 30 ESEM-FEG D1530, 
Hillsboro, OR).  
5.2.4 Hydrocortisone Loading in PLGA Microparticles 
20 mg of freeze-dried PLGA microparticles containing hydrocortisone were 
suspended in 10 mL of 0.1 M sodium hydroxide (NaOH) and stirred at 300 rpm for 24 
hours to make sure PLGA microparticles degrade completely. The solutions were filtered 
through a membrane filter with pore size of 0.45 µm (Millexâ syringe driven filter unit, 
Millipore Corporation, Bedford, MA) and then measured at the maximum absorbance 
wavelength of hydrocortisone (248 nm) with UV/VIS spectrometry (Lambda 40, 
PerkinElmer Instrument, Shelton, CT). PLGA microparticles with no hydrocortisone 
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loaded were prepared under the same condition and used as blank. Hydrocortisone 
standard solutions were prepared with concentrations of 5, 10, 20 and 30 µg/mL in 0.1 M 
NaOH.  
5.2.5 Incorporation of PLGA Microparticles in PVA Matrix 
The freeze-dried PLGA microparticles were dispersed in deionized water with 0.5 
wt% Tweenâ 80 as surfactant to make 10 wt% particles suspension through sonication 
for 30 seconds. PVA aqueous solution was prepared as previously reported. In brief, 
polymers were dissolved in deionized water at 84°C overnight to make 10 wt% aqueous 
solution. The solution was then cool down to room temperature before the incorporation 
of PLGA microparticles. The PLGA microparticles were added into the solutions with 
various ratios. The particle-polymer mixture was then sonicated for 60 seconds to ensure 
microparticles distributed evenly in polymer solutions. The mixture was cast between two 
glass slides with Teflonâ spacers of 1.5 mm thickness, and underwent 4 cycles of 2 hours 
freezing at -20°C and 1 hour thawing at room temperature. The ensuing composites were 
first dried in air overnight and then freeze-dried at -80°C for 48 hours. 
5.2.6 Characterization of PLGA-PVA Composites 
Thermal properties of PLGA microparticles, pure PVA films and PLGA-PVA 
composites were determined using differential scanning calorimetry (DSC) (Model 2010, 
TA Instruments, Wilmington, DE). 4 to 6 mg of samples were placed in hermetic 
aluminum pans and heated at a ramp rate of 5°C/min to 250°C with nitrogen as purging 
gas. 
ATR-FTIR spectroscopy (Nicolet Magna-IR 560 spectrometer, Madison, WI) was 
used to investigate the compositions of PLGA-PVA composite. The IR spectra of dry 
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PLGA-PVA composite were mounted on a zinc-selenium ATR crystal and the IR spectra 
are obtained using 128 scans and resolution of 2 cm-1. The IR spectrum of pure PVA film 
was also collected for comparison.   
5.2.7 Confocal Laser Scanning Microscopy 
The distribution of the PLGA microparticles in PVA matrices was evaluated 
using fluorescence technology with coumarin-6 as the fluorescence marker (Figure 5.3). 
Coumarin-6 is a hydrophobic laser dye a with maximum UV wavelength at 457 nm and 
fluorescence maxl  at 505 nm in ethanol [31]. The benzothiazole group enables coumarin-
6 to show high fluorescence efficiency (hfl=0.78 with excitation at 420 nm) in polar 
solvents, such as methanol and ethanol. Labhasetwar et al. [32] reported that 95.4% of the 
dye was trapped into nanoparticles with size of 277 to 372 nm during formulation. Desai 
et al.  [33] found that more than 99.4% of coumarin-6 remained in the particles of 120 nm 
over 48 hours.  
In our study, coumarin-6 (Aldrich Chem. Co.) was incorporated into PLGA 
microparticles with concentration of 2.5 µg dye/mg PLGA using single oil- in-water 
emulsion method. The loading efficiency of coumarin-6 in PLGA microparticles were 
determined by extracting coumarin-6 using ethanol for 24 hours. The solutions were 
filtered with Millipore membrane filter of 0.45 mm and measured at the maximum 
absorbance wavelength of coumarin-6 with UV/VIS spectrometry (Lambda 40, 
PerkinElmer Instrument, Shelton, CT). Standard solutions of coumarin-6 were prepared 
with concentrations of 5, 10, 20 and 30 mg/mL in ethanol.  
The PLGA microparticles containing coumarin-6 were embedded into PVA 
hydrogel matrix with the freeze-thawing method as previously described. Fluorescence 
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microscopy images were taken using confocal laser scanning microscopy (Radiance 2000, 
Bio Rad Laboratories, Richmond, CA) linked to a Diaphot® inverted microscopy (Nikon, 
Tokyo, Japan). Horizontal section images were taken with PlanAPO 60, 11.40 oil 
objective (Nikon, Tokyo, Japan), and coumarin-6 was excited at a wavelength of 488 nm. 
The depth of each step for dry composite film was 10 mm beginning from the surface. 
The composite was then immersed in PBS (pH 7.4). Confocal images of the same PLGA-
PVA composites were taken after 3 hours, 1 day, 1 week, and 2 weeks in PBS solution to 
investigate the physical changes.  
5.2.8 Surface Morphology of PLGA-PVA Composites 
Dry composites were put on aluminum stub through two sided tapes, and gold 
sputter coated (Denton Desk 1 Cold Sputter/etch, 35mA, Denton Vacuum, Inc. Cherry 
Hill, NJ). All images were taken with ESEM (Phillips XL 30 ESEM-FEG D1530, 
Hillsboro, OR). The surface morphology change of PLGA-PCA composite prior to and 
post swelling in PBS solution (pH 7.4) was investigated using environmental scanning 
electron microscopy (Phillips XL 30 ESEM-FEG D1530, Hillsboro, OR). The dry 
PLGA-PVA composites were gold sputter coated. ESEM images were taken with a 
secondary electron detector (SED) at 5.00kV. For wet samples, ESEM images were taken 
with a gaseous secondary electron detector (GSED) at 5.00kV under water pressure while 
the samples were still in wet state.  
5.3   Results and Discussion 
5.3.1 Preparation of Microparticles  
In this research, PLGA microparticles were produced using single emulsion. This 
process involves emulsification of a polymeric organic solution in a continuous aqueous 
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solution (oil- in-water emulsion). PLGA is first dissolved in a water immiscible, volatile 
organic solvent. The drug is added to the polymer solution. The polymer-solvent-drug 
mixture is then emulsified in an aqueous continuous phase to form discrete droplets. The 
droplets harden to form microparticles upon removal of the organic solvent. The solvent 
evaporation method has been used extensively to prepare PLA and PLGA microparticles. 
Several factors have been identified to influence the properties of the particles, including 
solvent, emulsifier, polymer concentration, energy input, drug properties and loading.  
Several methods have been utilized to achieve dispersion of the oil phase in the 
continuous water phase [4, 27, 34-36]. The most common method is to stir the whole 
solution either with a propeller blade attached to a variable speed motor or a magnetic stir 
bar [29]. As the speed of stirring increases, the size of the dispersed oil droplets decreases 
as a result of the high shear force induced by the stirring. Homogenization is also used to 
produce an emulsion [35, 37]. With this type of dispersion system, a homogenizer 
equipped with a rotor and stator type blade is attached to a variable high speed motor. As 
high shear is used to produce the emulsion, the resultant product has a much smaller 
particle size than the emulsion produced by conventional agitation. In our lab, a 
Brinkmann homogenizer (Brinkmann Instruments, Inc., Westbury, NY) was used to 
produce particles. The homogenizer is equipped with a foam reducing generator with saw 
teeth to improve emulsification efficiency and small shaft slots to minimize aeration and 
foaming. It has a digital speed control motor of 750 watts, and is able to handle a wide 
range of emulsifications from 0.1 to 3000 mL.  
 During the emulsion process, a stabilizer or emulsifier is often added to the 
formulation to stabilize the emulsion. Partially hydrolyzed PVA is the most popular 
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emulsifier for the production of PLGA. PVA is produced by polymerization of vinyl 
acetate to polyvinyl acetate (PVAc) followed by hydrolysis of PVAc to PVA. The 
hydrolysis reaction does not go to completion, and thus PVA is always a copolymer of 
PVA and PVAc. The hydrophilic hydroxyl groups and hydrophobic acetate groups make 
PVA a good surfactant to stabilize the emulsion. Other polymers, such as methylcellulose 
(MC), hydroxypropylmethylcellulose (HPMC), gelatin, have also been used as 
emulsifiers [38, 39].  
The concentration of PVA aqueous solution also plays an important part in 
particle size and size distribution. According to Sahoo et al. [40], PVA exists as single 
molecules in solution at concentration lower than 2.5% (w/v); while above this 
concentration, PVA molecules associates with each other and exhibit in aggregated forms 
and thus have an enhanced surfactant activity. As a result, the emulsions produced using 
higher concentration of PVA are more stable and the ensuing particles should have 
smaller size and narrower size distribution. In our experiment, we found that the size of 
PLGA microparticles decreased from 3.736 mm to 1.435 mm when using 5% PVA 
solution instead of 1% solution while other experiment parameters were kept the same. 
  DCM is the most commonly used solvent in the fabrication of PLGA 
microparticles due to its good solubility of the polymers and low solubility in water [3, 
41], which result in stable oil- in-water emulsions. Its low boiling point (39.8°C) allows 
fast removal of the solvent by evaporation under ambient conditions. DCM exhibits a 
good solubility for PLGA, making it convenient to control the properties of particles by 
adjusting the viscosity of the polymer concentration. Its low boiling point and high 
volatility allow for easy and rapid solvent removal, resulting in a minimal residual 
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solvent. In addition, its low solubility in water (2% v/v) yields a stable emulsion to 
produce good quality microparticle in terms of shapes, encapsulation efficiency as well as 
surface morphology. However, as a halogenated solvent, DCM is considered hazardous 
both to human beings and environment.  
Compared with DCM, ethyl acetate is an attractive choice from the view of 
toxicity issue. Its oral LD50 in rats is 11.3 g/kg compared to 2.12 g/kg for DCM (Merck 
Index). It has already been used as food flavor enhancer (apple flavor) orally for human 
[3, 41]. Ethyl acetate has been applied to fabricate microparticles via solvent evaporation 
and extraction [4, 42, 43]. However, disadvantages also exist for ethyl acetate as the 
solvent for the emulsion process. Ethyl acetate has a low solubility for PLGA (‘slightly 
soluble’ according to the manufacturer of PLGA, Alkermes Co., Cambridge, MA). Its 
moderate water solubility (10% v/v) is responsible for fast polymer precipitation which 
would result in irregular shaped microparticles, such as hollow, non-spherical and porous, 
and reduced drug encapsulation efficiency. Its boiling point (77ºC) is higher than DCM, 
indicating a lower volatility at ambient temperature and may lead to high level of residue 
and aggregation of particles. Therefore, in this part of research, experiments were carried 
out to find the optimal solvent for formation of PLGA microparticles.  
Particle size is an important factor for controlled drug release as it affects drug 
encapsulation efficiency and release profile. In case of biodegradable particles, particle 
size also affects the degradation of the particles. Small particles usually have a higher 
drug release rate and a more significant ‘initial burst’ effect than bigger particles [44, 45]. 
Also, smaller particles exhibit a lower drug loading efficiency. Cheng et al. reported that 
the particles with larger size had higher drug loading efficiency (46.1% for 8 µm) than 
 
143 
smaller particles (13.5% for 0.8 µm) [35]. Therefore, we use particle size, size 
distribution as well as particle shape and surface morphology as the standards to choose 
the optimal solvent.  
We first tested acetone and ethyl acetate, as both are less toxic than DCM. PLGA 
microparticles were fabricated using both solvents under the same conditions: 225 mg 
PLGA dissolved in 15 mL solvent (acetone or ethyl acetate), homogenized at 5000 rpm 
for 5 min.  Solvent extraction was used to remove the organic solvents. The ensuing 
particles showed different size and size distribution. For acetone as the solvent, nano-
sized particles were obtained with a mean size of 0.115 µm and a span of 0.230. For 
particles produced using ethyl acetate, micro-sized particles were obtained (mean size 
1.605 µm, span 1.173), which were more than 10 times larger than the ones using acetone. 
This difference in size and size distribution of particles was due to the varied interfacial 
tension for both solvents with water. Acetone is freely miscible with water, resulting in 
tiny oil droplets of polymer in continuous water phase. However, ethyl acetate is slightly 
miscible with water. The interfacial tension between ethyl acetate and water is greater 
and generates bigger oil phase droplets, leading to bigger particles. As we aimed to 
fabricate particles of micron sizes in our research, ethyl acetate was selected over acetone 
as a candidate to test the plausibility of replacing DCM as the organic solvent.  
 With ethyl acetate selected as a potential solvent candidate, the particles were 
fabricated to evaluate other factors that affect the properties of particles, including 
polymer concentration, oil phase volume, water phase volume, power input 
(homogenization speed), and emulsifier concentration.  
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 When using emulsion method, the basic idea is to break the oil phase into small 
droplets. Any factors that affect oil droplet formation will affect the final particle size. 
Changing the emulsion speed is the easiest way to fabricate particles with desired size. 
Small size particles are usually obtained using high emulsion speed and the size 
distribution tends to be narrower. This is due to higher energy breaks down the oil phase 
into smaller oil droplets which in turn will form smaller particles after the organic solvent 
evaporates out.  
Polymer concentration plays an important role in particle size control. High 
polymer concentration results in a more viscous solution which requires more energy to 
generate small droplets. Given the same homogenization speed, bigger particles will be 
produced for high concentration of polymers. Singh and O’Hagan [41] mentioned that a 
lower polymer concentration between 2-5% would result in microparticles of size 200 nm 
to 5 µm; while a concentration ranging from 10 to 16% usually results in larger particles 
in the range of 20 to 100 µm. These numbers just offers a reference for choosing polymer 
concentration range, as the particle size is affected by other process parameters as well.  
After emulsion using the homogenizer, ethyl acetate was removed through solvent 
extraction method, which was quenching the emulsion with excess water to extract ethyl 
acetate from the emulsion. Solvent extraction is more rapid than solvent evaporation for 
ethyl acetate, whose boiling point is well above room temperature (77°C). Overnight 
evaporation to remove ethyl acetate was reported by Birnbaum et al. [4] for PLGA 
microparticle formation, while 30 minutes was said to be enough for the extraction 
method to remove the organic solvents [27], However, as discussed by other researchers, 
rapid solvent removal may cause local explosion inside the droplets and lead to formation 
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of porous structures on the particle surface [27, 42]. In our experiments, some of the 
emulsion even became irregular precipitates after the addition of excess quenching water. 
In addition, this behavior was found to happen during the emulsification when high 
volume of PVA aqueous solution was used as emulsifier. Sah [42] also reported this 
phenomenon in his work, that precipitates instead of microspheres were formed when 80 
mL and 110 mL PVA solution was added in 8 mL PLGA ethyl acetate solution. This is 
due to the moderate solubility of ethyl acetate in water (10%). When the volume ratio of 
the water phase to the organic phase is close to or greater than 10:1, ethyl acetate phase 
diffuse into the water phase rapidly. The polymer lost the solvent to dissolve in and thus 
precipitated. Then one would question why this precipitation phenomenon does not occur 
with acetone as the organic phase, since acetone is freely miscible with water. The key to 
the question lies in the fact that the mixing energy of acetone with water is very low, 
resulting a uniform distribution of acetone molecules in water. Therefore, acetone is still 
available for the polymer in the continuous water phase. However, for the case of ethyl 
acetate, limited amount of ethyl acetate molecules interact with water molecules. Once 
the continuous water phase exceeds the solubility of ethyl acetate, the ethyl acetate 
molecules diffuse into the water phase, and become unavailable for the polymer 
molecules. As a result, the polymer molecules are isolated from the solvent and 
precipitate as the polymer itself does not dissolve in water. Therefore, caution should be 
taken during the preparation of the emulsion when using moderate water soluble organic 
solvent. Even for DCM, when using the oil- in-water emulsion, the ratio of the water 
phase to the organic phase should be kept below 50:1 to avoid the polymer precipitation. 
Another point worth mentioning is even if the ratio of the water phase to the organic 
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phase is kept below 10:1 when using ethyl acetate as the solvent, the addition of 
quenching water to the emulsion might also cause polymer precipitation. During the 
emulsion process, the organic phase containing PLGA merely breaks into small oil 
droplets and suspends in the continuous phase. Solid particles would not form until the 
removal of the organic solvent. Therefore, excess quenching water may cause the soft oil 
droplets aggregate and precipitate into irregular shaped particles. An example of this is 
shown in Figure 5.4. 10mL 1% PLGA ethyl acetate in 20 mL 1% PVA aqueous solution 
was stirred at 1000 rpm for 2 minutes and then 100 mL deionized water was added while 
stirring at 400 rpm. The total volume of water phase was 119.8 mL. The volume ratio of 
water phase to organic phase was about 12:1, which was above ethyl acetate solubility in 
water. As a result, PLGA precipitated into irregular shaped particles from the organic 
phase due to the rapid extraction of ethyl acetate by excess water.  
In order to avoid the drawback of fast removal of ethyl acetate, a method 
combining solvent evaporation and solvent extraction was used. The emulsions after 
homogenization were stirred at 400 rpm for one hour to allow ethyl acetate to diffuse into 
the continuous water phase to eliminate the aggregation and precipitation of the 
microparticles when excess quench water was added to the emulsion. The purpose of 
addition of quench water is to shorten the solvent removal time so that the incorporated 
drugs would not dissolve into the water phase during the solvent removal process [27].  
The effect of polymer concentration on particle size was studied by preparing 2 
and 4% (w/v) PLGA in ethyl acetate. 1% PVA aqueous solution was used as the water 
phase while the volume ratio of water phase to organic phase was kept below 10:1 to 
avoid PLGA precipitation. All emulsions were homogenized at 5000 rpm for 5 minutes. 
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The ensuing emulsions were then stirred at 400 rpm for one hour, and then 100 mL 
deionized water was added during stirring. Particle size and size distribution was 
analyzed using laser scattering technique (Table 5.1). SEM images were also taken to 
confirm the particle size. Comparing P41555 (sample number, see Table 5.1) and 
P21555 , only PLGA concentration in emulsions varied from 4% to 2% while all the 
other preparation conditions were the same, smaller particles were obtained when lower 
concentration was used (Figure 5.5). The same behavior was observed with P41255 and 
P21255.  
In the same experiment set, the effect of volume ratio of water phase to organic 
phase on particle size was also studied (Table 5.1). Smaller particles were formed with 
lower phase volume ratio (2:1 compared to 5:1). This result can be explained on the basis 
of available organic solvent for the emulsion. As discussed earlier, part of ethyl acetate 
diffuses into the continuous water phase due to its moderate water solubility. Less ethyl 
acetate is available for PLGA when higher volume of water phase is added. The available 
ethyl acetate was roughly estimated according to its solubility in water. The ‘real’ 
concentration of PLGA in ethyl acetate was higher than the theoretical concentration. 
With the same amount of PLGA and ethyl acetate, the emulsion of higher volume ratio of 
water phase to organic phase resulted in higher concentration of PLGA, which had higher 
viscosity and required more energy to break into droplets. Therefore, smaller particle 
sizes were obtained when the homogenization speed was kept at 5000 rpm.  
5.3.2 Loading of Hydrocortisone  
The loading of drugs into the delivery system is very important, as it affects the 
pharmaceutical effects of the therapeutic agents. For drug loading in PLGA 
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microparticles, different strategies have been used to test the drug loading. Some 
researchers dissolve PLGA together with the incorporated drugs with acetone or other 
PLGA dissolving solvents, and then precipitate the polymer out with a non-solvent in 
which the drug dissolves. After removal of the polymer precipitates, the drug content is 
determined with a quantitative method, such as HPLC and UV/VIS spectrometer. 
Another method to determine the drug loading is to utilize the degradation properties of 
PLGA, especially in presence of catalysts, such as bases or acids. First, a dilute base 
solution (usually sodium hydroxide, NaOH) is added to PLGA microparticles containing 
drugs. The microparticles dissolve after PLGA degrade into glycolic acid and lactic acid. 
The drug content is then analyzed through a suitable quantitative method. In our research, 
the second method was applied using 0.1 M NaOH as the media.  
10% (w/w) of hydrocortisone was prepared in PLGA in ethyl acetate solution. 
The concentrations of PLGA were 2 and 4% (w/v). For the 4% polymer solution, 
hydrocortisone did not dissolve in ethyl acetate completely with visible solid drug present 
in solution. Hydrocortisone is a hydrophobic drug with solubility in water of 280 mg/L at 
25°C. With 50 mL PVA aqueous solution as the water phase, there would be up to 14 mg 
hydrocortisone dissolving in water during the emulsion process. In order to avoid the 
dissolution of the drug in the water phase, both PVA solution and quench water were 
saturated with hydrocortisone. Particles were also prepared with non-saturated PVA and 
quench water as controls. The particles prepared using saturated solutions had relatively 
higher drug loading compared to the controls (Table 5.2). However, the loading was very 
low for all the particles despite the use of saturated solutions. This behavior was probably 
a result of increased solubility of hydrocortisone in water with the presence of ethyl 
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acetate. During the process of solvent removal, some of the incorporated hydrocortisone 
diffuses out of the oil droplets while ethyl acetate diffuses into the water phase. The 
solubility of hydrocortisone in ethyl acetate is higher than its solubility in water. As a 
result, hydrocortisone can still go into the water phase with the presence of ethyl acetate, 
even though the quench water and PVA solution are saturated with hydrocortisone.  
The purpose of adding quench water to the emulsions, as discussed earlier, is to 
shorten the solvent removal time so that the drugs would not diffuse out into the water 
phase. However, from the experiment described above, the excess quench water might 
have extracted more hydrocortisone to diffuse into water during extraction. Therefore, a 
set of experiments were performed to study whether the excess quench water affected 
hydrocortisone loading. DCM was also used as the organic solvent to produce emulsions, 
as a comparison to ethyl acetate. The emulsions were stirred overnight to evaporate the 
solvents for the Evaporation group (Table 5.3); for the Extraction group, the emulsions 
were first evaporated for one hour and then 100 mL quench water was added, the 
emulsions were further stirred for two hours. The loading was much lower than the 
theoretical values for both solvent removal methods (Table 5.3). The particles prepared 
with ethyl acetate had the same loading efficiency using either method; while for the 
particles prepared with DCM, the extraction method yielded a slightly higher loading 
efficiency. However, the extraction and evaporation methods were basically the same to 
DCM, since the volume of quench water was not enough to extract all DCM out of the 
organic phase. The incorporated hydrocortisone probably began to release from the 
microparticles during the overnight evaporation process, resulting in a lower loading 
efficiency. In both methods, the particles prepared using DCM had slightly higher 
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hydrocortisone loading than the ones prepared using ethyl acetate. The difference in the 
specific surface area might be the reason of this behavior. The specific surface area is 
defined as the ratio of the surface area to volume, and has units of 1/length. The average 
size of the particles prepared using ethyl acetate is considerably smaller than the size of 
the particles prepared using DCM, as confirmed in ESEM images (Figure 5.6 – Figure 
5.7), resulting in larger specific surface area to contact with the water phase, which leads 
to drug loss during the emulsion and solvent removal processes.  
The drug loading is essential to the release of  the incorporated therapeutic agents. 
The hydrocortisone loading from the above experiments was extremely low. It does not 
make any sense to incorporate the microparticles into a hydrogel matrix, which would 
bring the loading down further to nearly zero. Therefore, our task was to increase the 
loading of hydrocortisone. From the results of the earlier experiments, the low loading 
efficiency seemed to be a result of dissolution of hydrocortisone to the water phase. 
Therefore, adding more hydrocortisone to the organic phase might be a solution to the 
problem.  
400 mg PLGA and certain amounts of hydrocortisone were dissolved in 10 mL 
ethyl acetate. 50 mL 5% PVA aqueous solution was used as the water phase. After 5 
minutes of homogenization at 5000 rpm, the emulsion was transferred onto a stir plate 
and stirred at 400 rpm for one hour. 50 mL deionized water was then added to extract 
ethyl acetate out of the organic phase. The loading efficiency of hydrocortisone increased 
from 3.8% to 42.3% when the initial loading of hydrocortisone changed from 12% to 
22%  (Table 5.4). In another word, the loading efficiency increased about 11 fold when 
the initial concentration of hydrocortisone merely increased about 2 fold. This behavior is 
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probably due to the dissolution of hydrocortisone in the mixture solvent (water dispersed 
with ethyl acetate) reached the equilibrium.  
The polymer concentration in organic phase also affects the particle size and drug 
loading.  Keeping other conditions the same, higher polymer concentrations would result 
in bigger particles, which would lead to higher drug loading efficiency due to reduced 
specific surface area. The PLGA concentration was increased from 4% to 10% in DCM, 
with 10, 20 and 30 wt% hydrocortisone based on PLGA weight. DCM was chosen as the 
solvent, as ethyl acetate would result in PLGA precipitate from solution of high 
concentration when present in continuous water phase. For the same theoretical loading 
of 10 wt% hydrocortisone, the loading efficiency increased with increasing PLGA 
concentration: from 0.63% for 4% (w/v) PLGA in DCM (Table 5.3) to 42.1% for 10% 
(w/v) PLGA in DCM (Table 5.5).  
5.3.3 Presence of PVA Crystallites 
 As we proposed earlier in this chapter, the composite structure was held together 
with PVA crystallites serving as the crosslinking points. The formation of the crystallites 
occurred during the freeze-thawing and drying processes. In order to demonstrate the 
presence of PVA crystallites, DSC thermograms and ATR-FTIR spectra were obtained 
for PLGA-PVA composites with pure PVA films which were prepared under the same 
conditions. The PLGA-PVA composite has a PLGA/PVA ratio of 10:100 by weight.  
 As PLGA is an amorphous polymer, the DSC thermogram of PLGA 
microparticles only showed a glass transition around 48°C (Figure 5.8). Pure PVA film 
had a melting peak around 227°C, which is typical for semi-crystalline PVA. For the 
PLGA-PVA composite, the melting peak of PVA was still observed, however, it shifted 
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to a lower temperature, which is a result of  the hindrance of PLGA microparticles to the 
formation of PVA crystallites.    
 ATR-FTIR spectra were taken with 128 scans and resolution of 2 cm-1. For pure 
PVA film, the spectra showed a secondary alcohol stretch peak at 1086 cm-1, and a C-C 
stretching peak at 1141 cm-1, which was related to the degree of crystallinity by Peppas et 
al. [23, 46]. For PLGA-PVA composite film, the IR peak at 1754 cm-1 is the 
characteristic peak of esters, which demonstrated the presence of PLGA (Figure 5.9). The 
1086 cm-1 peak and 1141 cm-1 peak of PVA were still present in the spectrum of the 
composite, however, the height of 1141 cm-1 crystalline peak depressed due to the 
inference of PLGA microparticles to the formation of PVA crystallites.  
5.3.4 Particle Distribution in PVA Matrix 
 The distribution of PLGA microparticles in PVA hydrogel matrix would affect 
the drug release from the composite. Therefore, in this part of studies, the microparticle 
distribution was studied using confocal laser scanning microscopy with coumarin-6 as the 
fluorescent marker. Coumarin-6 is a hydrophobic fluorescent laser dye, which only 
dissolves in organic solvents [31]. The loading efficiency of coumarin-6 in the 
microparticles was determined as 97.3% using DCM as solvent using single oil- in-water 
emulsion. The high incorporation efficiency of coumarin-6 is due to its extremely low 
solubility in water.  
 The microparticles were incorporated in PVA hydrogel with varied concentrations: 
0.2, 1, 10 wt%. The composites were freeze-dried overnight. The confocal images were 
then taken for the dry composites. However, the images were too bright for the 
composites containing 10 wt% microparticles; while for the 0.2 wt% composites, the 
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particles were too scattered for good observations. As a result, the composite containing 1 
wt% microparticles was selected to study the distribution of microparticles in the 
hydrogel matrix.  
 The numbers of particles increased with increasing the depth of scanning, 
indicating the particle distribution was not homogenous in the hydrogel matrix (Figure 
5.10). This is a result of higher density of PLGA microparticles than 10% PVA aqueous 
solution. The swelling of the composites was fast and the equilibrium was reached within 
30 minutes (Figure 5.11). The confocal images were then taken for the swollen 
composites. The particles spread out in the swollen state due to the stretching of the 
hydrogels (Figure 5.12), resulting in fewer particles present in the same optical area. This 
agrees with the ESEM images taken prior to and post swelling of the composite, where 
the wet sample appeared to be in a more relaxed state with the particles rested on the 
PVA matrix surface (Figure 5.13). At each set time, the distribution of the particles 
showed the same trend as the dry composites—the numbers of particles increased with 
scanning depth. The particles were visible up to 2 weeks of swelling, while the 
fluorescent dye lost its power after repeated testing (Figure 5.14—5.16). Another reason 
for reduced numbers of particles is that PLGA microparticles degraded in the presence of 
water. However, the magnification of the confocal microscopy is not high enough to 
observe the degradation of the particles.  
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5.4   Conclusion 
 PLGA microparticles were prepared using single oil- in-water emulsion. Ethyl 
acetate was studied as a candidate to replace the regularly used dichloromethane (DCM) 
as the organic phase. Factors, including particle size and size distribution, particle shape 
and surface morphology, and most importantly, hydrocortisone loading efficiency, were 
used to determine the optimal solvent. Even though ethyl acetate has a lower toxic level 
than DCM, the removal of ethyl acetate is more difficult to form regular shaped particles. 
Therefore, DCM was chosen as the organic phase for the fabrication of PLGA 
microparticles.  
 PVA crystallites served as the physical crosslinking points to hold the composite 
structure together. The formation of the crystallites were confirmed with the presence of 
the melting peak of PVA crystallites in DSC thermogram. The melting peak shifted to a 
lower temperature compared to the melting peak of PVA crystallites in pure PVA film, 
indicating the size of the crystallites decreased due to the presence of PLGA 
microparticles. ATR-FTIR spectrum of the composite also showed a depressed IR peak at 
1141 cm-1, which was related to the degree of crystallinity in PVA.  
 The distributions of PLGA microparticles in PVA hydrogel matrix in dry and 
swollen states were studied using confocal laser microscopy with coumarin-6 as the 
fluorescent marker. The numbers of particles was found to increase along the scanning 
depth, indicating uneven distribution of the particles in the hydrogel matrix. The particle 
distribution showed the same trends in the swollen composites as well. The particles were 
visible up to 2 week after immersion in PBS solution (pH 7.4), which was a result of 
particle degradation and fluorescence decay.  
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Table 5.1: The effects of polymer concentration in oil phase and phase volume 
ratio on particle size 
 
Sample # Theoretical 
concentration1 
Volume 
ratio2 
Available 
EA*,3 (mL) 
Final PLGA 
concentration4  
Particle size 
(mm) 
P41555 4.0% 5:1 5.0 8.0% 3.569±1.665 
P41255 4.0% 2:1 8.0 5.0% 3.065±1.054 
P21555 2.0% 5:1 5.0 4.0% 2.981±1.145 
P21255 2.0% 2:1 8.0 2.5% 2.352±1.029 
 
* EA= ethyl acetate 
1 Theoretical concentration, 0
PLGA
EA
M
C
V
=  
 
2 water
EA
V
Volume Ratio
V
= , where VEA=10 mL 
 
3 Available EA, 0 1'EA EA waterV V . V= - ×  
 
4 Final PLGA concentration, 0
' PLGA
'
EA
M
C
V
=  
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Table 5.2: Effects of saturated PVA solution and quench water on hydrocortisone 
loading with 4% (w/v) PLGA in ethyl acetate.   
 
PLGA 
(mg) 
Hydrocortisone 
(mg) 
Saturated 
Solutions 
Actual 
Loading 
Loading 
Efficiency 
404.0 41.3 Y 0.6% 6.6% 
401.0 41.8 N 0.34% 3.74% 
200.0 19.3 Y 0.39% 4.29% 
201.0 20.3 N 0.14% 1.54% 
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Table 5.3:  Effects of evaporation and extraction on hydrocortisone loading with 4% 
(w/v) PLGA in organic solvents.  
 
PLGA 
(mg) 
Hydrocortisone 
(mg) Solvent
* Solvent Removal 
Method 
Particle size 
(mm) 
Loading 
efficiency 
400.0 40.8 EA Evaporation 3.097±1.243 0.23% 
401.0 - EA Evaporation 3.123±1.219 - 
402.0 40.3 EA Extraction 3.135±1.267 0.23% 
399.0 - EA Extraction 3.240±1.297 - 
400.0 41.0 DCM Evaporation 4.992±2.821 0.4% 
399.0 - DCM Evaporation 5.154±2.713 - 
402.0 41.5 DCM Extraction 7.717±6.890 0.63% 
400.0 - DCM Extraction 5.655±3.263 - 
 
* EA=ethyl acetate 
   DCM=dichloromethane 
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Table 5.4: Hydrocortisone loading efficiency with ethyl acetate as 
solvent with 4% (w/v) PLGA in ethyl acetate.  
 
Theoretical Loading Actual 
Loading 
Loading Efficiency 
12% 0.45% 3.75% 
15% 0.43% 2.87% 
19% 5.4% 28.4% 
22% 9.3% 42.3% 
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Table 5.5:  Hydrocortisone loading efficiency with DCM as 
solvent. PLGA concentration is 10% (w/v) in DCM. 
 
Theoretical Loading Actual 
Loading 
Loading Efficiency 
9.97% 4.2% 42.1% 
19.8% 15.6% 78.8% 
30.1% 23.8% 79.0% 
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Figure 5.1:  Schematic structure of PLGA-PVA composite 
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Hydrocortisone 
 
 
 
 
Figure 5.2: Structure and UV absorbance of hydrocortisone 
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Coumarin-6 
 
  
 
 
Figure 5.3:  Structure and UV absorbance of coumarin-6 
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Figure 5.4: PLGA precipitation due to excess extraction water with ethyl acetate as 
the solvent (magnification=500x) 
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P21555     P21255 
 
Figure 5.5: SEM images of PLGA microparticles of different sizes prepared with 
parameters shown in Table 5.1 (magnification=5000x) 
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A. Control particles (no hydrocortisone loaded) 
 
 
 
B. PLGA microparticles loaded with hydrocortisone 
 
 
Figure 5.6: ESEM images of PLGA microparticles prepared using ethyl acetate as the 
solvent (magnification=2500x) 
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A. Control PLGA microparticles (no hydrocortisone loaded) 
 
 
 
B. PLGA microparticles loaded with hydrocortisone 
  
Figure 5.7: ESEM images of PLGA microparticles using DCM as the solvent 
(magnification=2500x) 
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Figure 5.8: DSC Thermograms of PLGA microparticles, pure PVA film, PLGA-PVA 
composite. Ramp at 5°C/min with nitrogen as purging gas.  
 
PLGA microparticles 
PVA with 10 wt% particles 
100% PVA 
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Figure 5.9: ATR-FTIR spectra of  (A) pure PVA film, (B) PVA with 10 wt% PLGA 
microparticles (128 scans with resolution of 2 cm-1) 
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Figure 5.10: Images of dry composite with coumarin-6 as fluorescent marker using 
confocal laser scanning microscopy with d as the scanning depth. (magnification=200x) 
d=20µm 
Surface d=10µm 
d=30µm 
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Figure 5.11: Equilibrium swelling  of PLGA-PVA composite with 10 wt% PLGA 
microparticles in PBS solution (pH 7.4).  
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Figure 5.12: Confocal images of PLGA-PVA composite after 3 hours swelling in PBS 
solution (magnification=200x). 
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Figure 5.13: ESEM images of PVA hydrogel embedded with PLGA microparticles (A) 
prior to immersion in PBS solution (SED, gold sputter coated, 5.00kV, 500x); (B) post 
immersion in PBS (GSED, 0.6 torr water pressure, 5.00kV, 500x). 
B 
A 
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Figure 5.14: Confocal images of PLGA-PVA composite after 1 day swelling in PBS 
solution (magnification=200x). d is the scanning depth.  
surface d=10 d=20 
d=30 d=50 d=80 
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Figure 5.15: Confocal images of PLGA-PVA composite after 1 week swelling in PBS 
solution (magnification=200x). d is the scanning depth. 
surface d=10 d=20 
d=30 d=50 d=80 
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Figure 5.16: Confocal images of PLGA-PVA composite after 2 week swelling in PBS 
solution (magnification=200x). d is the scanning depth.  
surface d=10 
d=50 d=80 
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CHAPTER 6:EVALUATION OF DRUG RELEASE FROM COMPOSITES 
6.1   Introduction 
Hydrocortisone resembles the natural cortisol, which is the principal 
glucocorticoid hormone produced by the adrenal cortex, with glucocorticoid activity and 
some mineralcorticoid effects (Merck Index 12, 4828). The most important therapeutic 
property of the glucocorticoids is their ability to dramatically reduce the inflammatory 
response and to suppress allergic reactions. They inhibit the inflammatory response 
whether the inciting agent is radiant, mechanical, chemical, infectious, or immunological 
[1]. Although the administration of corticosteroids for their anti- inflammatory effects is 
palliative therapy because the underlying cause of the disease remains, the suppression of 
inflammation and its consequences has made these agents of great value clinically.  
In the anti- inflammatory actions, the corticosteroids inhibit not only the 
inflammatory process, which includes fibrin deposition, migration of leukocytes into the 
inflamed area and phagocytic activity, but also the later manifestations, including 
proliferation of capillaries and fibroblasts, deposition of collagen and cicatrisation [2]. 
Therefore, their actions cover the whole inflammatory response which consists of acute, 
chronic, and fibrotic encapsulation. The acute inflammatory reaction occurs within 24-
48 hours and when the triggering condition continues past the end of this response 
without any suppressive agent, a chronic inflammatory reaction occurs. This reaction 
continues for 1-2 weeks, after which either the fibrotic tissue is deposited or normal 
tissue regrowth occurs [3, 4]. Hydrocortisone is a short time acting glucocorticoid with a 
half life around 8-12 hours. Multiple daily administrations are necessary to maintain the 
effective therapeutic level if regular delivery system is used.  
 
182 
Multilayer matrix systems have been proposed to achieve sustained release of a 
therapeutic agents over a prolonged time [5]. The design usually consists of a matrix core 
containing the active agents and one or more layers outside the core layer. The propose of 
constructing multilayer systems is that the additional layers act as modulating barriers 
which can delay the interaction of incorporated drugs with the dissolution medium by 
controlling the diffusion of the drug and penetration of the medium, and at the meanwhile 
the surface available for the release is reduced. Qiu et al. [6] studied pseduephedrine 
hydrochloride and aminophylline release from layered matrix system consisting of a 
hydrophobic layer and press-coated hydrophilic and/or hydrophobic barrier layers, and 
near zero-order release was achieved for 10 hours. Charalambopoulou et al. [7] reported 
initial burst of 4-aminoazobenzene from cellulose acetate films was eliminated and the 
sustained release was achieved when using no drug loaded outer layer films.  
In this part of research, we aim to develop delivery systems for sustained release 
of hydrocortisone for a period of one month so as to suppress the inflammatory response 
without repeated doses. PLGA microparticles containing hydrocortisone are incorporated 
into PVA hydrogel matrix to form a single layer composite, which is further modified 
with adding pure PVA hydrogel layers with no hydrocortisone loaded to reduce the initial 
burst effect (Figure 6.1). The release of hydrocortisone from the single layer composite, 
three- layer composite is studied. In addition, an empirical model is developed based on 
the release from the single layer composite, pure PVA films and PLGA microparticles so 
that the release from a three- layer composite can be estimated.  
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6.2   Experimental  Section  
6.2.1 Preparation of Single Layer Composites 
The single layer composites were prepared as described in Chapter 5. The freeze-
dried PLGA microparticles containing hydrocortisone were dispersed in deionized water 
with 0.5 wt% Tweenâ 80 as surfactant to make 10 wt% particles suspension through 
sonication for 30 seconds. PVA aqueous solution was prepared by dissolving Elvanolâ  
71-30 in deionized water at 84°C overnight to make 10 wt% aqueous solution. The 
solution was then cooled to room temperature before the incorporation of PLGA 
microparticles. The PLGA microparticles were added into the solutions with various 
ratios: 25 wt% for the particles loaded with 4.2% hydrocortisone and 20 wt% for the ones 
with 23.8% hydrocortisone. The partic le-polymer mixture was then sonicated for 60 
seconds to ensure microparticles distributed evenly in polymer solutions. The mixture 
was cast between two glass slides with Teflonâ spacers of 1.5 mm thickness, and 
underwent 4 cycles of 2 hours freezing at -20°C and 1 hour thawing at room temperature. 
The ensuing composites were first dried in air overnight and then freeze-dried at -80°C 
for 48 hours. 
6.2.2 Fabrication of Three-Layer Composites 
For the multilayer samples, the PLGA microparticle/PVA solution was first cast 
between two glass slides with Teflonâ spacers of 1.5 mm thickness as described above 
for the single layer composites, and put into the freezer for 2 hours. A layer of PVA 
aqueous solution was cast onto the frozen PLGA-PVA composite with 1.5 mm spacers. 
The whole composite was kept at room temperature for 1 hour to thaw the frozen layer of 
PLGA-PVA and allow the newly added layer of PVA solution to interact with the 
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composite layer through hydrogen bonding and chain penetrating. The two-layer 
composite was then frozen at -20°C for 2 hours, and then another layer of PVA was cast 
onto the other side of PLGA-PVA composite with 1 hour thawing. The three- layer 
composite then underwent 2 cycles of 2 hours freezing at -20°C and 1 hour thawing at 
room temperature. The ensuing composites were first dried in air overnight and then 
freeze-dried at -80°C for 48 hours. 
6.2.3 Hydrocortisone Release  
The in vitro release study of hydrocortisone was performed in PBS solution 
(pH=7.4) using dissolution cells (Distek dissolution system 2100B, North Brunswick, NJ) 
at 37°C with stirring speed set at 150rpm. PLGA-PVA composites were weighed and put 
into 150 mL PBS solution (pH 7.4). At set time intervals, 3 mL solutions were taken 
using a syringe through a syringe filter with pore size of 0.45 µm (Millex® PVDF 
Durapore). The filter was back-washed with 3 mL fresh PBS solution to avoid particle 
loss on the filter and to maintain constant solution volume for release. The released 
hydrocortisone was analyzed with UV/VIS spectrometer (Lambda 40, PerkinElmer 
Instrument, Shelton, CT) at maximum absorbance wavelength of hydrocortisone at 
248nm. The standard hydrocortisone solutions for calibration were prepared with 
concentrations of 0.1, 0.5, 1, 5, 10, 20 and 30 µg/mL in PBS solution (pH 7.4). 
Hydrocortisone release from PLGA microparticles and PVA hydrogel films, was also 
studied and used as control groups. 
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6.3   Results and Discussion  
 
6.3.1 Release from PLGA Microparticles  
The purpose of this research is to develop polymer composites, with distinct 
profiles of release from using microparticles or hydrogel matrices alone. Therefore, the 
release of the model drug from the microparticles was studied first as a comparison group.  
The microparticles for the release studies were prepared from 10% PLGA in 
DCM solutions with actual hydrocortisone loading of 4.2%, 15.6% and 23.8% (Table 
6.1). The initial burst effect was significant for all three concentrations with large 
percentages of hydrocortisone released during the early stage of the dissolution studies 
(Figure 6.2). Within first two hours (the first data point for each curve), the particles 
containing 4.2% hydrocortisone released around 68% of the incorporated drug, while 
15.6% hydrocortisone loaded particles released about 78% of loaded drug and 76% for 
the 23.8% loaded particles.  
This fast release behavior was a result of uneven distribution of hydrocortisone in 
the microparticles. During the solvent removal process, hydrocortisone tends to diffuse 
out of the oil droplets with the organic solvent and attach to the particle surface. The 
initial amount of hydrocortisone added in the organic phase exceeded its solubility in 
DCM, especially for the particles of 15.6% and 23.8% actual loading. The hydrocortisone 
was not totally dissolved and would still present in its crystal form, leading to the rough 
surfaces of particles with high loading of hydrocortisone, which was confirmed by ESEM 
images (Figure 6.3). The drug content affected the surface morphology of the particles, as 
the presence of hydrocortisone interfered particle formation, resulting in irregular, 
possib le porous surface attached with drug  crystals which led to the initial fast release.  
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After the initial burst effect, the microparticles containing 4.2% hydrocortisone 
showed relatively better sustained release over one month in the dissolution studies than 
the 15.6% and 23.8% particles (Figure 6.2). The release from the 15.6% and 23.8% 
particles was fast and reached 87% and 89% within 24 hours, respectively; and almost 
remained the same level after that. For the 4.2% hydrocortisone loaded particles, the 
release by the end of 24 hours is 73%, which is still a relatively high value. However, this 
is typical for the release from microparticles, as it was reported that the rapid release 
during the first day or so normally accounts for 10-80% of the total drug loading [8].  
6.3.2 Release from Single Layer Composites 
 PLGA-PVA thin film composite was prepared by casting PLGA 
microparticle/PVA aqueous solution using spacers of 1.5 mm thickness. After drying, the 
thickness of the composite decreased to about 0.1 mm. The PLGA microparticles used 
were the ones loaded with 4.2% and 23.8% hydrocortisone.  
 The particles with 23.8% hydrocortisone were incorporated into PVA matrix with 
a percentage of 20% based on PVA weight. The ensuing composite was assigned as 
Composite 1 (Table 6.2). The release of hydrocortisone was evaluated for one month 
(Figure 6.4). As studied earlier, the release from the microparticles of 23.8% 
hydrocortisone was rather rapid with nearly 90% incorporated drug released in 24 hours. 
The release from pure PVA film was even faster than from the particles, with 90% of 
hydrocortisone released within 4 hours. Comparing to 87% of release from the pure PVA 
film within 2 hours, the release from PLGA microparticles showed relatively better 
control with an initial burst effect of 76% hydrocortisone released. The incorporation of 
microparticles into PVA matrix helped to lower the initial burst effect further to 68%, 
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which is still a quite high number. This is due to the diffusion of the drug molecules is 
rather rapid from the thin layer of the PVA matrix, as most of hydrocortisone distributed 
on the surface of the particles.  
 The surface morphology change of Composite 1 upon PLGA degradation was 
studied using ESEM (Figure 6.5). By the end of one week immersion in PBS, the 
particles showed some pores on the surface compared to the original composite. However, 
as the particles were covered by a layer of PVA, it is hard to tell the degree of 
degradation. From the image taken at three weeks, we could see that the particles exposed 
to water showed generous amount of pores on the surface. More degradation was 
observed for the particles exposed to water by 7 weeks. However, it was difficult to judge 
the degradation of the ones covered with PVA. The particles didn’t disappear at the end 
of the 7 weeks immersion, as the experiment was carried in vitro, where PLGA usually 
shows slower degradation than in vivo [9]. 
 The particles containing 4.2% hydrocortisone were incorporated into PVA matrix 
by 25 wt% based on PVA weight (Composite 2, Table 6.3). The release of 
hydrocortisone showed similar patterns (Figure 6.6) as Composite 1 for one month. As 
the particles with 4.2% hydrocortisone had better controlled release than the 23.8% 
loading ones, the release curve of its composite showed sustained release from 54% at the 
end of 1 day up to 92% after 5 weeks. The composite lowered the initial burst effect of 
the particles from 68% to 44% within 4 hours, and also lowered the release from 93% for 
pure PVA film and 73% for PLGA microparticles to 54% by the end of the first day. 
PVA hydrogel films serve as a diffusion barrier for both hydrocortisone and water 
molecules and delay of their interaction, resulting in reduced release. In addition, as the 
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particles were fixed in the hydrogel matrix, their contact with water was restricted, which 
possibly led to a slower degradation of the particles. As a result, the release of 
hydrocortisone was lowered for two weeks and then caught up to the release from the 
microparticles till the end of the dissolution study. The ESEM images of Composite 2 
(Figure 6.7) showed that the degradation of particles exposed to PBS solution was slower 
than those in Composite 1, which is a result of different hydrocortisone loading in the 
particles. However, just like the images of Composite 1, it is also difficult to tell the 
degree of the degradation of particles covered by PVA hydrogels.  
6.3.3 Release from Three-layer Composite 
The effect of three- layer structure on hydrocortisone release was first studied for 
the systems prepared with only PVA hydrogels. Three PVA films were prepared through 
solvent casting of aqueous solution containing PVA and hydrocortisone. The thin film 
was prepared using spacers of 1.5 mm, while the thick film was cast using spacers of  4.5 
mm. The three- layer film was prepared with casting additional two layers of PVA 
aqueous solution with no drug incorporated. Therefore, for the thin and thick films, 
hydrocortisone was evenly distributed in the hydrogels; while for the three- layer film, 
hydrocortisone was only incorporated in the middle layer (Table 6.4). As the thickness of 
the PVA films increases, the release of hydrocortisone decreases as seen in Figure 6.8. 
However, even though the thick film has the same thickness as the three- layer film, the 
release from the three-layer film showed better control of release with a near linear 
profile. The PVA outer layers with no drug incorporated served as diffusion barriers for 
hydrocortisone and water molecules, which slowed down the release.  
 
189 
As discussed earlier, the single layer PLGA-PVA composites showed better 
sustained release than either using microparticles or pure PVA film alone. However, the 
release in the first hour for the composites was still relatively high (52% for composite 1, 
42% for composite 2). With the results obtained for release from the PVA hydrogels 
discussed above, a three- layer PLGA-PVA composite was constructed based on 
Composite 2, which contains PLGA microparticles with 4.2% hydrocortisone (Table 6.5). 
The release from the three- layer composite was studied and compared with the release 
from PLGA microparticles and single layer composite (Figure 6.9). The addition of outer 
layers reduced the initial release from 42% to 17% within 30 minutes, and then caught up 
with the release from single layer by the end of 4 hours dissolution as the drug source of 
the early stage release was mainly the surface attached hydrocortisone. The outer layers 
of the composite also decreased the total amount of hydrocortisone by the end of one 
month with drug partitioning reached equilibrium.  
6.4 Modeling of Hydrocortisone Release from Three-layer Composite 
 The release of hydrocortisone from the composites (both single layer and three-
layer) is a complicated process with combined physicochemical phenomena of release 
from a hydrogel matrix and biodegradable microparticles. First, water penetrates into 
PVA hydrogel matrix and the hydrogel begins to swell. Hydrocortisone attached on the 
surface of the microparticles begins to diffuse after the hydrogel network becomes 
flexible upon water intrusion. With water present in the system, PLGA microparticles 
begin to undergo homogenous degradation. Once the degradation reaches the critical 
level, the bulk erosion occurs and the entrapped hydrocortisone is released through 
barriers of degraded particles and PVA matrices. It will be difficult to develop a model 
 
190 
containing all the phenomena, for the diffusion of a solute out of polymer networks or 
degradation of polymers alone are still challenges to researchers in the field of modeling. 
Therefore, in this work, we developed an empirical model describing the apparent drug 
release, which is not based on the exact physical or chemical mechanisms discussed 
above. 
 The power law semi-empirical equation has been used widely to estimate drug 
release from polymeric systems [10]: 
ntM =kt
M¥
           (6.1) 
 Here, tM  and M¥  are the absolute cumulative amount of drug released at time t  
and infinite time, respectively; k is a constant incorporating structural and geometric 
characteristic of the device, and n is the release exponent, indicative of the mechanism of 
drug release. When n=0.5, the equation is comparable to the solution of Fick’s second 
law of diffusion for short time release ( tM / M¥ <60%): 
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 Here, D is the drug diffusion coefficient within the polymeric system; l is the half 
thickness of the polymer film. From this equation, the constant k is related to the 
diffusion coefficient, D: 
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  Therefore, the diffusion coefficient of drug, D, can be calculated as: 
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 For microparticles containing 4.2% hydrocortisone, around 68% hydrocortisone 
was released during the first two hours dissolution. A slower release was observed after 
the initial rapid release and lasted for about one month till 95% of the incorporated 
hydrocortisone released (Figure 6.2). Based on this observation, the hydrocortisone 
release from PLGA microparticles, which are degradable, can be considered as two 
stages. In the first stage, the release occurs for hydrocortisone attached on the surface of 
the microparticles, resulting in rapid dissolution, or so-called initial burst. For this 
specific release profile, we assume that the initial burst mainly occurs in the first two 
hours, as 68% of hydrocortisone was released during the period. In the second stage, 
which is after two hours in this case, the particle degradation begins to take effect on the 
release. The release at this stage is governed by both the degradation of the microparticles 
and the diffusion of hydrocortisone. Using Gnuplot (version 3.7, Thomas Williams, Colin 
Kelley and many others) to fit the data for the release after two hours initial burst (Figure 
6.10), an equation was obtained as for the release from the microparticles containing 
4.2% hydrocortisone:  
( )043900038 06645 2.tM . t . , t  hours
M¥
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 For diffusion from spheres, the diffusion exponent n=0.43 [11]. Therefore, the 
second stage of hydrocortisone from PLGA microparticles can be considered as a process 
expressed with a constant apparent diffusion coefficient, DP,a. There are two factors that 
would affect the diffusion coefficient of hydrocortisone diffusion from PLGA 
microparticles. First, microparticles prepared using PLGA usually undergo bulk 
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degradation with polymer chains cleaved by hydrolysis until water-soluble fragments are 
formed. The degradation of particles results in a looser structure which offers fewer 
obstacles for the diffusion of hydrocortisone molecules through the particles into the 
releasing buffers, leading to the increase of the diffusion coefficient. However, at any 
given moment, the concentration of the drug decreases, which would bring a negative 
effect on the diffusion coefficient. With these two opposite factors working together, a 
constant value is possibly obtained, which can be assumed to be the apparent diffusion 
coefficient to simplify the complicated chemical and physical combined phenomena into 
a simple expression. Therefore, the model developed in this research is empirical, which 
is based on the experimental data obtained in the release studies.  
 The purpose of incorporation of particles into hydrogel matrix or multilayer 
matrix is to modulate the release of drugs by adding diffusion resistances. The source of 
hydrocortisone is from PLGA microparticles. As we have already assumed that 
hydrocortisone release from the microparticles within the first two hours is from the 
surface of the particles and no degradation occurs during this short period, the release of 
the drug from the composites can be considered to be controlled by only diffusion of 
hydrocortisone through the PVA hydrogel matrix. However, at this stage, only the drug 
attached on the particle surface is available for the diffusion in the composite. Therefore, 
a factor of 68% is used to modify the initial release for both single layer and three- layer 
composite.  
 For the three- layer composite, the incorporated drug diffuses from the surface of 
the particles into the surrounding PVA matrix and then the outer layers of pure PVA 
hydrogel on each side of the single layer composite. The three sequence layers of PVA 
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exhibit diffusion resistance in a serial order. The total resistance can be treated as the sum 
of the resistance of every single layer. Therefore, the first step is to write an expression 
for the resistance of diffusion through the composites.  
 The transfers of energy, heat and mass are analogous to each other. The 
composite walls of layers made of different materials have been used widely in heat 
transfer problems. The energy flux is evaluated using the Fourier rate equation [12]: 
xq dT-k
A dx
=          (6.6) 
 Here, qx is the energy transfer rate, A is the cross-sectional area for heat transfer, k 
is the thermal conductivity, and dT/dx is the temperature gradient. For a flat wall with 
constant thermal conductivity:  
x
kA
q T
L
= D           (6.7) 
 Here, kA/L is characteristic of a flat wall and is designated the thermal 
conductance. The reciprocal of the thermal conductance, L/kA, is the thermal resistance.  
 For steady flow of energy through composite walls, the total thermal resistance is: 
i
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 Similarly, the mass flux of diffusion can be written as the following [13]: 
zJ dC-D
A dz
=                (6.9) 
 Jz is the diffusion rate, A is the cross-sectional area for diffusion, D is the 
diffusion coefficient, and dC/dz is the concentration gradient. Comparing equation 6.9 to 
equation 6.6, we can see D is analogous to k. Therefore, the resistance of diffusion can be 
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written as L/DA with comparison to the thermal resistance L/kA. In case of pure diffusion, 
the total resistance can be written as:  
i
T i
i i
L
R = R =
D Aå å                 (6.10) 
 For the three- layer composite, the short term release is governed by diffusion, the 
total diffusion resistance is: 
3L,C SL, C PVA
T
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        (6.11) 
 Here, D3L,C, DSL,C, and DPVA are the diffusion coefficient of hydrocortisone in 
three- layer composite, single layer composite and pure PVA films, respectively; L3L,C, 
LSL,C, and LPVA are the half thickness of each layer, in this case, LSL,C=LPVA=1/3 L3L,C;  
A3L,C, ASL,C, and APVA are the cross-sectional areas for each layer, and are identical to each 
other.  
 Using equations 6.3 and 6.11, the hydrocortisone release from the three- layer 
composite can be written based on curving fitting of the release from PVA films and 
PLGA-PVA single layer composite. In addition, as we stated in the earlier assumption 
that only 68% incorporated hydrocortisone was available for the diffusion during the two 
hours initial release, a factor of 0.68 was used to obtain the release based on the total 
amount of hydrocortisone incorporated in the system (Table 6.6). The empirical model of 
the first two-hour release from the three- layer composite was shown in Figure 6.11.  
 For the release after two hours till the end of the release studies, the degradation 
of PLGA microparticles began to play a role in hydrocortisone release. As we discussed 
earlier, the release of hydrocortisone from PLGA microparticles can be considered as a 
process expressed by a constant apparent diffusion coefficient, DP,a, after the initial burst. 
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Therefore, an expression for the total diffusion resistance for the single layer and three-
layer composites: 
( )pC CT
C, a C p,a p,a C C
m rL L
R = = x+  1-x
D A D A D A
×
× ×       (6.12) 
Here, DC,a is the apparent diffusion coefficient of composites (both single layer 
and three-layer); rp is the average radius of the microparticles; m  is a factor to describe 
the change of diffusion resistance after the particles incorporated in the hydrogel matrix; 
x is the percentage of microparticles in the composite. Ap,a is the surface area of particles 
available for diffusion: 
2, ,
, 3
3
4
4 3
Ptotal Ptotal
P a P P P
PP
V V
A N A r
rr
= × = × =
× ×
p
p
        (6.13) 
Here, Np is the numbers of the particles incorporated in PVA matrix; Ap is the 
surface area of single particle; Vp, total is the volume of the microparticles in the composite. 
If we assume the densities of PLGA and PVA are identical: 
, , ,Ptotal C a C aV x A L= × ×        (6.14) 
For hydrocortisone release from the single layer composite after initial two hours, 
a curve fitting (Figure 6.12) gave an equation, which is listed in Table 6.7. Combine 
equations 6.12 to 6.14, the factor, m, was calculated as 7.54. This parameter represents 
the change of diffusion resistance of release from the microparticle after being 
incorporated in the hydrogel matrix. A value greater than unit indicates an increase of 
diffusion resistance for release from the particles embedded in the hydrogel matrix. It is a 
result of limited contact of PLGA microparticles with PBS solution, which would lead to 
possible slower release and degradation rate. The resistance for the three- layer composite 
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was calculated using equation 6.12, and an empirical model of released hydrocortisone 
was obtained with the addition of the amount of hydrocortisone that was released by the 
end of two hours initial release (Figure 6.13). Combine the initial burst release and long-
term release, the profile of hydrocortisone release from three- layer composite in the 
duration of the release study was obtained:  
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     The model showed good agreement with the experimental data for almost the 
whole range of dissolution studies except for the release from 1 day to 3 days (Figure 
6.14) with the empirical model showed lower values compared to the experimental data. 
This is due to the simplifications made for the development of the model. 
The empirical model can be used to estimate how release is affected by system 
factors, and offer useful information when constructing multilayer composites for 
controlled drug release. The addition of pure PVA layers is to control the diffusion of 
hydrocortisone from the multilayer system, which almost resembles a reservoir type 
delivery system except for the open sides. Therefore, the three-layer composite can be 
treated as a hybrid-type of reservoir/matrix system, which improves the release kinetics 
of a matrix system to near zero-order release of a reservoir device.  
The thickness of the hydrogel layers affects the release. As seen in equation 6.3, 
the release rate constant, k, decreases with increasing film thickness if the diffusion 
coefficient, D, remains constant. The effect of pure PVA outer layer thickness on 
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hydrocortisone release was investigated using the model with a relation between the outer 
layer thickness (LPVA) and the single layer composite thickness (LSL): 
PVA SLL a L= ×          (6.16) 
The empirical model was used to estimate the release profiles for composites with 
different thickness of outer layers (Figure 6.15). In our experiment, a=1, as spacers of 
same thickness were used to prepare the composites. As the outer layer thickness 
increases, the total diffusion resistance will increase according to equation 6.11, assuming 
other parameters remain the same. The initial release is thus reduced. The total release 
does not go completion as more drug molecules would be trapped inside the hydrogel 
layers at partitioning equilibrium when the outer layer thickness increases. The thickness 
of the outer layer also affects the second stage release in our assumption, in which the 
degradation of PLGA microparticles occurs. The slight decrease of the slopes with 
increasing outer PVA layer thickness indicates an increase of the diffusion resistance. 
Besides the obvious reason we mentioned above that resistance increases with increasing 
the layer thickness, it is also a result of slower degradation of PLGA microparticle with 
more constrained mass transfer through thicker hydrogel layers. Therefore, the thickness 
of outer layer hydrogel mainly affects the initial release, and to a lesser extent, it also 
affects the degradation of the microparticles, resulting in total reduced amount of release.  
The effect of particle size on release was also studied with different values 
assigned to the radius of particles. In the process of modeling, we assumed the average 
radius of particles was 5 mm. In Figure 6.16, we can see the particle size played an 
important role in the release during the second stage, i.e., release associated with PLGA 
degradation. Bigger particles lead to slower release, which is reasonable for microparticle 
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systems, since the available release area decreases with increase of particle size. The 
distance that drug molecules have to diffuse through the particles also increases, resulting 
in a slower release. However, as we assumed that the drug was released from the surface 
of the particles in the initial burst stage, the particle size would not affect the diffusion of 
the drug from the particle surface. Therefore, the initial release is not affected by the 
changing of the particles.  
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6.5   Conclusion 
 
 In this chapter, the release of hydrocortisone from different drug delivery systems 
was studied and discussed. The loading of hydrocortisone affected the morphology of 
PLGA microparticles, and thus played an important role on hydrocortisone release from 
the particles. The release was more rapid with higher content of drug incorporated, as 
hydrocortisone might present in the form of crystals on the surface of the microparticles 
with high concentrations. 
Incorporation of PLGA microparticles into PVA hydrogel films reduced the rapid 
initial release which was significant in the delivery systems of microparticles or PVA 
hydrogel films alone. The multilayer system showed better control of release than simple 
monolithic films, and further reduced the initial burst effect of the single layer PLGA-
PVA composite in the early stage of release.  
The empirical model developed based on the release of hydrocortisone from 
single layer PLGA-PVA composite, PLGA microparticles and various PVA hydrogel 
films showed good agreement with the experimental data of three- layer composite for the 
duration of the dissolution studies. It simplified the complicated physical and chemical 
processes involving in the release of hydrocortisone into a pair of simple expressions 
which describe the early stage of release and long term release, respectively. The effects 
of outer PVA hydrogel layer thickness and PLGA microparticle size on the release were 
also investigated using the empirical model. 
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Table 6.1: Hydrocortisone loading in PLGA microparticles for release studies 
 
Theoretical Loading Actual Loading Loading Efficiency 
9.97% 4.2% 42.1% 
19.8% 15.6% 78.8% 
30.1% 23.8% 79.0% 
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Table 6.2: Hydrocortisone loading in different delivery systems for Composite 1 
 
Samples Hydrocortisone loading Description 
Particles 23.8% PLGA microparticles 
Composite 1 3.8% 20 wt% PLGA particles in PVA film 
PVA film 3.9% Pure PVA film 
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Table 6.3: Hydrocortisone loading in different delivery systems for Composite 2 
 
Samples Hydrocortisone loading Description 
Particles 4.2% PLGA microparticles 
Composite 2 0.8% 25 wt% PLGA particles 
PVA film 1.3% Pure PVA film 
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Table 6.4: Pure PVA hydrogel film loaded with hydrocortisone 
 
Samples Thickness 
(mm) 
Hydrocortisone 
loading 
Structure 
Thin film 1 ~0.10 1.3% 
 
 
Thin film 2 ~0.10 3.9% 
 
 
Thick film ~0.30 1.3% 
 
 
Three- layer 
film ~0.30 1.3% 
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Table 6.5: Hydrocortisone loading of three- layer composite 
 
Samples Thickness (mm) Hydrocortisone 
loading 
Description 
Particles NA 4.2% PLGA microparticles 
Composite 2 ~0.10 0.8% 25 wt% PLGA particles 
Three- layer ~0.30 0.27% 
Middle layer with 25 wt% 
particles 
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Table 6.6: Empirical modeling of hydrocortisone release during the first two hours 
of studies ( t 2hours £ ) with the assumption that the drug released from the surface of 
the microparticles.  
Delivery Systems Dimension1 Equation Method 
PLGA 
microparticles D~0.01 mm NA NA 
PVA film L~0.05 mm 0.5y=0.0108 t×  
Curve fitting 
using Gnuplot 
Three- layer PVA 
film L~0.15 mm 
0.5y=0.00462 t×  
Curve fitting 
using Gnuplot 
PLGA-PVA single 
layer composite 
L~0.05 mm 0.5y=0.0105 t×  
Curve fitting 
using Gnuplot 
PLGA-PVA three-
layer composite L~0.15 mm 
0.5y=0.00452 t×  
Empirical model 
using Eqn. 6.11 
 
1 Dimension: D is the diameter of PLGA microparticles; L is the half thickness of PVA 
films and PLGA-PVA composites.  
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Table 6.7: Empirical modeling of hydrocortisone release after the initial burst effect  
with the degradation of PLGA microparticles ( t 2 hours > ). 
Delivery Systems Dimension1 Equation Method 
PLGA 
microparticles D~0.01 mm 
0.439y=0.0038 t +0.6645×  
Curve fitting 
using Gnuplot 
PLGA-PVA 
single layer 
composite 
L~0.05 mm 
0.5y=0.0002765 t +0.4287×
 
Curve fitting 
using Gnuplot 
PLGA-PVA 
three- layer 
composite 
L~0.15 mm 0.5y=0.0002763 t +0.3838×  
Empirical model 
using Eqn. 6.12 
 
1 Dimension: D is the diameter of PLGA microparticles; L is the half thickness of PLGA-
PVA composites.  
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     (A) 
 
 
 
   
     (B) 
Figure 6.1: Schematics of (A) Single layer composite with PLGA microparticles in 
PVA matrix; (B) Three- layer composite of PLGA-PVA—single layer composite in the 
middle layer with a layer of PVA on each side. 
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Figure 6.2: Hydrocortisone release from PLGA microparticles 
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Figure 6.3: ESEM images of PLGA microparticles prepared using 10% (w/v) PLGA 
in DCM solution with varied loading of hydrocortisone.  
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Figure 6.4: Hydrocortisone release from Composite 1, 20% PLGA particles with 
23.8% hydrocortisone, in PBS solution (pH 7.4).  
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Figure 6.5: Surface morphology of Composite 1, 20% PLGA particles in PVA film,  
upon immersion in PBS solution (pH 7.4) using ESEM.  
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Figure 6.6: Hydrocortisone release from Composit e 2, 25% PLGA particles with 4.2% 
hydrocortisone, in PBS solution (pH 7.4). 
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Figure 6.7: Surface morphology of Composite 2, 25% PLGA particles in PVA film, 
upon immersion in PBS solution (pH 7.4) using ESEM.  
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Figure 6.8: Hydrocortisone release from hydrogel systems of pure PVA with varied 
thickness and structures.  
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Figure 6.9: Hydrocortisone release from three- layer composite based on Composite 2 
in PBS solution (pH 7.4) with comparison to release from single layer composite and 
release from PLGA microparticles.  
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Figure 6.10: Curve fitting of release from PLGA microparticles with 4.2% 
hydrocortisone after two hours initial release to obtain the apparent diffusion coefficient. 
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Figure 6.11: Empirical model of hydrocortisone release from three- layer PLGA-PVA 
composite within two hours initial release.  
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Figure 6.12: Curve fitting of hydrocortisone release from single layer composite after 
two hours initial release to obtain the value of the factor, m.  
 
221 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
0 4 8 12 16 20 24 28 32
Time (day)
R
el
ea
se
d
 H
yd
ro
co
rt
is
o
n
e
Experimental Data
Empirical Model
 
 
Figure 6.13: Empirical model of hydrocortisone release from three- layer PLGA-PVA 
composite after two hours initial release till the end of release studies 
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Figure 6.14: Empirical model of hydrocortisone release from three- layer PLGA-PVA 
composite over the length of release studies.  
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Figure 6.15: Estimation of the outer layer film thickness effects on release using the 
empirical model with a defined in Eqn. 6.16. 
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Figure 6.16: Estimation of particle size effects on release using the empirical model 
with r being the mean radius of  PLGA microparticles (unit in mm).  
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CHAPTER 7:RECOMMENDATIONS 
The overall objective of this research was to develop new polymeric systems for 
controlled release of therapeutic agents, through physical blending of polymers with 
known biocompatibilities. Two different approaches were adopted using a semicrystalline 
polymer, polyvinyl alcohol (PVA), as the main polymer which can form toxic-free 
hydrogel networks with its crystallites serving as physical crosslinking points.  
In the first approach, a hydrophilic polymer, polyvinyl pyrrolidone (PVP), with 
strong polar side groups was selected and evaluated as a candidate to generate novel 
hydrogels through the formation of homogenous blends with PVA. As PVA and PVP 
have been studied extensively on their miscibility in the literature, this part of our work 
brought the research further to use the blends as hydrogels with possible application as 
polymeric carriers for controlled drug release. Dry PVA/PVP blends were miscible over 
the range tested in this work, however, PVP was found to dissolve out of the hydrogel 
networks after immersion in PBS solution (pH 7.4). The dissolution of PVP was a result 
of re-distribution of hydrogen bonds in PVA/PVP blends in presence of water. The 
ensuing hydrogels exhibited varied mechanical properties and swelling behaviors related 
to the initial compositions of PVP in the blend systems. The release of a hydrophilic 
model drug, vitamin B12, was found to occur with most of the drug released in 30 minutes 
from thin blend films. The release rate of vitamin B12 increased with increasing initial 
PVP composition.  
The second approach of this work was to construct polymeric composites of 
various designs based on PVA as well. Microparticles (5-10 µm) fabricated using a 
biodegradable, biocompatible polymer, poly (lactide-co-glycolide) (PLGA), were 
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embedded into the 3-D hydrogel matrix of PVA. Compared to the blending of PVA and 
PVP, the mixing of PLGA microparticles and PVA hydrogels is on a macroscopic level 
rather than a molecular level, however, this approach also benefits from the formation of 
physically crosslinked matrices with PVA crystallites as the crosslinking points. This 
research is unique as it combined the advantages of biodegradable particles and tissue-
like hydrogels, which offered multiple controls on the release of incorporated model drug. 
The distribution of the microparticles in the hydrogel matrix was studied using confocal 
laser scanning microscopy, which offered useful information on the inner structures of 
the composites while maintaining the integrity the samples. The release of the model drug 
from the polymer composites, especially the three- layer composite design, showed better 
control of the significant initial burst effect of the microparticles and rapid release of the 
hydrogels. The empirical model developed based on the power law for hydrocortisone 
release from the three- layer composite showed good agreement with the experimental 
data, and verified the two-stage release assumption.  
As discussed above, the specific aims stated in Chapter 3 have been carried out 
and fulfilled. However, there are still a lot of developments that one can do beyond the 
research conducted in this work, as scientific research will never come to an end, and 
exciting, interesting projects are always waiting for researchers to explore. Therefore, the 
following sections are contributed to further development of the work described in this 
thesis, with the hope of offering useful ideas for future research.  
7.1 Polymer Blending  
In our research, PVA and PVP formed homogeneous polymer blends through the 
formation of hydrogen bonds between their polar side groups. However, only one 
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molecular weight was studied for both PVA and PVP. As the dissolution of PVP is a 
result of competition of hydrogen bonds among PVA, PVP and water molecules, a 
diagram of PVP dissolution versus time for varied compositions of PVA and PVP with 
different molecular weight would offer a general idea how the two polymers interact with 
each other in the presence of water. Furthermore, as studied in Chapter 4, the mechanical 
properties, swelling behaviors and the estimated average mesh sizes of ensuing hydrogels 
after dissolution of PVP are related to the initially blended PVP composition. It would be 
beneficial to create a chart containing the information of the properties listed above based 
on the PVP compositions. 
In the applications of PVA/PVP blends for controlled drug delivery, we only 
tested model drug release from monolithic films. As discussed in Section 2.2 and Chapter 
6, devices can be fabricated into different designs with varied dominating mechanisms of 
release. As hydrogels with different average mesh size can be obtained after PVP 
dissolution, it would be interesting if we combine these hydrogels with varied mesh size 
into one device, such as multilayer design, to control the release of incorporated drugs.  
In the process of this work, polymers other than PVP were used to form polymer 
blends with PVA as well, including poly (ethylene glycol) (PEG-10,000) and Eudragit® 
S-100, which is a copolymer of methyl methacrylic acid and ethylacrylate with 1:1 ratio. 
PEG has a weak polar C-O bond in its structure, and obviously it is not strong enough to 
form hydrogen bonds with the hydroxyl group of PVA. As a result, the PVA/PEG blends 
are not homogeneous. The carbonyl group of Eudragit® S-100 forms strong hydrogen 
bonds with the hydroxyl group of PVA. However, the presence of the hydrophobic 
moiety, the ester group in Eudragit® S-100, is not compatible with PVA, resulting in 
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Eudragit® S-100 unevenly distributed in the amorphous regions of PVA. However, the 
release of vitamin B12 from the PVA/ Eudragit® S-100 blends was found to be slower 
than from pure PVA film. Therefore, it would be an interesting research if one can 
construct a drug delivery system of PVA with localized Eudragit regions containing 
therapeutic agents, as the carbonyl groups of Eudragit are stronger in polarity for the 
formation of hydrogen bonds. 
7.2 PLGA-PVA Composites 
Incorporation of PLGA microparticles in the PVA hydrogel matrix, as we 
discussed in Chapter 5 and 6, modulated the model drug release through control the 
degradation of the microparticles and diffusion of water and drug molecules. However, 
despite author’s effort, the degradation of PLGA microparticles was not determined 
quantitatively. ESEM images were excellent, straightforward demonstration for particle 
degradation over time. However, the images only showed the surface morphologies, and 
no information could be obtained for the overall particle degradation in the hydrogel 
matrix. In our research, we attempted to use reserved phase HPLC to detect the 
concentrations of lactic acid and glycolic acid, which are the final products of PLGA 
degradation. Different solutions were tested as the mobile phase; however, all were in 
low pH, which is around 2.4 to 3.5. The low pH is necessary for the detection of organic 
acids, as association/deassociation equilibrium occurs in water:  
R-COOH «  R-COO- + H+ 
 If the mobile phase pH is not low enough, the acids would present in two forms, 
and thus show two HPLC peaks, which is not desirable for concentration determination. 
The mobile phase we tested included 0.1 M phosphate acid, 0.2 M potassium phosphate 
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(KH2PO4), 0.2 M ammonium phosphate (NH4H2PO4). However, only lactic acid and 
glycolic acid standard solutions could be detected using HPLC; while for the samples of 
PLGA-PVA composites, the HPLC peaks were not detectable. This result is 
disappointing, yet not unreasonable, for the degradation of PLGA has many middle 
products other than lactic acid and glycolic acid as the degradation is a process of random 
chain scission. Only water soluble oligomers and monomers can diffuse out of the 
PLGA-PVA systems and be detected. As a result, the concentrations of the monomers, 
lactic acid and glycolic acid, can be very low which is not easy to be detected with the 
presence of other water soluble oligomers. A commonly used method for PLA/PLGA 
microparticle degradation is GPC, though which the average molecular weight (Mn) of 
the polymers is determined. As the limitation in the facilities in the laboratory, we did not 
perform this experiment. However, it would be beneficial if one can determine Mn by 
dissolving the degraded microparticles in a solvent of PLGA, which does not dissolve 
PVA, to reveal the degradation behaviors of PLGA microparticles embedded in PVA 
hydrogel matrix. 
 For the release of model drug from the PLGA-PVA composites, the amount of 
particles embedded in the hydrogel matrix was limited to 20% for single layer and three-
layer composites. It would be a good practice if different percentages of particles are 
incorporated into the hydrogel matrix and test the drug release. Furthermore, the loading 
of hydrocortisone remains as a challenge. Dichloromethane (DCM) was demonstrated to 
be more suitable to prepare particle than ethyl acetate. However, mixtures of organic 
solvents may have better solubility of hydrocortisone, and thus improve the loading. 
Other particle preparation methods, such as oil- in-oil emulsion and spray drying, avoid 
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the water phase used in oil- in-water emulsion, and thus may offer higher drug loading 
efficiency. Therefore, experiments can be set up to test loading efficiency of model drugs 
into PLA/PLGA microparticles using different fabrication methods.  
The degradation of PLGA 50:50 microparticles in vitro was more than one month 
in our work, due to the particle size and the fact that the particles were embedded in a 
hydrogel matrix, which limited the contact of particles with water. We used 0.1 M NaOH 
to accelerate the degradation. PLGA microparticles were found to disappear and pores of 
similar dimensions replaced where the particles were sitting originally on the surface 
(ESEM images, not shown in this thesis). Therefore, polymer composites can possibly be 
used in tissue engineering associating drug delivery. Growth factors, anti- inflammatory 
drugs or other therapeutic agents can be incorporated in the biodegradable particles, 
which are then embedded in a matrix. The therapeutic agents are released when the 
particles degrade, and inter-connected pores can be formed for cell attachment and tissue 
regrowth. The association of tissue engineering and drug delivery has become a new 
trend in biomedical field. The newly approved drug eluting stent of Johnson & Johnson is 
an excellent example. Therefore, it would be an exciting research if one explores the 
possible applications of polymeric composites developed in this work for tissue repair 
and tissue engineering.  
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